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Abstract 
Ribosomes are responsible for the synthesis of all cellular proteins.  It was initially 
believed that translating nascent chains would not interact with the ribosome exit tunnel, 
however, a small but increasing number of proteins have been identified that interact with 
the exit tunnel to induce translational arrest.  Escherichia coli (E.coli) secretion monitor 
(SecM) is one such stalling peptide.  SecM monitors the SecYEG translocon export 
activity through its own translocation to the periplasm and upregulates translation of SecA, 
an ATPase involved in the SecYEG translocation machinery, when translocation is 
reduced.  How stalling peptides interact with the ribosome exit tunnel is not fully 
understood, however, a key feature required is an essential amino acid arrest motif at their 
C-terminus, and additionally some peptides, including SecM, undergo compaction of the 
nascent chain within the exit tunnel upon stalling.   
 
In this study analysis of SecM peptides with both alanine and conservative mutations of 
key arrest motif residues were investigated.  This identified three conservative mutants that 
can retain a degree of stalling; and this level of stalling is further increased when coupled 
with mutation of a non-essential arrest motif residue P153A.  Further analysis of these 
mutants by pegylation assays indicates that this increase in stalling ability is due to the 
ability of the P153A mutation to reintroduce compaction of the nascent chain within the 
exit tunnel, possibly due to the improved flexibility of the nascent chain provided by the 
removal of the restrictive proline residue.   These methods highlight the significance of the 
interactions between the nascent chain and the exit tunnel, which contribute to translation 
arrest. 
 
This study also examines the ability of stalling peptides to undergo translation arrest in 
ribosomes of alternative domains, investigating in particular the ability of E.coli SecM and 
TnaC and fungal Neurospora crassa (N.crassa) AAP to arrest in eukaryotic Wheat Germ 
and prokaryotic E.coli ribosomes.  This study concludes that stalling peptides only induce 
translation arrest in ribosomes of the same domain.  In addition, it also revealed the ability 
of inducible stalling peptides to undergo translational pausing, prior to the commitment to 
full translation arrest, a process that does not appear to occur in intrinsic stalling peptides. 
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1 Introduction 
1.1 The ribosome 
1.1.1 General Introduction 
The ribosome is the cellular machinery that synthesises proteins from the substrate amino 
acids and is the most complex ribozyme in the cell, composed of both protein and RNA it 
is the RNA moieties that are responsible for the catalytic activity.  Genomic DNA is 
transcribed to messenger RNA (mRNA) by RNA polymerase, which is then in turn 
translated to the peptide sequence by the ribosome.  The ribosome is responsible for a 2 
x107-fold rate of enhancement in peptide bond formation, which is achieved through 
enabling the optimum positioning of substrates, (Sievers et al., 2004).  It was initially 
believed that ribosomes were non-discriminating against the proteins they synthesised, in 
order to allow them to process such a huge number of different peptides.  However, this is 
not the case and there is a small but increasing number of peptides that have been found to 
interact with the ribosome and stall their own translation.  Ribosome stalling can have 
multiple functions including: to disrupt the secondary structure of the bound mRNA, 
thereby exposing downstream Shine-Dalgarno sequences; regulating 
transcription/translation of downstream genes; or enabling secondary functions such as cis-
chaperoning. 
 
1.1.2 Ribosome Structure 
The ribosome consists of two separate subunits, the complete 70S prokaryotic ribosome 
has a large 50S and a small 30S subunit and has a total mass of ~2.3 MDa, whilst 
eukaryotic 80S ribosomes consist of 60S and 40S large and small subunits respectively, 
and can have a molecular weight up to 4.3 MDa (Melnikov et al., 2012).  In bacteria the 
large ribosomal subunit is composed of 2 ribosomal RNAs (rRNA) (23S and 5S) and ~31 
proteins, whilst the small ribosomal subunit is composed of one rRNA (16S) and ~21 
proteins.  In comparison, in eukaryotes the ribosome consists of 80 ribosomal proteins (79 
in yeast) and four rRNA chains (28S, 5.8S, and 5S in the large subunit and 18S in the small 
subunit).  These large and small subunits exist separately in the cytoplasm until they are 
brought together by initiation factors (IFs) to synthesise protein.  X-ray crystallographic 
studies identified that the catalytic peptidyl transferase centre (PTC) was composed solely 
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of rRNA, with the nearest protein moiety at least 18 Å away (Nissen et al., 2000).  This 
confirmed earlier suggestions that the ribosome functioned as a ribozyme (Noller et al., 
1992). The detailed mechanism of peptide bond synthesis within the PTC will be explained 
in the following section, 1.1.3. 
 
There are 3 transfer RNA (tRNA) binding sites at the interface between the large and small 
subunits at the PTC: the A (aminoacyl), P (peptidyl) and E (exit) sites, which are 
highlighted in Figure 1.1A and B (Ramakrishnan, 2002).  The A site is responsible for 
accepting the incoming aminoacylated tRNA molecule carrying the next amino acid to be 
added to the peptide being synthesised; whilst the P site accommodates the tRNA molecule 
carrying the growing polypeptide chain; and the E site contains the deacylated tRNA 
molecule that has dissociated from the peptide chain prior to being ejected from the 
ribosome.  During the translation process, mRNA enters from the side of the 30S subunit 
close to ribosomal proteins S11 and S7 and moves stepwise, one codon at a time, through 
the ribosome between the large and small subunits, see Figure 1.1C (Yusupova et al., 
2001).  The small subunit binds mRNA and the tRNA anticodon stem-loops, and is 
responsible for maintaining the accuracy of the translation process during mRNA codon 
and tRNA anti-codon base pairing.  The large subunit contains the PTC and its role is to 
bind the acceptor arms of the tRNA molecules and catalyse the peptide bond formation 
between the incoming A site amino acid and P site peptide chain.  As will be discussed 
further in later sections, the ribosome also relies on additional protein factors such as 
GTPases that are activated to promote translation. 
 
Despite the differences in mass, the prokaryotic and eukaryotic ribosomes share an 
evolutionarily conserved core structure consisting of 34 conserved proteins (15 in the small 
and 19 in the large subunit) and ~4,400 RNA nucleotides (Lecompte et al., 2002; Melnikov 
et al., 2012).  These conserved regions contain the main active sites of the ribosome 
including the decoding site, PTC and tRNA binding sites (Spahn et al., 2001).  Outwith 
this conserved core, the ribosomes contain insertions and extensions to the core protein and 
rRNA segments, as well as additional domain-specific proteins.  For instance the 70S 
prokaryotic ribosome contains 20 bacteria-specific proteins (6 in the 30S subunit and 14 in 
the 50S subunit), whilst the eukaryotic ribosome contains 46 proteins that have no bacterial 
homologs (18 in the 40S subunit and 28 in the 60S subunit) (Melnikov et al., 2012).  The 
majority of these protein and rRNA extensions are located on the solvent-exposed surface  
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Figure 1.1 Structural overview of the prokaryotic 70S ribosome and the path of the mRNA between 
the ribosome subunits. A. An x-ray crystallographic structure of the complete 70S ribosome and B. 
Separated 50S and 30S subunits.  The 50S subunit is illustrated in white and 30S in blue, with the A, P and E 
sites indicated in red, green and yellow respectively.  Structure reproduced from Ramakrishnan (2002). C. 
The path of the mRNA through the 30S ribosomal subunit viewed from the subunit interface and D. from the 
solvent aspect.  The mRNA enters at the back of the platform close to ribosomal proteins S11 and S7 and 
exits between the head and the shoulder regions of the ribosome.  The A and P site codons are indicated in 
orange and red respectively and the ribosomal proteins are indicated in purple and 16S rRNA in light blue.  
Structure reproduced from Yusupova et al., (2001).  
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of the ribosome enabling them to be accessible to interacting partners such as translation 
factors and chaperones (Ben-Shem et al., 2011).  The differences in complexity of 
prokaryotic and eukaryotic ribosomes are reflected in their assembly, with bacterial 
ribosome biogenesis requires relatively few non-ribosomal factors (Shajani et al., 2011), 
whilst eukaryotic ribosomes require the assistance of approximately 200 maturation factors 
(Panse and Johnson, 2010).  In addition eukaryotic ribosome assembly is also 
compartmentalised, initially in the nucleolus before the pre-ribosomes are exported to the 
nucleoplasm and then finally to the cytoplasm upon final maturation (Panse and Johnson, 
2010).  Whilst sharing a conserved core there can also be variations in the composition of 
ribosomes within prokaryotes and eukaryotes, and also to a smaller degree within the same 
species under different growth and stress conditions.  These differences occur through 
alterations in the length and sequence of, predominantly, the rRNA components of the 
ribosome, although sometimes it may be due to an additional, or one fewer, ribosomal 
proteins.  The mass of eukaryotic ribosomes can vary by ~1 MDa, and this is 
predominantly due to insertions in eukaryotic-specific RNA expansions segments 
(Yusupova and Yusupov, 2014).   
 
It should be noted that in eukaryotes, in addition to cytoplasmic ribosomes, mitochondria 
and chloroplasts also contain structurally distinct ribosomes.  Both organelles originated 
from early endosymbiotic events between eubacteria and eukaryotes, with the closest 
relation of mitochondria being α-Proteobacteria, whilst chloroplasts are related to 
cyanobacteria (Gray, 1993).  Through the course of evolution, mitochondrial ribosomes 
have become structurally diverse from both cytoplasmic and bacterial ribosomes, with the 
complete 55S mammalian mitochondrial ribosome composed of a large 39S subunit and 
the small 28S subunit.  They have also evolved to synthesise only a small number of 
peptides with mammalian mitochondrial ribosomes responsible for synthesising only 13 
membrane proteins that are involved in oxidative phosphorylation or ATP generation 
(Amunts et al., 2014; Greber et al., 2014; Kaushal et al., 2014).  The 70S chloroplast 
ribosomes are similar to eubacteria, comprising a small 30S and a large 50S subunit, with 
few differences in rRNA and orthologs to 50 Escherichia coli (E.coli) ribosomal proteins, 
lacking only L25 and L30, whilst containing an additional six proteins termed Plastid-
Specific Ribosomal Proteins (PSRPs) (Sharma et al., 2007).  The chloroplast genome 
encodes approximately 120 genes, categorised into two main classes, those that encode 
constituents of the genetic system and those that encode systems of the photosynthetic 
system (Tiller and Bock, 2014).  
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1.1.3 Ribosome Function 
1.1.3.1 Overview of translation 
The primary function of the ribosome occurs at the PTC where, in comparison to substrates 
free in solution, the rate of peptide bond formation is enhanced by lowering the entropy of 
activation through the optimum positioning of substrates and/or water exclusion within the 
active site (Sievers et al., 2004).  The PTC is well adapted for this role and can maintain 
efficient transfer of amino acids from A site aminoacyl tRNAs to the growing peptide 
chain attached to the P site peptidyl tRNA, despite the wide range in their size, structure 
and chemical properties.  There are 3 key steps to translation: initiation, elongation and 
termination, which are subsequently followed by recycling of the separated components to 
begin a new cycle.  The process of elongation is similar between prokaryotes and 
eukaryotes with the features of the ribosome involved in these processes such as the PTC 
and decoding centres highly conserved.  However, the two systems differ greatly in the 
mechanism of initiation of translation, which involves greater complexity in eukaryotes 
and requires more accessory factors to proceed correctly.  The following sub-sections are a 
description of prokaryotic translation with the differences between prokaryotic and 
eukaryotic translation highlighted after.   
 
1.1.3.2 Formation of the translation initiation complex 
Initiation of translation in prokaryotes requires the formation of an active initiation 
complex consisting of both ribosomal subunits (50S and 30S), formylated aminoacyl 
initiator tRNA (fMet-tRNAfMet), the mRNA to be translated and the three initiation factors 
(IF1, IF2 and IF3) (Simonetti et al., 2008).  The initiator tRNA contains formylated 
methionine, fMet-tRNAfMet, which is produced by methionyl-tRNA transformylase 
(Guillon et al., 1992; Lee et al., 1991).  Formylation distinguishes initiator tRNA from 
elongation Met-tRNAs, increasing binding to Initiation Factors and reducing affinity for 
Elongation Factors, and enabling the tRNA to enter directly into the ribosome P site 
(Seong and Rajbhandary, 1987a, b).  X-ray crystallographic structures confirmed that IF1 
binds to the 30S ribosomal A site, preventing tRNA binding to this site and ensuring that 
the initiator tRNA, fMet-tRNAfMet, binds only to the P site (Carter et al., 2001).  It also 
increases the affinity of IF2, a small GTPase, for the ribosome (Zucker and Hershey, 
1986).  The function of IF2·GTP  is to bind fMet-tRNAfMet and aid its binding to the 30S
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Figure 1.2 Prokaryotic translation initiation.  A. Initiation Factor (IF) 3 binds to the 30S ribosomal 
subunit. B. The mRNA Shine-Dalgarno (SD) sequence interacts with and binds to the 30S subunit.  C. This is 
followed by the binding of initiator fMet-tRNAfMet, IF1 and IF2, constituting the 30S Initiation Complex.  D.  
Hydrolysis of GTP by IF2 results in release of IF3 from the complex.  E. Subsequent release of the remaining 
Initiation Factors IF1 and IF2 enables the binding of the 50S subunit.  The process of protein synthesis then 
continues into the elongation, termination and recycling stages.   
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ribosomal subunit (Lockwood et al., 1971).  The final initiation factor, IF3, binds to the E 
site of the 30S subunit (Dallas and Noller, 2001), preventing its association with the 50S 
subunit until after formation of the initiation complex (Subramanian and Davis, 1970).  It 
also aids the selection of initiator tRNA, fMet-tRNAfMet, through destabilising the binding 
of incorrect tRNAs at the ribosome P site (Hartz et al., 1990). 
 
The initiation complex combines in a multi-step process that begins with the interaction of 
the 16S rRNA of the 30S ribosomal subunit, containing bound IF3 (Figure 1.2A), with the 
complimentary, purine-rich Shine-Dalgarno sequence of the mRNA (Figure 1.2B).  The 
Shine-Dalgarno sequence contains up to 9 nucleotides (5’-ACCUCCUUA-3’) and is 
located 5-9 bases upstream from the AUG initiation codon, and serves to recruit the 
ribosome subunits directly to the initiation site of the mRNA (Shine and Dalgarno, 1974).  
This is followed by binding of IF1, IF2 and initiator fMet-tRNAfMet to form the 30S 
Initiation Complex (Figure 1.2C).  IF2, a GTPase, promotes 50S subunit docking which 
subsequently induces GTP hydrolysis and results in the spontaneous release of IF3 (Figure 
1.2D) (Antoun et al., 2006).  Formation of the 70S ribosome is followed by release of IF1 
and IF2, leaving fMet-tRNAfMet situated in the P site in preparation for continuation into 
the peptide elongation cycle (Figure 1.2E) (Grigoriadou et al., 2007).  As translation 
initiation is not restricted by the position of the AUG start site within the mRNA, 
prokaryotic mRNA can contain more than one open reading frame (ORF) with initiation 
able to occur at multiple sites within the mRNA (Laursen et al., 2005).  In addition, as 
transcription and translation are coupled, translation is able to begin immediately upon 
synthesis of the 5’ end of mRNA.  It is also possible for multiple ribosomes to translate the 
same mRNA transcript creating chains of polyribosomes (polysomes). 
 
1.1.3.2 Translation Elongation Cycle 
The elongation cycle proceeds by the sequential addition of amino acids to the extending 
polypeptide chain.  Firstly, the amino acids are paired with the correct tRNA in the 
cytoplasm by aminoacyl-tRNA synthetases.  For each particular amino acid there is a 
specific aminoacyl-tRNA synthetase enzyme to catalyse their attachment to their 
corresponding tRNA.  Aminoacylation of tRNA by aminoacyl-tRNA synthetases occurs 
through activation of the amino acids with ATP to generate aminoacyl-adenylates, 
followed by transfer of the amino acid to the relevant tRNA (Figure 1.3) (Ibba and Soll, 
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2000).  The cell ensures the selection of the correct tRNA by subjecting aminoacyl-tRNA 
synthetases to kinetic proofreading, which is achieved by formation of a high energy 
intermediate during the aminoacylation steps (Guth and Francklyn, 2007).  The high 
activation energy required to bind the correct tRNA and amino acid discriminates against 
erroneous pairings and results in an irreversible formation pathway.  Following this, 
ternary complexes of aminoacyl tRNAs, elongation factor Tu (EF-Tu) and GTP are 
subsequently formed and directed to the ribosome by EF-Tu (Figure 1.4A) (Nissen et al., 
1995).  The sequence of the peptide is determined by complimentary base pairing between 
the mRNA codon situated in the A site and the anticodon of the tRNA carrying the amino 
acid.  Once the tRNA-EF-Tu complex enters the ribosome A site (Figure 1.4B), if correct 
base pairing occurs, conformational changes occur within the ribosome.  The ribosome is 
unable to pre-determine what tRNA will enter the A site and therefore correct base pairing 
is achieved by random sampling until the correct codon-anticodon match is achieved.  This 
is recognised as it is kinetically more favourable and induces changes in the G domain of 
the EF-Tu (Rodnina et al., 1995), ultimately inducing hydrolysis of GTP by the GTPase 
EF-Tu (Figure 1.4C), followed by dissociation of EF-Tu-GDP enabling aminoacyl-tRNA 
to be accommodated in the A site (Figure 1.4D and 1.5B) (Pape et al., 1998; Rodnina et al., 
1996).  The interactions between the 16S rRNA and mRNA also have a role in tRNA 
selection and accuracy with correct tRNA binding inducing rearrangements in the 30S 
subunit at the conserved and essential 16S rRNA bases G530, A1492 and G530 of the 16S 
RNA that contact the codon-anticodon helix in the A site of the 30S subunit (Ogle et al., 
2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 The path of an amino acid from the cytoplasm to the ribosome.  The correct amino acid is 
attached to its corresponding tRNA by a specific aminoacyl-tRNA synthetase in an ATP dependent step.  
The aminoacyl-tRNA then interacts with EF-Tu and is delivered to the ribosome where the correct tRNA is 
selected through detection of the correct codon-anticodon pairing.
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Figure 1.4 Steps of translation elongation.  A.  Elongating peptide resides in the ribosome exit tunnel with the associated tRNA situated in the ribosome P site.  B. A complex of 
aminoacyl tRNA, elongation factor Tu (EF) and GTP enter the ribosome A site. C. Correct base pairing of the A site tRNA with the mRNA results in hydrolysis of GTP by EF-Tu. D.  
This is followed by dissociation of EF-Tu-GDP and accommodation of the aminoacyl-tRNA in the A site in preparation for peptide bond synthesis.
28 
 
Catalysis of peptide bond formation then occurs at the peptidyl transferase centre and 
involves the nucleophilic attack of the -amino group of the aminoacyl-tRNA that is 
situated in the A site, on the peptidyl-tRNA located in the P site (Figure 1.5C and 1.6) 
(Beringer et al., 2005; Weinger et al., 2004).  This creates a ribosome in the pre-
translocational state whereby the peptide chain is transferred to the A site tRNA thus 
resulting in a deacylated tRNA in the P site (Figure 1.5D).  The process of translocation 
involves the movement of tRNA molecules through the ribosome, concurrent with a shift 
in the mRNA reading frame of 3 nucleotides, exposing the next mRNA codon (Frank et 
al., 2007).  This translocation is promoted through the ratcheting movement of the small 
and large subunits, during which the subunits move ~ 6o relative to each other 
(Agirrezabala et al., 2008; Frank and Agrawal, 2000; Julian et al., 2008).  Single-molecule 
FRET experiments have demonstrated that this is a spontaneous rotational movement that 
fluctuates between the unratcheted and ratcheted states until binding of EF-G and 
movement of the deacylated P site tRNA into the 50S E site stabilises the rotated state 
(Blanchard et al., 2004; Cornish et al., 2008).  Elongation factor G (EF-G), a GTPase, 
binds to the peptidyl-tRNA in the A site and facilitates its translocation to the P site whilst 
deacylated P site tRNA is translocated to the E site prior to its ejection from the ribosome 
(Figure 1.5E & F) (Moazed and Noller, 1989; Wilson and Noller, 1998).  The movement 
of the tRNAs into the hybrid states are sequential, with the P/E tRNA hybrid first followed 
by the A/P switch (Munro et al., 2007; Pan et al., 2007).  Following translocation the one 
amino acid residue extended peptidyl-tRNA is situated in the ribosome P site ready to 
repeat the elongation process until synthesis of the peptide is complete, at which point 
translation termination is undertaken as explained in the following section.  
 
1.1.3.3 Translation Termination 
The elongation process is repeated until an mRNA stop codon (UAA, UAG or UGA) 
enters the ribosome A site.  This stop codon is recognised by Class I release factors, RF1 
and RF2, which cleave the nascent polypeptide from the P site tRNA by hydrolysis of the 
ester bond as there is no amino acid to transfer to, thereby releasing the peptide from the 
ribosome.  Both RF1 and RF2 recognise the UAA stop codon whilst UAG is only 
recognised by RF1 and UGA is recognised by only RF2 (Scolnick et al., 1968).  RF3, a 
class II release factor is a GTPase and binds to RF1/2on the ribosome and promotes their 
rapid dissociation (Freistroffer et al., 1997).  Interaction of RF3 with RF1 or RF2 results in  
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Figure 1.5 The process of translocation.  A. Peptidyl-tRNA is situated in the P site; B. In complex with EF-Tu-GTP, aminoacyl-tRNA enters the A site and, in the event of correct 
base pairing, hydrolysis of GTP occurs and EF-Tu-GDP dissociates; C. The peptidyl-tRNA undergoes nucleophilic attack from the -amino group of the aminoacyl-tRNA; D. The 
ribosome is in the pre-translocational state with peptidyl-tRNA in the A site and a deacylated tRNA in the P site; E. Upon subunit ratcheting the 3′ end of the peptidyl-tRNA in the A 
site and the deacylated tRNA in the P site that are in contact with the 50S subunit spontaneously move to the P site and E site respectively, forming a hybrid state; F. Translocation is 
completed by the binding of EF-G-GTP which binds to the peptidyl-tRNA in the A site and facilitates its translocation to the P site, whilst deacylated P site tRNA is translocated to the 
E site prior to its ejection from the ribosome. 
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Figure 1.6 Overview of peptide bond formation.  Nucleophilic attack of the peptidyl-tRNA in the P site by 
the -amino group of the aminoacyl-tRNA in the A site results in peptide bond synthesis and extension of 
the peptide chain by one amino acid. 
 
a rapid exchange of GDP for GTP, which is then subsequently hydrolysed to promote 
dissociation of RF3 (Zavialov et al., 2001).  The ribosome is recycled for another round of 
translation in a GTP dependant step by the binding of ribosomal recycling factor (RRF) 
and EF-G, resulting in dissociation of the ribosome into separate 30S and 50S subunits.  
The bound mRNA and tRNA are released and the separate subunits bind initiation factor 
IF3 to prevent immediate and premature re-assembly (Peske et al., 2005; Zavialov et al., 
2005).  
 
1.1.3.4 Differences in eukaryotic translation  
1.1.3.4.1 Eukaryotic translation initiation 
As stated previously, the process of translation initiation is more complex in eukaryotes, 
with the following section briefly covering these differences.  In prokaryotes, translation 
initiation requires only 3 initiation factors (IF1, IF2 and IF3) and it is the recognition of the 
Shine-Dalgarno sequence of the mRNA by the anti-Shine-Dalgarno sequence of the 16S 
rRNA that positions the start site codon at the ribosome P site.  In eukaryotes this process 
requires at least 10 initiation factors, some of which are multi-subunit protein complexes 
(Jackson et al., 2010).  Unlike the prokaryotic fMet-tRNAfMet, the initiator tRNA (Met-
tRNAi) in the cytoplasm of eukaryotes is not formylated, instead, post-transcriptional 
modifications distinguish it from elongation Met-tRNA (Sonenberg and Hinnebusch, 
2009).  Formylation of initiator Met-tRNA does, however, still occur in eukaryotic 
chloroplasts and mitochondria, which as stated previously evolved as a result of 
endosymbiosis with bacterium (Guillemaut and Weil, 1975; Smith and Marcker, 1968).   
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Unlike prokaryotes where the ribosome-initiation complex can bind at any point on the 
mRNA where the Shine-Dalgarno sequence is located at the start codon, eukaryotes locate 
the translation start site by scanning from the end of the mRNA in a 5’ to 3’ direction.  
Eukaryotic mRNAs undergo post-transcriptional modifications resulting in the addition of 
a 5’ cap, consisting of a modified GTP (m7G) (Shatkin, 1976), and a 3’ poly-A tail 
containing 150 or more adenine nucleotides (Sheets and Wickens, 1989).  The poly-A tail 
functions to stabilise the mRNA and interact with the 5’ end of the same mRNA, binding 
via eIF-4G, which binds both Poly-A Binding Protein (PABP) and eIF-4E, resulting in a 
closed-loop structure of the mRNA (Gallie, 1991; Wells et al., 1998) (Figure 1.7).  The 5’ 
cap is recognised by the small (40S) ribosomal subunit and assists in the formation of the 
pre-initiation complex (PIC) with eukaryotic initiation factors (eIFs) and Met-tRNAi 
(Pestova and Kolupaeva, 2002).  The eukaryotic pre-initiation complex begins scanning 
from the 5’ untranslated region (5’UTR) of the mRNA until it reaches an AUG start codon 
located within a Kozak sequence, the consensus sequence of which is 
GCC(A/G)CCAUGG (Kozak, 1986, 1987).  The start codon is identified by base pairing 
with the anti-codon of Met-tRNAi (Cigan et al., 1988), and its recognition results in 
displacement of the Initiation Factors by the joining of the 60S subunit and the progression 
of translation initiation (Pestova et al., 2000). 
 
 
 
AAAAAAAAAAAAAAAA
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Figure 1.7 The mechanism of cap-dependent eukaryotic translation initiation.  Eukaryotic mRNA exists 
in a closed-loop conformation due to the interactions of the 5’cap with the 3’ poly-A tail via eIF4G binding 
to PABP and eIF4E.  The 40S ribosome subunit is recruited via eIF3 interactions.   
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1.1.3.4.2 Eukaryotic translation termination and ribosome recycling 
Eukaryotic translation termination also occurs in response to recognition of an mRNA stop 
codon (UAA, UAG or UGA) in the ribosome A site and requires two release factors, eRF1 
and eRF3 (Zhouravleva et al., 1995).  The Release Factors bind to the ribosome A site in a 
complex as eRF1/eRF3/GTP, with eRF1 responsible for recognition of the stop codon in 
the ribosome A site.  Unlike prokaryotes that also contain RF2, in eukaryotes eRF1 is 
responsible for recognising all three potential stop codons.  eRF3 is a GTPase and, after 
binding to the A site, causes hydrolysis of GTP, which in turn results in hydrolysis of the 
peptidyl-tRNA by eRF1 and release of the peptide chain from the ribosome (Alkalaeva et 
al., 2006).  Ribosome recycling follows and is mediated by ABCE1, an ATPase and a 
member of the ATP-binding cassette (ABC) family of proteins, which dissociates the 60S 
subunit from the mRNA/tRNA/40S complex (Pisarev et al., 2010).  Subsequent mRNA 
and tRNA release is mediated by initiation factors eIF3, eIF1, eIF1A and eIF3j, a loosely 
associated subunit of eIF3 (Pisarev et al., 2007). 
 
1.1.3.5 Translational recoding 
There are circumstances where exceptions can occur during the normal cycle of translation 
elongation and the ribosome can undergo programmed translational recoding caused by a 
ribosomal frameshift (Gesteland et al., 1992).  Whilst the AUG start site determines the 
translational reading frame there are situations where this reading frame can be shifted by 
one base, either in the 5’ (-1) or 3’ (+1) direction, or in some circumstances, at translational 
hop sites, the ribosome may skip larger sections of nucleotides before continuing back into 
translation (Belew et al., 2014; Herbst et al., 1994; Plant et al., 2003).  Although present in 
all domains of life, frameshifting is a method highly utilised by viruses to increase the 
coding capacity of their genomes (Miller et al., 1997).  These occurrences require a 
translational pause during elongation in order to occur and are generally mRNA mediated, 
however, some are mediated by the peptide nascent chain.   
 
Ribosomal frameshifting requires two key factors, a ‘slippery site’ on the mRNA where 
tRNA shift/mis-alignment is accommodated and a downstream mRNA stimulatory 
structure that functions to enable frameshifting to occur (Namy et al., 2004).  This 
downstream structure may be an mRNA pseudoknot or a slowly translated region of 
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mRNA, the purpose of which is to provide an energetic barrier to elongation, resulting in 
the ribosome pausing over the slippery site and thus providing an opportunity for 
frameshifting to occur (Kontos et al., 2001).  Examples of genes that undergo 
frameshifting are prfB in E.coli, which encodes Release Factor (Craigen and Caskey, 
1986), and eukaryotic ornithine decarboxylase antizyme, Antizyme 1 (AZ1) (Matsufuji et 
al., 1995). 
 
Translational hopping occurs when the ribosome bypasses larger regions of nucleotides 
before resuming translation, an example of which is gene product 60 (gp60) in 
bacteriophage T4.  This is a single polypeptide that is encoded by a discontinuous reading 
frame that bypasses a 50 nucleotide non-coding region (Huang et al., 1988).  The features 
that are necessary for gp60 translational hopping include glycine GGA codons flanking 
either side of the 50 nucleotide coding gap, a stop codon following the first glycine codon, 
mRNA stem-loop structure and a nascent peptide signal (Samatova et al., 2014; Wills et 
al., 2008).  Translational hopping is not completely efficient as whilst nearly all ribosomes 
are able to disengage from the mRNA at the first glycine codon, only about 50% resume 
translation at the downstream open reading frame (Herr et al., 2000). 
 
Finally, translational recoding can also take place on the same mRNA creating two 
different translational products within the same reading frame, an example of this is 2A 
peptides found in viruses.  These 2A peptides undergo a ‘stop-carry on’ form of re-coding, 
whereby translation pauses at the final proline codon of the 2A peptide and recruits release 
factors to undergo stop codon-independent translation termination.  The first peptide is 
released whilst translation reinitiates at the same codon, thus enabling two peptides to be 
produced from the same reading frame (Doronina et al., 2008; Luke et al., 2008).   
Numerous 2A peptides have been identified and whilst there appears to be high 
conservation in the C-terminus sequence there is a high degree of variability in the N-
terminus, yet despite this mutagenesis studies indicate that all residues of the 2A peptide 
are important to stalling function (Sharma et al., 2012).  These studies indicate that 2A 
nascent chain interactions with the ribosome are necessary to alter ribosomal conformation 
and promote translation termination in the absence of a stop codon (Sharma et al., 2012). 
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1.1.4 Ribosome Exit Tunnel 
1.1.4.1 Structure and properties of the ribosome exit tunnel 
During translation the growing polypeptides leave the ribosome via the exit tunnel that is 
~100 Å in length and leads away from the PTC, through the large ribosomal subunit, 
exiting into the cytoplasm.  Early evidence for the presence of the exit tunnel came from 
experiments that indicated 30 to 35 residues of the most recently synthesised part of the 
nascent chain were protected from proteolytic cleavage, indicating that these residues 
could still be contained within the ribosome (Malkin and Rich, 1967).  Following this, the 
location of the exit tunnel opening at the opposite side of the large subunit from the PTC 
was detected by antibody binding to nascent peptides (Bernabeu and Lake, 1982).  Later, 
visualization by cryo-Electron Microscopy (cryo-EM) confirmed the existence and 
location of ribosome exit tunnel (Frank et al., 1995), and more recently nascent 
polypeptides have even been visualized within the ribosome exit tunnel by cryo-EM 
(Becker et al., 2009; Bhushan et al., 2010a; Seidelt et al., 2009).   
 
The tunnel walls are formed predominantly of hydrophilic residues of the 23S rRNA and it 
has an average diameter of ~20 Å.  In addition, there are some protein contributions to the 
exit tunnel, with a constriction point 20-35 Å from the PTC formed by proteins L4 and L22 
where the diameter narrows to ~10 Å.  The role of the constriction site is not clear but it is 
speculated that it could have roles in sensing the nature of the polypeptide (Nakatogawa 
and Ito, 2002).  Also located near to the exit tunnel opening is ribosomal protein L39e in 
eukaryotes, or equivalently an extension of L23 in prokaryotes (Ben-Shem et al., 2010; 
Harms et al., 2001; Schuwirth et al., 2005; Selmer et al., 2006), see Figure 1.8. 
 
Overall the tunnel has an electronegative potential (Lu and Deutsch, 2008) and although 
there are still some hydrophobic residues lining the surface of the tunnel these are disperse 
and there are no defined patches of hydrophobicity, which provides the tunnel with a 
relatively ‘non-stick’ nature (Nissen et al., 2000).  Despite the initial belief of a passive 
role played by the ribosomal exit tunnel there is growing evidence indicating that 
interactions occur between the nascent chain and the ribosome exit tunnel to regulate 
translation of specific peptides, this will be discussed in Section 1.2.  
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Figure 1.8 Structures of the 50S prokaryotic and 60S eukaryotic large ribosome subunits.  A. 
Prokaryotic and B. Eukaryotic large ribosomal subunits, highlighting the path of the nascent chain through 
the exit tunnel.  Note, proteins L4 and L22 which form the narrowest part of the exit tunnel at the constriction 
site.  Also proteins L23 in prokaryotes and L39 in eukaryotes form contacts within the tunnel at the distal end 
near the exit tunnel opening.  Structures reproduced from A. (Houben et al., 2005) and B. (Nissen et al., 
2000). 
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1.1.4.2 Nascent chain folding within the ribosome exit tunnel 
Early proteolytic digestion experiments of nascent chains within the ribosome indicated 
that between 30 and 35 amino acid residues are contained within the ribosome exit tunnel 
(Malkin and Rich, 1967).  Whilst large-scale protein folding within the ribosome exit 
tunnel is not plausible due to the confines of the exit tunnel diameter, the dimensions are 
compatible with the formation of basic protein secondary structure such as alpha helices 
(Voss et al., 2006).  Indeed through calculations and simulations it can be shown that 
alpha-helical structures are stabilised within the ribosome exit tunnel and nascent chains 
may in fact be entropically driven to form these structures (Ziv et al., 2005). 
 
The ribosome exit tunnel does not have a uniform conformation throughout its length and  
experimental evidence indicates the existence of distinct ‘folding zones’ within the exit 
tunnel where formation of nascent chain secondary structure is favoured (Lu and Deutsch, 
2005a).  Protein tagging with methoxy-polyethylene glycol maleimide (PEG-mal) can be 
employed to assess when residues have traversed the ribosome exit tunnel, this method is 
known as pegylation.  Pegylation studies were used to assess the folding of nascent chains 
with those that were engineered to contain segments of poly-alanines, which have a high 
propensity for alpha-helix formation, forming helical structures close to the PTC and also 
at the distal end of the exit tunnel (Lu and Deutsch, 2005a).  Meanwhile, other pegylation 
studies have shown that native transmembrane segments form helices at lower points in the 
exit tunnel (Tu and Deutsch, 2010) and indeed  analysis of peptides with regions of high 
alpha-helical propensity also showed helix formation only at the distal end of the exit 
tunnel (Bhushan et al., 2010a).  None formed helical structures in the middle of the exit 
tunnel in the area coinciding with the constriction point.  However, fluorescence resonance 
energy transfer (FRET) assays, which gave the first direct measure of secondary structure 
within the tunnel, indicated that a transmembrane sequence in a nascent membrane protein 
compacts into an alpha-helical structure close to the PTC and maintains this structure 
throughout the length of its passage through the exit tunnel (Woolhead et al., 2004).  
Although, as determined in the same study, this is not the case for all peptides as a 
secretory protein was shown to traverse the exit tunnel in an extended conformation 
(Woolhead et al., 2004).   
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Further to this, the formation of more complex tertiary structure was again prohibited in 
the confines further up the exit tunnel but could take place within the last 20 Å at the distal 
end, within an area termed the ‘folding vestibule’ (Kosolapov and Deutsch, 2009; Tu et al., 
2014).  These findings were also supported by computational simulation results which 
corroborated that tertiary structure formation can occur within the distal folding vestibule 
(O'Brien et al., 2010).  This leads to the conclusion that it is a combination of factors 
between the environment of the exit tunnel and the nature of the nascent chain, including 
factors such as: hydrophobicity, length and helix propensity, which determines whether a 
nascent chain will form alpha-helical structures as it traverses the exit tunnel and also 
whether it maintains this structure. 
 
1.1.4.3 Nascent chain interactions with the ribosome exit tunnel 
There is a wide range of evidence indicating that the nascent chain can communicate with 
the ribosome on which it is being translated, through interactions with the ribosome exit 
tunnel.  There appear to be many functions of this communication, both positive and 
negative, some of which will be discussed here.  One function may be to recruit molecular 
chaperones and other auxiliary factors to the ribosome prior to release of the nascent chain.  
For instance, it has been demonstrated in E.coli, using leader peptidase (Lep) as a model 
inner membrane protein, that nascent chains that are too short to have exited the ribosome 
exit tunnel can still recruit SRP from within the tunnel.  In this particular case, the signal is 
transferred from within the ribosome tunnel by inducing a conformational change in the 
ribosomal tunnel protein L23 (Bornemann et al., 2008).  Further evidence has shown that 
this interaction coincides with transmembrane domain compaction in the E.coli exit tunnel 
(Robinson et al., 2012).  Another example is the gating of the endoplasmic reticulum 
translocon pore in eukaryotes which is controlled by transmembrane proteins during their 
translation whilst they are still contained within the exit tunnel (Liao et al., 1997). 
 
The nascent chain interactions with the exit tunnel can also function to cause translation 
arrest of the ribosome on which the peptide is being synthesised and stall its own 
translation.  Translation arrest can be short or long term and can have several different 
functions.  For instance, evidence has recently emerged of a post-initiation translational 
pausing, occurring at the 5th codon of mRNA, due to interactions between the first few 
amino acids translated and the ribosome exit tunnel.  It is believed that the function of this 
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short term arrest is to enable the short nascent chain to sense the environment and ensure it 
correctly enters into the ribosome exit tunnel from the PTC prior to the ribosome 
committing to translation elongation (Han et al., 2014).  Long term translational pausing 
due to interactions between the nascent chain and the ribosome exit tunnel functions to 
control the synthesis of downstream peptides within the same operon and is discussed in 
depth in the following Section 1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
1.2 Translational arrest peptides 
1.2.1 General overview of stalling peptides 
Contrary to initial belief of the ribosome exit tunnel being ‘non-stick’, not all peptides pass 
through the ribosome tunnel unhindered, some undergo translation arrest and ribosome 
stalling (Nakatogawa and Ito, 2002), and are termed translational arrest peptides.  The 
function of this controlled ribosome stalling is to provide another level of cellular control 
to gene and protein expression, enabling regulation of transcription and translation of 
downstream genes on the same operon.  Translation arrest is tightly controlled as aberrant 
ribosome stalling is detrimental to the cell.  The downstream regulation as a result of 
translation arrest can be either positive or negative depending on the individual peptides, 
specific examples of which will be given in the following sections. 
 
Peptides which undergo translational stalling contain essential amino acid residues or a 
series of essential residues, termed an arrest motif.  It is these amino acid residues, not the 
mRNA sequence that encodes them that are responsible for regulating translation arrest 
through interactions with the ribosome exit tunnel.  This is supported experimentally 
through studies in which silent base mutations were introduced into the mRNA codons that 
did not alter the amino acid sequence.  This resulted in no effect on translation arrest, 
however, mutations of the same codons to sequences specifying alternative amino acids 
abolished arrest (Fang et al., 2000).  Additionally ribosome mutations altering both 23S 
rRNA and L22 components of exit tunnel resulted in abolishment of the arrest function of 
stalling peptides such as SecM (Nakatogawa and Ito, 2002).  A selection of stalling 
peptides and their essential residues are illustrated in Table 1.1.  This table highlights the 
variability of amino acid arrest sequences indicating that the methods of stalling differ, to 
some degree, for each peptide.  The interactions between the nascent chain and the 
ribosome exit tunnel mediate a cis-acting arrest signal and therefore stalling only occurs on 
the ribosome upon which the peptide is being synthesised.  This stalling can occur at two 
points, either during translation elongation or termination.  Stalling during translation 
elongation can itself occur at either  the peptidyl transfer step whereby the peptidyl-tRNA 
remains stalled in the P site, examples of peptides undergoing stalling at this point include: 
SecM, MifM and ErmCL (Chiba and Ito, 2012; Muto et al., 2006; Vazquez-Laslop et al., 
2008); or it can occur at the translocation step whereby the peptidyl-tRNA remains in the 
A site, as is the case for the  CGS1 peptide (Onouchi et al., 2005).  Peptides which undergo 
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Intrinsic  P site A site  
[1] SecM E.coli     F x x x x W I x x x x G I R A G P 
[2] SecM mutant     x x x x x x x x x x P P I R x G P 
[3] SecM M.succiniciproducens    x x x x x x x x x x H A P I R G S P 
[4] Experimentally obtained            F x x Y x I W P P P 
[5] MifM B.subtilis R I x x W I x x x x x M N x x x x x x x x 
Inducible  Inducer molecule 
[6] AAP N.crassa        D Y L x x x x W x x x x x * + Arginine 
[7] TnaC E.coli        W x x x D x x I x x x x P * + Tryptophan 
[8] TnaC P.vulgaris        W x x x D x x L x x x x P x + Tryptophan 
[9] ErmCL            M x x x x I F V I x + Erythromycin 
Distance from ribosome P site -19 -18 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 +1  
 
Table 1.1 Stalling motifs of selected translational arrest peptides as determined by mutational analysis.  Only essential stalling residues are noted, non-essential residues are 
denoted by an ‘x’.  The residues occupying the ribosome A and P sites are shown on the right of the table.  Some peptides stall with their respective stop codons in the ribosome A site 
and this is denoted in the table by an asterisk (*).  Arrest sequences from [1] (Nakatogawa and Ito, 2002); [2] & [3] (Yap and Bernstein, 2009); [4] (Tanner et al., 2009); [5] (Chiba et 
al., 2009); [6] (Spevak et al., 2010); [7] (Cruz-Vera and Yanofsky, 2008); [8] (Cruz-Vera et al., 2009); [9] (Vazquez-Laslop et al., 2008). 
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translation termination arrest stall with a stop codon in the ribosome A site, examples of 
these stalling peptides include TnaC and AAP (Gong et al., 2001; Wang et al., 1998).  
 
Translational arrest peptides can undergo one of two forms of translational arrest, either 
inducible or intrinsic.  Inducible stalling peptides arrest only occurs when an effector 
molecule, such as an antibiotic or metabolite binds to the ribosome, for instance, ErmCL 
stalling in the presence of erythromycin (Vazquez-Laslop et al., 2008), or TnaC, which 
undergoes stalling when free tryptophan binds to the ribosome (Gong et al., 2001).  
Alternatively stalling may be intrinsic, whereby arrest occurs without a cofactor and is 
only released upon interaction with other cellular components, such as in the case of SecM 
(Nakatogawa and Ito, 2002) or MifM (Chiba et al., 2009).  In the case of these intrinsically 
stalled peptides they must be of sufficient length to traverse the exit tunnel to enable them 
to interact with extra-ribosomal factors to release stalling (Butkus et al., 2003). 
 
In order to perform their function, translation arrest peptides must avoid detection by the 
intrinsic control mechanisms of the cell that are designed to sense and release stalled 
ribosomes.  In bacteria, there are three different methods of rescuing stalled ribosomes, 
transfer messenger RNA (tmRNA) undertakes trans-translation to release stalling (Janssen 
and Hayes, 2012), whilst ArfA (YhdL) (Chadani et al., 2012) and ArfB (YaeJ) (Chadani et 
al., 2011; Gagnon et al., 2012) both induce peptidyl-tRNA hydrolysis by distinct 
mechanisms.  Meanwhile in eukaryotes several mechanisms are used to sense stalled 
ribosomes and return normal function.  These include ubiquitination, which tags peptides 
stalled during translation and targets them for degradation (Bengtson and Joazeiro, 2010), 
and also the three types of co-translational mRNA surveillance mechanisms:  nonsense-
mediated decay (NMD), no-go decay (NGD) and nonstop decay (NSD).  NMD identifies 
mRNAs that contain a premature termination codon, whilst NSD identifies mRNAs 
without a termination codon and NGD targets mRNAs that contain sequences capable of 
potentially inducing ribosome stalling (Shoemaker and Green, 2012). 
 
These methods rely on detecting stalled ribosomes with an empty A site occurring as a 
result of truncated mRNA or a shortage of amino acids or tRNA, however, many stalling 
peptides evade detection as the A site is occupied upon arrest (Garza-Sanchez et al., 2006; 
Muto et al., 2006; Onouchi et al., 2005).  Whilst stalling peptides avoid detection under 
normal conditions, cells maintain control against overactive or prolonged stalling of arrest 
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peptides, as this is detrimental to the cell.  For example, deliberate overexpression of SecM 
results in a sequestering of tRNA-Pro in the stalled SecM-Ribosome nascent chain (RNC) 
complexes.  This depletion of tRNA-Pro results in a subset of stalled SecM-RNCs 
containing empty A sites and it is these that are targeted and released by tmRNA (Garza-
Sanchez et al., 2006).  Similarly, overexpression of tnaC  results in depletion of tRNA-Pro 
(Gong et al., 2006), with this elevated stalling rescued by Ribosome Recycling Factor 
(RRF) and Release Factor 3 (RF3) (Gong et al., 2007).  These examples indicate that 
whilst correctly functioning translation arrest peptides can operate in the cell, aberrant 
peptide stalling is not tolerated and is released.  
 
In terms of evolution, translation arrest is a relatively recent adaption with the stalling 
peptides established to date having limited phylogenic distribution especially in 
comparison to the ribosome itself, which evolved very early and is therefore highly 
conserved across both prokaryotes and eukaryotes.  Some examples of the limited 
distribution of stalling peptides are highlighted in Figure 1.9.  For instance, SecM is only 
present in the orders Enterobacteriales and Pasteurellales (van der Sluis and Driessen, 
2006), whilst TnaC occurs in the γ-proteobacterial orders Enterobacteriales, 
Pasteurellales, and also Vibrionales (Cruz-Vera and Yanofsky, 2008).  Meanwhile MifM 
is further removed from these and is found in the Firmicutes phylum in the Bacillales order 
in the class Bacilli (Chiba et al., 2009).  This restricted phylogenic distribution may 
account for the species-specificity that has been demonstrated between some bacterial 
stalling peptides (Chiba et al., 2011).  The situation in eukaryotes appears slightly broader 
but there are still no universal eukaryotic stalling peptides, for instance, the Upstream 
Open Reading Frames (uORFs) of CGS1, AAP and AdoMetDC are present within all 
plants, fungi and vertebrates respectively (Hood et al., 2007; Ito and Chiba, 2013).  Due to 
the divergence between stalling peptides it is difficult to formulate a bioinformatical search 
to identify novel stalling peptides and as a consequence the list of stalling peptides remains 
incomplete. 
 
The following sections contain a more detailed look at the three main translation arrest 
peptides investigated in this thesis: E.coli SecM, E.coli TnaC and Neurospora crassa 
(N.crassa) AAP; as well as a more general summary of some other stalling peptides of 
interest. 
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Figure 1.9 Phylogenic tree highlighting the distribution of selected translation arrest peptides SecM, 
TnaC and MifM.  MifM is found in the Firmicutes phylum in the Bacillales order in the class Bacilli, 
shown in blue.  SecM (green) and TnaC (orange) occur in the γ-proteobacterial orders Enterobacteriales, 
Pasteurellales, and, additionally for TnaC, also Vibrionales. Diagram adapted from Ito and Chiba (2013). 
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1.2.2 SecM – Secretion monitor 
Secretion Monitor (SecM) is a 170 amino acid peptide encoded upstream of the open 
reading frame (ORF) for SecA, an ATPase involved in the SecYEG translocation 
machinery.  SecM monitors cell export activity through its own translocation to the 
periplasm and upregulates translation of SecA when translocation is reduced.  Once 
exported to the cytoplasm the function of SecM is complete and it is rapidly degraded by 
tail-specific proteases (Nakatogawa and Ito, 2001).  The SecM peptide contains a signal 
sequence in its N-terminal which co-translationally targets it to the Sec translocation 
machinery at the cell membrane (Nakatogawa et al., 2005), and an arrest motif in its C-
terminal which interacts with the ribosome exit tunnel and induces elongation arrest at Pro-
166 (Nakatogawa and Ito, 2002).   
 
When the SecM-SecA mRNA is initially transcribed the SecA Shine-Dalgarno sequence is 
disguised by the mRNA secondary structure.   Stalling of the ribosome translating SecM 
disrupts this mRNA hairpin exposing the Shine-Dalgarno sequence, thus enabling 
translation of SecA (McNicholas et al., 1997).  Under normal conditions when the 
secretion status of the cell is sufficient, the stalling of SecM translation is transient, with a 
half-life of less than 1 minute, and the translation of SecA is basal (Nakatogawa and Ito, 
2001).  This transient stalling is released by the ‘pulling’ of the polypeptide through the 
SecYEG translocation machinery (Butkus et al., 2003).  However, when cell secretion is 
impaired, this release of stalling does not occur and the Shine-Dalgarno sequence of SecA 
remains exposed, resulting in its upregulated translation and thus increased production of 
SecA.  Additionally, SecM also functions as a cis-chaperone, its co-translational targeting 
to the membrane via its signal sequence results in the localisation of SecA production in 
the vicinity of the membrane and in doing so aids its efficient incorporation into the Sec 
translocation machinery where it functions (Nakatogawa et al., 2005).  An outline of SecM 
translation in both secretion sufficient and secretion deficient conditions is shown in Figure 
1.10. 
 
Through a systematic process of alanine-scanning mutagenesis Nakatogawa and Ito (2002) 
identified the essential arrest motif of SecM to be: 150-FxxxxWIxxxxGIRAGP-166.  
Furthermore they identified that Pro-166 and Arg-163 residues are essential; Trp-155, Ile-
156 and Gly-165 are important; and Phe-150, Gly-161, Ile-162 and Ala-164 are partially 
required for stalling.  Translation is arrested 5 residues prior to the SecM stop codon at 
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Glycine-165, at this point tRNA-Pro166 is situated in the A site but is not incorporated into 
the peptide, however, it is still essential for stalling (Muto et al., 2006).  Arrest is entirely 
cis-mediated by interactions occurring within the exit tunnel, as deletion of the N-terminal 
122 residues, leaving only the last 44 residues which would still be contained within the 
ribosome exit tunnel, still allowed for arrest to occur, (Nakatogawa and Ito, 2002). 
 
Since the elucidation of the key arrest motif residues, research has identified Arg-163 as 
the essential residue required for SecM stalling, with the exact positioning of this residue 
in the amino acid sequence essential for arrest (Yap and Bernstein, 2009).   Molecular-
dynamics flexible fitting (MDFF) modelling was used to visualise in atomic detail the 
structure of the stalled SecM nascent chain within the exit tunnel (Gumbart et al., 2012).  
This method enables atomic structures to be fitted into electron density maps by optimising 
the correlation of calculated and observed electron density maps thereby enabling high- 
resolution structures to be simulated (Trabuco et al., 2008).  This has indicated that Arg-
163 forms the key interactions with the ribosomal exit tunnel through interactions with 23S 
rRNA nucleotide A2062, whilst the other amino acid residues function to stabilise it  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Summary of SecM translation and translocation.  Under normal secretion conditions the 
stalling of SecM is transient as it is transported to the membrane and translocated through SecYEG, which 
releases stalling.  In deficient secretion conditions, stalling of SecM is prolonged, the Shine-Dalgarno (SD) 
sequence of SecA is exposed and as a result SecA translation is upregulated.   
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through the correct positioning of the nascent chain within the exit tunnel.  Indeed the 
mutation A2062U has been shown to abolish arrest of both SecM and ErmC stalling 
peptides (Vazquez-Laslop et al., 2010).  Movement of the SecM nascent chain within the 
ribosome exit tunnel is key to its stalling, fluorescence resonance energy transfer (FRET) 
analysis has revealed that the C-terminus of SecM is in an extended conformation until 
synthesis of the arrest motif is complete, at which point the nascent chain undergoes 
compaction.  This compaction is thought to be critical for the positioning of key residues, 
in particular Arg-163, within the exit tunnel, as mutations which prevent compaction, for 
instance mutation of non-essential amino acids 157-160 to proline, causes severe 
translation arrest defects.  In support of this, in the same study, modification of Pro-153, a 
non-essential amino acid, to alanine was shown to restore translation arrest of wild type 
SecM in non-stalling L22-mutated ribosomes, by enabling increased freedom of movement 
of the nascent chain by removal of the restrictive proline residue (Woolhead et al., 2006).  
This increased freedom of movement is believed to allow the repositioning of the nascent 
chain within the exit tunnel which enables essential contacts to be formed. 
 
Conformation of the SecM peptide within the ribosome exit tunnel was visualised by cryo-
EM, with key interactions seen to take place in the upper tunnel between the SecM nascent 
chain and 23S rRNA nucleotides A2062, U2585 and U2609 and in the mid-tunnel with 
nucleotide A751 (Bhushan et al., 2011).   A2062 is a highly flexible nucleotide (Fulle and 
Gohlke, 2009), which in the stalled SecM-RNC complex adopts a position flat against the 
ribosome exit tunnel wall, thought to be due to the constraints of the bulky SecM residues 
Arg-163 and also Ile-162.  This restrained positioning of A2062, as a result of Arg-163, 
appears to be key to stalling as it has recently been shown that the orientation of A2062 
initiates a relay signal through A2503 that results in PTC inactivation (Vazquez-Laslop et 
al., 2010).  In addition to this key interaction, rRNA nucleotide U2585 also interacts with 
SecM in the vicinity of Ala-164, whilst U2609 interacts with the 3 amino acid region of 
160-QAQ-158 of SecM.  Furthermore, in the mid-tunnel the interaction between rRNA 
nucleotide A751 and SecM occurs in the proximity of Trp-155 and Ile-156 of SecM 
(Bhushan et al., 2011).  Biochemical experimental approaches identified arrest suppressing 
mutations in the ribosome which coincide with the narrowest part of the ribosome tunnel, 
the constriction point, these key residues include A2058 and A749-A753 of 23S ribosomal 
RNA; Gly-91 and Ala-93 in L22 ribosomal protein (Nakatogawa and Ito, 2002); and also 
residues 82-84 of L22 (Woolhead et al., 2006). 
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The signal relayed to the PTC by interaction of Arg-163 with rRNA nucleotide A2062 was 
shown to result in a shift in the ester linkage of tRNA-Gly in the ribosome P site by 
approximately 2 Å (Bhushan et al., 2011) (Figure 1.11).  Even slight increases in distance 
between the tRNA molecules in the PTC can affect the efficiency of peptidyl transfer at the 
PTC (Schmeing et al., 2005; Simonovic and Steitz, 2009), and therefore this ratcheting 
motion results in the A76 ester linkage shifting and preventing nucleophilic attack of the α-
aminoacyl group of the A site tRNA-Pro, on the carbonyl carbon of the P site tRNA-Gly, 
and ultimately resulting in SecM translation arrest (Bhushan et al., 2011).  This method of 
stalling is also aided by the presence of proline in the A site which naturally undergoes 
slower peptidyl transfer in comparison to other amino acids (Pavlov et al., 2009). 
 
These studies reinforce the early findings that illustrated that the essential arrest residues, 
as elucidated by Nakatogawa and Ito (2002), were spaced apart at the C-terminus and not 
in a continual sequence, suggesting that it is not the detection of a continuous sequence but 
instead the positioning and recognition of individual residues of the nascent chain within 
the exit tunnel that enable arrest.  Indeed, as discussed the current evidence indicates that 
the critical factors in SecM stalling are the positioning of Arg-163 to interact with rRNA 
nucleotide A2062 and the subsequent ratcheting of the ester linkage of tRNA-Gly.  
 
1.2.3 TnaC 
TnaC is the leader peptide of the tryptophanase (tna) operon and functions to induce 
ribosome stalling to control downstream gene expression, however, unlike SecM which 
undergoes translation elongation arrest, TnaC stalls by inhibiting translation termination.  
TnaC is located upstream of the tnaA and tnaB genes, which encode for tryptophanase and 
a tryptophan specific permease respectively (Gong and Yanofsky, 2002) (Figure 1.12A).  
The tryptophanase enzyme is important as it enables bacteria to degrade L-tryptophan to, 
pyruvate and ammonia allowing them to use tryptophan as a source of carbon, nitrogen and 
energy (Snell, 1975).  Also as mentioned previously, TnaC is an inducible stalling peptide 
and only undergoes arrest in the presence of high concentrations of inducer molecule 
tryptophan (Gong et al., 2001).  In contrast to the 170 amino acid SecM protein, at 24 
amino acids in length TnaC is much shorter and remains fully contained within the 
ribosome exit tunnel throughout stalling (Figure 1.12B). 
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Figure 1.11 SecM arrest upon tRNA-Gly ratcheting.  Schematic diagram of the interaction of the SecM 
nascent chain at selected points within the ribosome exit tunnel resulting in the optimal positioning of Arg-
163.  This residue interacts with 23S rRNA nucleotide A2062 to initiate a relay that ultimately results in the 
PTC inactivation through a ratcheting of the tRNA-Gly, preventing peptidyl transfer with the A site tRNA-
Pro.  Diagram reproduced from Bhushan et al., (2011). 
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The tna operon contains a 220-nucleotide spacer region separating the stop codon of tnaC 
from the downstream tnaA start codon, as shown in Figure 1.12A, which contains many 
Rho-dependant transcription termination binding sites (Stewart et al., 1986).  If insufficient 
levels of free tryptophan are present then transcription is terminated in the leader region by 
the action of Rho factors, preventing the synthesis of the downstream tnaA and tnaB genes 
(Gong et al., 2001; Stewart et al., 1986).  However, if sufficient levels of free tryptophan 
are present then TnaC will undergo inducible arrest upon reaching the tnaC stop codon.  
This is due to the bound tryptophan inhibiting Release Factor 2-mediated hydrolysis of the 
terminal peptidyl-tRNAPro and TnaC peptidyl transfer, resulting in the stalled ribosome 
remaining attached to the mRNA transcript.  The stalled TnaC•70S complex blocks the 
Rho termination binding sites preventing downstream transcription termination and 
enabling tnaA and tnaB transcription to continue (Gong et al., 2001).   This process results 
in reduction of the free tryptophan in the cytoplasm by the subsequent action of these 
enzymes and stalling therefore only continues until non-inducing levels of tryptophan are 
restored.   
 
The exact position of tryptophan binding has not yet been confirmed, with cryo-EM 
structures of the TnaC-stalled ribosome that have so far been obtained lacking a bound 
tryptophan molecule (Seidelt et al., 2009).  However, it is believed to bind close to the 
ribosome A site, as addition of tryptophanyl-tRNATrp as the terminal residue can substitute 
for free tryptophan binding in stalling (Gong and Yanofsky, 2002).  Binding of tryptophan 
also blocks the methylation of 23S rRNA residue A2572 a nucleotide located in the 
peptidyl transferase centre indicating that it binds in this region (Cruz-Vera et al., 2006).  
More recent studies have suggested that the interaction of the TnaC residue Ile-19 with 
23S rRNA nucleotide A2058 in the ribosome exit tunnel plays an important role in the 
sensing of the tryptophan molecule by the ribosome, although it was inconclusive if this 
was by directly creating a tryptophan binding site within the ribosome exit tunnel by or 
allosterically influencing tryptophan binding at the PTC (Martinez et al., 2014). 
 
Mutational analysis identified the key arrest motif of the E.coli tna operon as: 12-
WxxxDxxIxxxxP-24 (Cruz-Vera and Yanofsky, 2008).  The terminal proline residue, Pro-
24, is located in the ribosome P site whilst the Trp-12 residue is located near the 
L4/L22exit tunnel constriction, as determined by crosslinking of Lys-11 of TnaC-tRNAPro 
to A750 of 23S RNA (Cruz-Vera et al., 2005).  These results have also subsequently been 
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Figure 1.12 Tryptophanase (tna) operon and SecM and TnaC peptides stalled on the ribosome.  A. 
Schematic representation of the tryptophanase operon indicating tnaC upstream of tnaA and tnaB on the 
mRNA, with the 220 nucleotide spacer region containing Rho transcription termination sites, separating 
them. B. Comparison of SecM and TnaC peptides stalled on the ribosome. Note SecM undergoes elongation 
arrest at residue Gly-165 with this amino acid in the P site and tRNA-Pro166 in the A site.  Although a 
peptide bond is not formed, Pro-166 is still essential for stalling.  TnaC undergoes arrest at Pro-24 only upon 
the binding of free tryptophan, the exact binding site of which is yet to be confirmed but is believed to be 
close to the ribosome A site (Gong and Yanofsky, 2002). 
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supported by the visualisation of the TnaC nascent chain stalled within the ribosome exit 
tunnel by cryo-EM (Seidelt et al., 2009).  Trp-12 of TnaC-tRNAPro is responsible for 
inducing specific alterations in the ribosomal PTC that enables free tryptophan to bind, 
resulting in peptidyl transferase inhibition (Cruz-Vera et al., 2006).  A key residue of the 
tunnel constriction point, A788, was also found to undergo reduced methylation in the 
presence of Trp12 of TnaC (Cruz-Vera et al., 2005). 
 
Cryo-EM structures revealed interesting insights into the interactions between the TnaC 
nascent chain and the ribosome, highlighting the importance of specific rRNA nucleotides.  
In particular it has shown that 23S rRNA nucleotides A2602 and U2585, which are located 
close to the PTC, adopt distinct conformations in 70S·TnaC complex and that U2585 in 
particular shifts position to interact with the essential Pro-24 residue of TnaC (Seidelt et 
al., 2009).  The positioning of A2602 and U2585 in the 70S·TnaC complex conflicts with 
any potential binding of release factors (Laurberg et al., 2008; Weixlbaumer et al., 2008), 
suggesting that even if the RFs bound, correct positioning of their GGQ motif within the 
PTC would be unable to occur, thereby preventing efficient hydrolysis and release of the 
nascent chain.  Indeed, previous studies have highlighted the importance of A2602 in 
peptidyl-tRNA hydrolysis and nascent chain release from the ribosome (Polacek et al., 
2003; Youngman et al., 2004), whilst other studies have revealed that mutation of the 
U2585 region of rRNA results in a reduction of the maximum level of tnaC operon 
induction (Yang et al., 2009). 
 
Similarly to SecM, the positioning of the TnaC nascent chain within the ribosome exit 
tunnel is critical for stalling, with the exact spacing between amino acid residues, Pro-24 
and Trp-12, shown to be essential for stalling (Gong and Yanofsky, 2002).  Cryo-EM 
analysis of TnaC stalled RNC complexes indicate that, unlike SecM, the TnaC nascent 
chain remains in an extended conformation upon stalling (Seidelt et al., 2009).   Within the 
ribosome exit tunnel the cryo-EM structures indicated proximity between rRNA 
nucleotides G2061 and A2062 with the TnaC residues Arg-23 and Asp-21 respectively.  
Also strong density existed between the Lys-18 residue of TnaC and the U2609 and A752 
rRNA nucleotides within the tunnel wall, whilst the adjacent A751 residue is in close 
vicinity to Phe-13.  In support of these being key contacts, previous experiments have 
shown that mutation of U2609 and insertions at A751 eliminate induction of stalling by 
tryptophan (Cruz-Vera et al., 2005).  Also, as stated previously, interactions between Ile-19 
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of the TnaC nascent chain and 23S rRNA nucleotide A2058 have been shown to result in 
the creation of a tryptophan binding site within the ribosome (Martinez et al., 2014). 
 
TnaC forms two substantial contacts with the β-hairpin of ribosomal protein L22, one at 
Arg-95 of the L22 protein with Thr-9 of TnaC, with the other at the tip of the L22 loop 
placing Lys-90 and Arg-92 in close proximity of the key residue Trp-12 of TnaC.  Indeed 
Cruz-Vera et al (2005) also found that Lys-90 of ribosomal protein L22 and U2609 of 23S 
rRNA are essential for ribosome stalling, both of which are also located near the putative 
position of Trp-12 in the ribosome exit tunnel.  It is interesting to note that Trp-155 of 
SecM is located 11 residues from the arrest point and is thought to occupy a similar 
position within the exit tunnel.  These residues are located near the constriction point 
supporting the original views that this point in the tunnel acts as a ‘discriminating gate’ and 
is involved in key interactions with the nascent chain which influence stalling 
(Nakatogawa and Ito, 2002).  
 
1.2.4 AAP – Arginine Attenuator Peptide 
The fungal arginine attenuator peptide (AAP) is a eukaryotic regulatory stalling peptide 
located in an upstream open reading frame (uORF) of mRNA specifying the small subunit 
of arginine-specific carbamoyl phosphate synthetase (Werner et al., 1985).  Like TnaC, it 
is an inducible stalling peptide and functions in response to high concentrations of arginine 
(Wang and Sachs, 1997).  As a result of AAP-mediated translation arrest the ribosome 
stalls at the AAP termination codon, resulting in a blocking of the mRNA to additional 
ribosomes preventing them from scanning downstream to the initiation codon of the 
carbamoyl phosphatase synthetase, thereby reducing expression of this enzyme (Gaba et 
al., 2001; Wang and Sachs, 1997).  This thesis focusses on N.crassa AAP, which 
modulates downstream expression of the arg-2 gene, however, it is evolutionarily 
conserved amongst fungi, with AAP homologs encoded by all uORFs of genes specifying 
the carbamoyl phosphate synthetase enzymes that have thus far been characterised in fungi 
(Baek and Kenerley, 1998; Shen and Ebbole, 1997; Werner et al., 1987).  Additionally, in 
vitro translation assays have established that N.crassa AAP can initiate Arg-mediated 
stalling of fungal, plant and animal ribosomes highlighting the conservation between these 
ribosome systems (Fang et al., 2004). 
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N.crassa AAP is 24 amino acids in length, with residues 9-20 having been identified as the 
minimum domain required to confer stalling function with the essential amino acids 
determined as: 12-DYLxxxxW-19 (Spevak et al., 2010).  In contrast to a lot of other 
stalling peptides, there was no strict requirement as to the identity of the amino acid in the 
P site of the ribosome upon translation arrest (see Table 1.1 for comparison).  Further to 
this, whilst the length of AAP peptides is conserved across different fungal species, there is 
notable sequence divergence of the AAP C-terminus (Hood et al., 2007; Spevak et al., 
2010).  As with other stalling peptides, it has been confirmed that AAP stalling is 
dependent on the amino acid sequence and not the mRNA sequence encoding it (Fang et 
al., 2000).   
 
It has been shown that binding of arginine induces AAP-mediated ribosome stalling 
through a change in conformation of the AAP nascent chain within the ribosome exit 
tunnel.  This was established by site-specific crosslinking, which indicated that at high 
concentrations of arginine, a photo-reactive crosslinker positioned at Val-7 of AAP had 
reduced reactivity with ribosomal protein L17 (L22) and increased interaction with the L4 
protein, than it did at low arginine concentrations (Wu et al., 2012).  In support of this 
interaction, cryo-EM analysis has shown that residues 6 and 7 of AAP form a contact with 
the distal extension of the L4 protein (Bhushan et al., 2010b).  The AAP nascent chain also 
appears to form a contact around residues 11 and 12 with ribosomal protein L17 (L22) and 
rRNA nucleotide A751 on one side of the tunnel and the proximal extension of L4 on the 
other.  These are key residues of AAP, as their mutation results in abolishment of stalling 
(Freitag et al., 1996; Hood et al., 2007), indicating that these are important regions of 
contact.  In addition to the interactions between AAP and the ribosomal proteins L17 (L22) 
and L4, cryo-EM analysis also identified the key interactions between the AAP nascent 
chain and specific rRNA nucleotides: U2585, A2062, A2058 and A751 (Bhushan et al., 
2010b).  As with the importance of the A2062 rRNA nucleotide contact in both SecM and 
TnaC translation arrest (Bhushan et al., 2011; Seidelt et al., 2009), the cryo-EM data for 
AAP also indicated a strong density in this region that may accommodate a specific 
orientation of this base (Bhushan et al., 2010b).  The importance of this nucleotide in 
AAP-mediated ribosome stalling is also highlighted by the fact that mutation of Ala-24, 
which is located in its vicinity, and is most likely to interact with it, abolishes stalling 
(Wang and Sachs, 1997). 
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1.2.5 Comparison of SecM, TnaC and AAP interactions with the ribosome exit tunnel 
The cryo-EM data for the three stalling peptides: SecM, TnaC and AAP highlight broad 
similarities between the main points of interaction with the rRNA and protein moieties of 
the ribosome exit tunnel, despite the lack of sequence conservation between the nascent 
chains themselves, see Figure 1.13 for an overview.  A2062 in particular, appears to play a 
key role in the stalling function of many arrest peptides, possibly forming the link between 
the nascent chain within the ribosome exit tunnel and the transfer of the stalling signal to 
the PTC to undergo translation arrest.  Other common regions of interaction appear to be 
23S rRNA nucleotides: U2585, U2609 and A751, as well as the ribosomal proteins L4 and 
L22.  The interactions between the nascent chain and the exit tunnel, despite being in 
similar regions, do not necessarily have the same degree of impact on the stalling function 
of the peptide.  For instance, all 3 peptides interacted with rRNA nucleotide U2585, 
however, whilst mutations in this region significantly reduce TnaC stalling (Yang et al., 
2009), they are shown to have a less notable effect on SecM stalling (Bhushan et al., 
2011).  Therefore despite the overall commonalities between the stalling peptides, it is 
believed that each undergoes a unique series of interactions with the ribosome exit tunnel 
to induce stalling. 
 
1.2.6 Other translation arrest peptides 
1.2.6.1 Antibiotic-induced stalling peptides 
As well as the 3 stalling peptides focussed on in this thesis, there exists a growing number 
of other peptides which have been identified as undergoing translation arrest, all with 
various different functions and modes of arrest.  For instance, there are a subset of bacterial 
stalling peptides which undergo arrest only in the presence of specific antibiotics 
(reviewed in (Ramu et al., 2009).  Translation arrest of these drug-dependent ribosome 
stalling peptides results in upregulation of antibiotic resistance genes.  Of the antibiotic-
dependant translation arrest peptides, the Erm-leader peptide class is one of the best 
characterised.  Erythromycin and other macrolide antibiotics bind to the ribosome exit 
tunnel in close proximity to the PTC, inhibiting translation by constricting the tunnel and 
thus impeding the path of the nascent chain, ultimately resulting in peptidyl-tRNA drop-off 
(Menninger, 1985; Tenson et al., 2003).  Erm methyltransferases, encoded by the erm 
gene, function by dimethylating the 23S rRNA nucleotide A2053, which is located at the  
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Figure 1.13 Comparison of cryo-EM data of AAP, TnaC and SecM peptides arrested within the ribosome exit tunnel. Highlighted are the regions of specific interactions between 
the nascent chain and the ribosome exit tunnel.  Diagrams modified from Bhushan et al., (2010b) and Bhushan et al., (2011).
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drug binding site, which in turn renders ribosomes resistant to macrolide binding (Skinner 
et al., 1983).   
 
A well-defined Erm-leader peptide is ErmCL, a 19 amino acid leader peptide found in 
Staphylococcus aureus and other bacteria, which induces expression of the downstream 
ermC gene (Gryczan et al., 1980; Horinouchi and Weisblum, 1980).  In the absence of 
erythromycin the full length ErmCL peptide is translated, whilst translation of ermC is 
attenuated as the Shine-Dalgarno sequence is masked by the mRNA secondary structure.  
The essential amino acid arrest motif of ErmCL has been shown to be composed of 6-
IFVI-9, with Ile-9 situated in the ribosome P site upon arrest (Mayford and Weisblum, 
1989).  Stalling causes alteration of the mRNA secondary structure which exposes the 
Shine-Dalgarno sequence of ermC resulting in the activation of its expression.  The N-
terminal 5 amino acids can be mutated but cannot be deleted, indicating that they 
contribute essential, but non-specific, interactions within the exit tunnel (Vazquez-Laslop 
et al., 2008).  Evidence of interactions within the exit tunnel is supported by the fact that 
deletion of Met-82 to Arg-84 in ribosomal protein L22 and mutation of rRNA residue 
A2062 alleviate the elongation arrest (Vazquez-Laslop et al., 2008). 
 
The role of the antibiotic was initially believed to be relatively non-specific, serving only 
to act as a partial obstruction within the ribosome exit tunnel causing the nascent chain to 
subtly alter course, resulting in key interactions between the nascent chain and the exit 
tunnel to induce translation arrest.  However, it now appears that it may play a dual role, 
both in modifying the path of the nascent chain but also in preparing the PTC for stalling 
through allosteric modification of key 23S rRNA nucleotides.  Studies have shown that 
binding of the antibiotic to the ribosome exit tunnel results in repositioning of the rRNA 
nucleotides U2585 and A2602, even in the absence of contacts between the nascent chain 
and the antibiotic, indicating it is the antibiotic and not the nascent chain that predisposes 
the PTC for stalling (Sothiselvam et al., 2014).  Studies previous to this had indicated that 
may be the case, for example studies on ErmCL revealed that the specific atomic structure 
of the antibiotic and the interactions it undertakes with either the nascent chain or the 
ribosome were essential for stalling (Vazquez-Laslop et al., 2011).  Whilst the common 
peptide-sensing rRNA nucleotide A2062, as well as U1782, interact with the peptide, other 
rRNA nucleotides, C2610 and A2503, were found to be responsible for recognition of the 
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antibiotic.  Successful translation arrest required generation of an arrest signal from both 
correct recognition of the antibiotic and the nascent chain (Vazquez-Laslop et al., 2011). 
 
Cryo-EM structures of the antibiotic-induced leader peptide, ErmBL, stalled on the 
ribosome have recently been elucidated and support a role for antibiotic binding in altering 
the path of the nascent chain within the exit tunnel (Arenz et al., 2014) (see Figure 1.14).  
The amino acid sequence of this peptide varies considerably from ErmCL, as does its 
mechanism of action, for instance, whilst mutation of 23S rRNA nucleotides A2062 and 
A2503 abolishes stalling of ErmAL1 and ErmCL leader peptides, it has no influence on 
ErmBL and ErmDL arrest (Vazquez-Laslop et al., 2010).  The cryo-EM study conclusively 
revealed binding of erythromycin created a constriction within the exit tunnel causing the 
path of the nascent chain to be altered.  This in turn resulted in the nascent chain forming 
stable contacts with specific 23S rRNA nucleotides in the tunnel wall.  In particular, Arg-7 
interacts with U2586 whilst Val-9 and Asp-10 contact the PTC at U2585.  This ultimately 
resulted in the stabilisation of the uninduced state of U2585, which in turn blocked 
accommodation of tRNA-Lys11 in the ribosome A site, thus preventing peptide bond 
formation and resulting in stalling of the ribosome (Arenz et al., 2014). 
 
As more cryo-EM structures of translation arrest peptides are obtained it will be highly 
interesting to discover how the relay pathways they undergo to communicate between the 
nascent chain and the PTC vary.  As can be seen from the structures obtained already, 
whilst there seems to be a general consensus of interacting nucleotides, each stalling 
peptide appears to utilise a distinct message relay system to induce translation arrest. 
 
1.2.6.2 Experimentally obtained stalling peptides 
Due to the diversity of amino acid stalling sequences it is impossible to develop a 
bioinformatics program to efficiently identify potential arrest sequences from genomic 
libraries.  As an alternative, researchers have instead sought to identify novel stalling 
sequences through experimental methods.  Indeed through one such experimental 
screening of random libraries, the novel stalling sequence FxxYxIWPPP was identified 
(Tanner et al., 2009).  Similarly to the method of SecM arrest, the final proline remains in 
the A site and is not incorporated into the nascent chain upon arrest.  Unlike SecM  
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A.                                         B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 ErmBL in the ribosome exit tunnel. A. Schematic of the cryo-EM visualisation of ErmBL in 
the absence of erythromycin and B. in the presence of erythromycin, indicating the influence of erythromycin 
binding to the exit tunnel resulting in the alteration of the path of the nascent chain.  This subsequently 
enables the formation of new, stable interactions of the nascent chain with the exit tunnel resulting in the 
induction of stalling.  Diagram reproduced from Arenz et al., (2014). 
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however, tRNA-Asp and tRNA-Trp can substitute for the final proline and still undergo 
arrest.  The results also indicate that the nascent chain undergoes a unique set of 
interactions with the ribosome exit tunnel as this novel peptide has differing responses to 
exit tunnel mutations in comparison to SecM or TnaC. 
 
1.2.6.3 Mammalian uORFs encoding stalling peptides 
There have been a small number of stalling peptides identified in mammalian cells that can 
undergo translation arrest.  One such peptide is XBP1u, a mammalian translational arrest 
peptide that when activated encodes XBP1s, a transcription factor responsible for 
transcribing genes involved in the endoplasmic reticulum (ER) stress response (Pavitt and 
Ron, 2012).  To be activated the XBP1u mRNA must be translocated to the ER membrane 
where a 26-nucleotide intron is spliced by the transmembrane endoribonuclease, Ire1α, to 
generate XBP1s mRNA (Yoshida et al., 2001).  Localization requires a hydrophobic 
region, HR2 (codons 186-208), a membrane-targeting signal that is only present in the 
XBP1u protein (total length - 261 codons) (Yanagitani et al., 2009).  The purpose of 
translational stalling is to ensure that the peptide sequence, HR2, maintains localization of 
the mRNA at the ER membrane thus enabling efficient splicing of the XBP1u mRNA 
(Yanagitani et al., 2011).  During translation arrest, Asn-261 is located in the ribosome A 
site (Ingolia et al., 2011), with serial truncation analysis demonstrating that the C-terminal 
region Lys-236 to Asn-261 constitutes the minimal sequence required for arrest, whilst 
alanine-scanning mutagenesis identified 14 specific amino acid residues as being essential 
for arrest (Yanagitani et al., 2011).  The essential arrest motif was determined as 236-
xxxxxYxPPxLxxWGxHQxSWKPLMN-261, whilst L246A and W256A mutations in 
particular were shown to strongly abolish translational stalling (Yanagitani et al., 2011).  
Translational stalling of XBP1u is fundamental to enable mRNA splicing and therefore 
enable translation of the active transcription factor XBP1s. 
 
Another mammalian stalling peptide that has been identified is the uORF leader peptide of 
polyamine biosynthetic enzyme S-adenosyl-methionine decarboxylase (AdoMetDC).  This 
uORF encodes a hexapeptide MAGDIS and is feedback repressed by polyamines, the exact 
mechanism of which still needs to be identified (Hill and Morris, 1993).  Stalling occurs at 
the point of translation termination (Law et al., 2001), with Ser-tRNA situated in the 
ribosome P site, and prevents ribosomal scanning to the downstream initiation codon 
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(Raney et al., 2002).  Mutational analysis of the sequence specificity indicates that the 
aspartic acid must be present at codon 4, whilst either isoleucine or valine can function at 
codon 5, meanwhile the identity of the other residues appears less stringent (Mize et al., 
1998).   
 
From these two examples alone the variation in mammalian stalling peptides is evident and 
further research is required to clearly define the abundance and determine the various 
mechanisms of action of stalling peptides in mammalian cells.  Despite the relatively late 
evolutionary emergence of translational arrest peptides it is clear that they play important 
roles throughout all domains. 
 
1.2.6.4 Summary of translation arrest peptides 
This introduction has selected just a few relevant examples of translation arrest peptides 
and does not cover the large array of divergent stalling peptides that have so far been 
identified.  From those featured it is clear that stalling peptides are diverse in both their 
amino acid sequences and their interactions with the ribosome.  There are, however, some 
commonalities which can be observed, for instance, in the proximity of the PTC, 23S 
rRNA nucleotides A2062 and U2585 are common interaction points for many stalling 
peptides to relay arrest signals to the PTC.  What is not known is whether the relay 
pathway back to the PTC that follows is always the same, and certainly the subsequent 
behaviour of the peptides within the PTC to implement stalling is different.  For instance, 
SecM tRNA-Gly undergoes a ratcheting movement that moves it away from the A site 
tRNA-Pro and obstructs peptide bond formation, which is not seen in the other stalling 
peptides.  Further down the length of the exit tunnel near the tunnel constriction point there 
are further common interactions with the ribosomal proteins L4 and L22 (L17) as well as 
23S rRNA nucleotide A751, with interactions in this area appearing to have an important 
role in nascent chain conformation within the ribosome exit tunnel.  These interactions 
have implications on stalling despite the distance from the PTC.   
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1.3 Project Aims 
The aims of this project are to investigate the properties of translational arrest motifs and 
ribosome interactions with the nascent chain during translation.  Chapter 3 of this project 
will examine the sequence specificity of the SecM translation arrest motif and the 
properties of the amino acids which are essential for their interaction with the ribosome 
exit tunnel.  This will be done through analysis of systematic mutations of the key arrest 
motif residues of SecM to both alanine and conservative residues by CTABr precipitation 
assays (as detailed in Section 2.5.3), enabling direct analysis of the level of stalling of 
these mutant peptides in comparison to wild type SecM, to determine the effect of the 
mutations.  It will also explore the influence of the structure of SecM by increasing the 
freedom of movement of the nascent chain within the exit tunnel, the importance of which 
was initially highlighted in previous studies by Woolhead et al., (2006).  Following on 
from this Chapter 4 will explore the compaction of the SecM nascent chain within the exit 
tunnel upon stalling.  This will be done through analysis of selected conservative mutations 
by pegylation assays (see Section 2.5.4) and will also be expanded further to investigate in-
depth the effect of the flexibility of the nascent chain within the exit tunnel on translation 
arrest.  Use of pegylation as a technique enables direct measurement of the level of 
compaction of the nascent chain within the full length of the ribosome exit tunnel as will 
be explained further in Chapter 4. 
 
Chapter 5 will expand the scope of this thesis to investigate the specificity of translation 
arrest motifs of both prokaryotic and eukaryotic translation arrest peptides and explore the 
ability of these peptides to undergo stalling in ribosomes of alternative domains.  This is an 
area in which past studies have yet to provide any conclusive answers.  This study will 
draw clear conclusions through the use of two different assays, CTABr precipitation, as 
employed previously in Chapter 3, and a puromycin release assay (detailed in Section 
2.5.5).  Finally, Appendix 1 presents preliminary experimental evidence of SecM arrest 
sequence application, based on the knowledge gained from the study of SecM, to generate 
stable constructs containing proteins of interest attached to the N-terminus of the SecM 
arrest motif.  These SecM arrest motifs will be modified and tested to identify alterations 
that result in prolonged translation arrest.  The purpose of this is to create stable ribosome-
nascent chain complexes that enable the timing and process of co-translational protein 
folding and exit from the ribosome tunnel of different proteins of interest to be 
investigated.   
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2 Materials and Methods 
2.1 General reagents 
Agilent Technologies UK Ltd., Wokingham, Berkshire, UK 
PfuTurbo DNA Polymerase; QuikChange Multi Site-Directed Mutagenesis Kit; 
QuikChange Site-Directed Mutagenesis Kit 
 
BioRad Laboratories Ltd., Hemel Hempstead, Hampshire, UK 
Agarose 
 
Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK  
Ammonium persulphate (APS); Ethylenediaminetetraacetic acid (EDTA); Glucose; 
Glycerol; Glycine; Methanol; Potassium hydroxide (KOH); Sucrose; Tris base 
 
Formedium Ltd., Hunstanton, Norfolk, UK  
Bacterial Agar; Tryptone; Yeast Extract Powder  
 
Integrated DNA Technologies, Leuven, Belgium 
Oligonucleotide primers 
 
Invitrogen Ltd., Paisley, UK  
PureLink PCR Purification Kit; SeeBlue Pre-stained Standard 
 
Kodak, Hemel Hempstead, Hertfordshire, UK  
X-ray film  
 
Melford Laboratories Ltd., Chelsworth, Ipswich, UK  
Dithiothreitol (DTT); Isopropyl-β-D-thiogalactopyranoside (IPTG) 
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Merck Millipore, Billerica, MA, USA 
Amicon Ultra 0.5 ml Centrifugal Filters (10K); Cetyltrimethylammonium bromide;           
di-Potassium hydrogen phosphate (K2HPO4) 
 
New England Bioscience (UK) Ltd., Hitchin, Hertfordshire, UK  
100 mM dNTPs (dATP, dCTP, dGTP, dTTP); 10x T4 DNA Ligase Buffer; T4 DNA 
Ligase; Prestained Protein Marker, Broad Range (7-175 kDa) 
 
PerkinElmer, Cambridge, UK 
EXPRESS Protein Labelling Mix (35S Met) 
 
Promega, Southampton, UK  
1 kb DNA Ladder; 100 bp DNA Ladder; 100 mM rNTPs (rATP, rCTP, rGTP, rUTP); 
Bovine Serum Albumin (BSA); Dithiothreitol (DTT); E. coli S30 Extract System for 
Linear Templates; HindIII; KpnI; Mfe1; Recombinant RNasin Ribonuclease Inhibitor; 
RNA Polymerase Transcription Buffer; SP6 RNA Polymerase; T7 RNA Polymerase; 
Wheat Germ Extract; XbaI 
 
Qiagen Ltd., Crawley, West Sussex, UK  
Nuclease-free Water; QIAquick Gel Extraction Kit; QIAprep Spin Miniprep Kit 
 
Roche Diagnostic Ltd., Burgess Hill, UK  
Creatine kinase; Dpn1; tRNA from E. coli MRE 600 
 
Severn Biotech Ltd., Kidderminster, Worcestershire, UK  
30 % Acrylamide [Acrylamide: Bis-acrylamide ratio 37.5:1] 
 
Sigma-Aldrich Ltd., Gillingham, Dorset, UK  
Adenosine 3′,5′-cyclic monophosphate (cAMP); Adenosine 5′-triphosphate (ATP);  
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Ammonium persulphate; Ampicillin; β-mercaptoethanol; Brilliant blue; Bromophenol 
blue; Calcium chloride (CaCl2); Creatine phosphate; Ethidium bromide; Folinic acid; 
Hydrochloric acid; Isopropanol; L-Amino acids; L-Glutathione oxidised; Lysozyme; 
Magnesium acetate (MgOAc); Methoxypolyethylene glycol maleimide (PEG-mal); 
N,N,N’,N’-Tetramethylethylenediamine (TEMED); PIPES; Phosphoenol pyruvate; 
Poly(ethylene glycol) MW 8000; Potassium Glutamate (KGlu); Puromycin; Pyruvate 
kinase from Bacillus stearothermophilus; Phenylmethylsulphonyl fluoride (PMSF); 
Ribonuclease A from bovine pancreas; Tricine 
 
Takara Bio Europe, Saint-Germain-en-Laye, France 
Ex Taq DNA Polymerase; Ex Taq DNA Polymerase Buffer 
 
Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA 
Slide-A-Lyzer Dialysis Cassette 3,500 MWCO 
 
VWR International Ltd., Lutterworth, Leicestershire, UK  
Acetone; Ammonium acetate (NH4OAc); Disodium hydrogen orthophosphate (Na2HPO4); 
Ethanol; Glacial acetic acid; 2-(4-(2-Hydroxyethyl) -1-piperazinyl)-ethanesulphonic acid 
(HEPES); Magnesium chloride (MgCl2); Potassium acetate (KOAc); Potassium 
dihydrogen orthophosphate (KH2PO4); Potassium chloride (KCl); Sodium acetate 
(NaOAc); Sodium chloride (NaCl); Sodium dodecyl sulphate (SDS); Trichloroacetic acid 
(TCA) 
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2.2 General buffers and solutions 
 
Competent cell buffer 60 mM CaCl2, 15% (v/v) glycerol, 10 mM PIPES (pH 7).  
 
Gel fixing solution 40% (v/v) methanol, 7% (v/v) Glacial acetic acid.  
 
6x DNA loading buffer 30% (v/v) glycerol, 0.25% (w/v) bromophenol blue.  
 
LB media 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl.   
 
LB agar 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 
1.5% (w/v) agar. 
 
PEG buffer   20 mM HEPES (pH 7.2), 100 mM NaCl, 5 mM MgCl2. 
 
RNC (Ribosome Nascent 20 mM HEPES (pH 7.5), 14 mM MgOAc, 100 mM KOAc. 
Chain) buffer  
 
Run-out premix 0.75 mM HEPES (pH 7.5), 7.5 mM DTT, 21.3 mM MgOAc, 
75 µM each amino acid, 6 mM ATP, 20 mg/mL phosphoenol 
pyruvate, 0.14 mg/mL pyruvate kinase. 
 
2x SDS PAGE Sample 125 mM Tris-HCL (pH 6.8), 20% (v/v) glycerol, 4% (w/v)  
Buffer   SDS, 5% 2-mercaptoehtanol, 0.04 % (w/v) bromophenol 
blue. 
 
SDS-PAGE resolving gel 375 mM Tris (pH 8.8), 12.5% Acrylamide, 0.1% (w/v) SDS, 
solution  0.05% (v/v) ammonium persulphate, 0.005% (v/v) TEMED. 
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10x SDS-PAGE running 0.25 M Tris, 1.92 M glycine, 1% (w/v) SDS.   
buffer   
     
SDS-PAGE stacking gel 125 mM Tris (pH 6.8), 6% Acrylamide, 0.1% (w/v) SDS, 
solution  0.05% (v/v) ammonium persulphate, 0.005% (v/v) TEMED. 
 
S-30 extract Buffer 1 20 mM HEPES (pH 7.5), 14 mM MgOAc, 100 mM KCl,     
6 mM β-mercaptoethanol, 0.5 mM PMSF. 
 
S-30 extract Buffer 2 20 mM HEPES (pH 7.5), 14 mM MgOAc, 100 mM KCl,     
1 mM DTT, 0.5 mM PMSF. 
 
S-30 extract Buffer 3 20 mM HEPES (pH 7.5), 14 mM MgOAc, 100 mM KOAc,  
1 mM DTT, 0.5 mM PMSF. 
 
SOC media 2 % (w/v) Tryptone, 0.5 % (w/v) Yeast Extract, 0.05 % (w/v) 
NaCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM Glucose. 
 
50x TAE buffer 2 M  Tris, 5.71 % (v/v) glacial acetic acid, 0.05 M EDTA 
(pH 8.0).  
 
2.5x Translation premix 137.5 mM HEPES (pH 7.5), 520 mM KGlu, 68.75 mM 
NH4OAc, 48.25 mM MgOAc, 4.25 mM DTT, 3 mM ATP, 2 
mM each rNTPs, 625 µg/mL creatine kinase, 200 mM 
creatine phosphate, 444 µg/mL E. coli tRNA, 2 mM IPTG, 
60 mg/mL PEG 8000, 170 µM folinic acid, 1.6 mM cAMP. 
 
10x Tricine gel Anode 1 M Tris, 1 M tricine, 1% (w/v) SDS. 
running buffer 
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10x Tricine gel Cathode 2 M Tris (pH 8.9). 
running buffer 
 
Tricine separating gel 496 mM Tris (pH 8.45), 8.4% Acrylamide, 6.5% (v/v)  
solution  glycerol, 0.07% (v/v) ammonium persulphate, 0.004% (v/v) 
TEMED. 
 
Tricine spacer gel solution 1 M Tris (pH 8.45), 10% Acrylamide, 0.07% (v/v) 
ammonium persulphate, 0.004% (v/v) TEMED. 
 
Tricine stacking gel solution 750 mM Tris (pH 8.45), 4% Acrylamide, 0.07% (v/v) 
ammonium persulphate, 0.004% (v/v) TEMED. 
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2.3 Escherichia coli strains and plasmid vectors 
2.3.1 Escherichia coli strains 
The following E.coli strains were used in this thesis: 
 
C41 F- ompT hsdSB (rB
- mB
-) gal dcm (DE3) 
 
DH5-α F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, 
mk
+) phoA supE44 thi-1 gyrA96 relA1 λ- 
 
MC4100  F- (araD139) Δ(argF-lac)169 λ- e14- flhD5301 Δ(fruK-
yeiR)725(fruA25) relA1 rpsL150(Strr) rbsR22 Δ(fimB-
fimE)632(::IS1) deoC1 
 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
 
XL10-Gold Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 
recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZΔM15 Tn10 (Tetr) 
Amy Camr] 
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2.3.2 Plasmid vectors 
Two plasmid vectors were used in the work detailed in this thesis, pTrc99A and pGEM-
4Z.  pTrc99A contains an inducible promoter that is chemically induced by isopropyl-β-D-
thiogalactopyranoside (IPTG) whilst pGEM-4Z, depending on the orientation of the 
inserted gene of interest, is either SP6 or T7 polymerase dependant (Figure 2.1).   
 
A full summary of all the constructs used in this study can be found in Appendix 2 whilst 
Appendix 3 contains a brief explanation of how the various SecM, AAP, TnaC and B2M 
constructs were designed and generated. 
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A. 
 
 
 
B. 
 
 
Figure 2.1 pTrc99A and pGEM-4Z plasmid maps.  A. pTrc99A plasmid vector indicating KpnI, XbaI and 
HindIII restriction sites used in this study.  B. pGEM-4Z plasmid vector indicating KpnI and XbaI restriction 
sites used in this study.  All plasmid constructs used in this thesis were in the SP6 promoter orientation. 
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2.4 General Molecular Biology Methods 
2.4.1 Preparation of LB plates 
LB-agar was autoclaved and allowed to cool before ampicillin was added to a final 
concentration of 100 µg/mL, mixed well and then the plates poured under sterile 
conditions. 
 
2.4.2 Preparation of competent bacterial cells 
Bacterial strains, either XL1-Blue or DH5α, were streaked out on a LB plate in the absence 
of antibiotics and incubated overnight (~16 hours) at 37oC.  Single colonies were picked 
and used to inoculate 5 mL LB broth which was then incubated overnight (~16 hours) in a 
shaking incubator at 37oC.  300 µL of this culture was then used to inoculate 50 mL of pre-
autoclaved LB broth and incubated with moderate shaking (250 rpm) until the Optical 
Density (OD) reached 0.375 at 595 nm.  Following this the culture was chilled on ice for 
10 minutes, before being centrifuged in sterile falcon tubes at 2,500 rpm for 7 minutes at 
4oC to pellet the bacteria.  The supernatant was removed and the pellet re-suspended in 10 
mL Competent cell buffer (see Section 2.1.2 for details) before being centrifuged again at 
2500 rpm for 5 minutes at 4oC.  Again the supernatant was discarded and the pellet was re-
suspended in 10 mL Competent cell buffer, incubated on ice for 30 minutes and then 
centrifuged at 2,500 rpm for 5 minutes at 4oC.  The pellet was then re-suspended in 2 mL 
Competent cell buffer and the cells then aliquoted into sterile eppendorf tubes, frozen on 
dry ice and stored at -80oC. 
 
2.4.3 Transformation of competent bacteria 
XL1-blue and XL10-Gold cells were used for site directed mutagenesis whilst DH5α cells 
were used for transformations of established plasmids for mini preps.  An aliquot of 
competent cells was thawed on ice and 1 µL of the relevant plasmid DNA added.  This was 
incubated on ice for 30 minutes before being heat shocked at 42oC for 2 minutes and 
returned to ice for 5 minutes.  1 mL of LB media was then added and incubated at 37oC for 
1 hour with shaking.  Following this it was then centrifuged at 7,000 rpm for 5 minutes at 
room temperature.  800 µL of the supernatant was then removed and discarded and the 
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remainder used to re-suspend the pellet.  This was then transferred to an LB-ampicillin 
plate and incubated overnight (~16 hours) at 37oC. 
 
2.4.4 Small-scale preparation of plasmid DNA (mini-prep) 
From the bacterial transformation a single colony was picked and used to inoculate 5 mL 
LB broth containing 100 µg/mL of ampicillin which was then incubated overnight (~16 
hours) in a shaking incubator at 37oC.  Plasmid DNA was purified using Qiagen QIAprep 
Spin Miniprep kit.  The overnight culture was centrifuged at 3,500 rpm for 10 minutes to 
pellet the cells.  The pellet was re-suspended in 250 µL Buffer P1 and transferred to a 
sterile eppendorf tube.  Cells were lysed by addition of 250 µL Buffer P2, which was then 
neutralised after 5 minutes by addition of 350 µL Buffer N3.  The sample was then 
centrifuged at 13,400 rpm for 10 minutes and the supernatant transferred to a QIAprep spin 
column.  The columns were centrifuged at 13,400 rpm for 1 minute, the flow-through 
discarded and the column washed with 750 µL Buffer PE and again centrifuged at 13,400 
rpm for 1 minute.  The flow-through was again discarded and the column spun again at 
13,400 rpm for 2 minutes to remove residual wash buffer.  The plasmid DNA was eluted 
into a sterile eppendorf by addition of 100 µL nuclease-free water to the column and 
centrifugation at 13,400 rpm for 1 minute.  Plasmid DNA was then stored at -20oC. 
 
2.4.5 Polymerase chain reaction 
2.4.5.1 DNA amplification by Polymerase Chain Reaction (PCR) 
Forward and reverse oligonucleotide primers were designed to amplify the DNA sequence 
of interest, including any appropriate restriction enzyme cut sites.  All primers used in this 
study were synthesised by Integrated DNA Technologies.  PCR reactions were set up in 
thin-walled PCR tubes on ice, using either plasmid or genomic DNA as a template.  PCR 
reactions were set up using the following general protocol: 
 
DNA template  (~1 µg/µL)     1 µL   
Forward primer (100 pMol)     1 µL  
Reverse primer (100 pMol)     1 µL 
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10x DNA polymerase buffer     10 µL 
dNTP mix (2.5 mM each: dATP, dCTP, dGTP, dTTP) 8 µL 
Ex Taq DNA Polymerase     0.5 µL 
ddH2O        78.5 µL 
 
PCR reactions were out in a thermocycler using the following standard conditions: 
 
94oC  (Initial denaturing)  1 minute 
 
94oC (Denaturing)   30 seconds 
56oC (Primer annealing)  30 – 60 seconds 30 Cycles 
72oC (Elongation)   2 minutes/kb 
 
72oC  (Final elongation)  8 minutes 
4oC     Hold 
 
This standard protocol could be adjusted to account for the melting temperatures of the 
primers being used.  Generally the optimal annealing temperature is 5oC lower than the 
lowest melting temperature of the primers. 
 
Once the PCR was complete the products were PCR purified (see Section 2.2.6) and run on 
an agarose gel (see Section 2.2.7) to confirm that a product of the correct size was 
obtained.   
 
2.4.5.2 Site-directed mutagenesis PCR 
2.4.5.2.1 Single point mutations 
Single point mutations were inserted into constructs using the QuikChange Site-Directed 
Mutagenesis kit (Agilent).  Forward and reverse primers were designed according to the 
74 
 
manufacturer’s instructions to incorporate the desired mutation.  PCR reactions were set up 
in thin-walled PCR tubes on ice as follows: 
 
Plasmid DNA template (~1 µg/µL)    1 µL 
Forward primer (100 pMol)     1 µL  
Reverse primer (100 pMol)     1 µL 
10x reaction buffer      5 µL 
dNTP mix (10 mM each: dATP, dCTP, dGTP, dTTP) 1 µL 
PfuTurbo DNA polymerase     1 µL 
ddH2O        41 µL 
 
Once set up the PCR was performed in a thermocycler using the following program: 
 
95oC  (Initial denaturing)  30 seconds 
 
95oC (Denaturing)   30 seconds 
58oC (Primer annealing)  1 minute  18 Cycles 
72oC (Elongation)   1 minute/kb  
 
72oC  (Final elongation)  10 minutes 
4oC     Hold 
 
Once complete the PCR products were treated with 1 µL Dpn1 restriction enzyme and 
incubated for 1 hour at 37oC, to digest methylated parental DNA.  1 µL of reaction mix 
was then transformed into 50 µL competent XL-1 blue cells (see Section 2.2.3).  Following 
incubation of agar plates overnight, single colonies were picked and grown in 5 mL LB-
broth containing 100 µg/mL of ampicillin overnight (~16 hours) in a shaking 37oC 
incubator.  The following day plasmids were isolated by small-scale DNA preparation (see 
75 
 
Section 2.2.4), before being sent for sequencing to confirm the correct mutation had been 
obtained (see Section 2.2.11).  
 
2.4.5.2.2 Multiple point mutations 
Multiple point mutations to the same construct were done simultaneously using the 
QuikChange Multi Site-Directed Mutagenesis kit (Agilent).  Only forward primers were 
required and were designed according to the manufacturer’s instructions to incorporate the 
desired mutation.  PCR reactions were set up in thin-walled PCR tubes on ice as follows: 
 
Plasmid DNA template  (~1 µg/µL)    1 µL 
Forward primer (100 ng 1-3 primers or 50 ng 4-5 primers) 1 µL of each 
10x reaction buffer      2.5 µL 
dNTP mix (10 mM each: dATP, dCTP, dGTP, dTTP) 1 µL 
QuikChange Multi enzyme blend    1 µL 
ddH2O        Final volume of 25 µL 
 
PCR was performed in a thermocycler using the following program: 
 
95oC  (Initial denaturing)  1 minute 
 
95oC (Denaturing)   1 minute 
58oC (Primer annealing)  1 minute  30 Cycles 
72oC (Elongation)   2 minutes/kb  
 
4oC     Hold 
 
Once complete the PCR products were treated with 1 µL Dpn1 restriction enzyme and 
incubated for 1 hour at 37oC, to digest methylated parental DNA.  1 µL of reaction mix 
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was transformed into 50 µL competent XL-10 Gold ultracompetent cells (see Section 
2.2.3).  Single colonies were picked from the antibiotic LB-agar plates and grown in 
overnight cultures before plasmids were isolated the following day by small-scale DNA 
preparation (see Section 2.2.4).  Following this they were sent for sequencing to confirm 
incorporation of the correct mutations (see Section 2.2.11).  
 
2.4.6 Purification of PCR products 
PCR products were purified using the PureLink PCR Purification Kit (Invitrogen).  To 
bind DNA to the column 1 volume of PCR sample was mixed with 4 volumes of Binding 
Buffer (B2) in an eppendorf.  This was then transferred to a PureLink Spin Column and 
centrifuged at 13,400 rpm for 1 minute.  The flow-through was discarded and the column 
washed with 650 µL Wash Buffer and centrifuged at 13,400 rpm for 1 minute.  Again the 
flow-through was discarded and the column centrifuged at 13,400 rpm for 2 minutes to 
remove any residual wash buffer.  The collection tube was then transferred to a fresh 
eppendorf and the PCR product eluted by applying 50 µL ddH2O to the column and 
centrifuging at 13,400 rpm for 1 minute.  The PCR product was run on an agarose gel (see 
Section 2.2.7) to confirm the purification was successful and the correct size of PCR 
product had been produced. 
 
2.4.7 DNA agarose gel electrophoresis 
1% (w/v) agarose powder was dissolved in 1x TAE buffer (see Section 2.1.2 for details) by 
boiling in a microwave, and then allowed to cool before addition of 0.5 µg/mL ethidium 
bromide.  This was then poured into a sealed horizontal gel tank containing a loading comb 
and allowed to set before being immersed in 1x TAE buffer and the loading comb 
removed.  DNA samples were prepared by addition of 6x Loading buffer before being 
loaded onto the gel and run beside either a 100 bp or 1 kb DNA ladder (Promega).  
Electrophoresis was carried out at 100 volts for ~30 minutes and the gel was visualised, 
and images recorded, using a BioRad Molecular Imager ChemiDoc XRS+ System. 
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2.4.8 DNA purification from agarose gels 
DNA samples were separated by gel electrophoresis (see Section 2.2.7) and purified by gel 
extraction using the QIAquick Gel Extraction Kit (Qiagen).  The gel was visualised on a 
UV light box and bands of the correct size were excised with a sharp scalpel and placed in 
sterile eppendorf tubes.  3 volumes of Buffer QG per 1 volume of gel was added and 
incubated at 50oC for 10 minutes or until the gel was completely dissolved.  Once the gel 
was dissolved 1 volume of isopropanol was added and mixed before the solution was 
transferred to a 2 mL collection tube and centrifuged at 13,400 rpm for 1 minute.  The 
flow-through was discarded and the column washed with 0.75 mL Buffer PE and 
centrifuged at 13,400 rpm for 1 minute.  Again the flow-through was discarded and the 
column spun for an additional 2 minutes at 13,400 rpm to remove any residual wash 
buffer.  The column was then transferred to a sterile eppendorf and the DNA eluted by 
addition of 30 µL of ddH2O to the centre of the column and spinning at 13,400 rpm for 1 
minute, before being stored at -20oC. 
 
2.4.9 Restriction endonuclease digestion 
Pairs of restriction enzymes were selectively chosen to cut plasmid DNA or PCR products 
at specific sites.  Restriction digestions were set up as follows: 
 
Plasmid DNA/PCR product  (~1 µg/µL)    10 µL 
Restriction enzyme buffer (as recommended by manufacturer) 1.5 µL 
Restriction enzyme 1       0.5 µL 
Restriction enzyme 2 (optional)     0.5 µL 
10x BSA (as recommended by manufacturer)   1.5 µL 
ddH2O         Final volume 15 µL 
 
Reactions were incubated at 37oC for 1 hour and then, depending on manufacturer’s 
instructions, heat inactivated at 65oC for 20 minutes.  Samples were then stored in the 
short-term at 4oC or for longer periods of time at -20oC.   
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2.4.10 Ligation of DNA 
Plasmid vectors and PCR products cut using the same pair of restriction enzymes were run 
on an agarose gel and then purified by gel extraction (see Section 2.2.8) before being 
ligated as follows: 
 
10x T4 DNA ligase buffer   2 µL 
T4 DNA ligase    1 µL 
Insert DNA - PCR product (~1 µg/µL) 6 µL 
Vector DNA - Plasmid (~1 µg/µL)  1 µL 
ddH2O      10 µL 
 
Reactions were incubated at room temperature for 1 hour before being transformed into 
competent DH5α cells as previously described in Section 2.2.3.  The plasmid was isolated 
by small-scale DNA preparation as described earlier (see Section 2.2.4) and sent for 
sequencing (see Section 2.2.11) to confirm the ligation had been successful. 
 
2.4.11 DNA sequencing 
Plasmid DNA to be sequenced was mini-prepped and samples sent to the Sequencing 
Service at the School of Life Sciences, University of Dundee.  Results were analysed by 
comparison to known nucleotide sequences using BLAST and the Swiss Institute of 
Bioinformatics (SIB) ExPASy translate online software.   
 
2.4.12 In vitro transcription 
RNA was transcribed from linear DNA as follows.  The reactions were set up in thin-
walled PCR tubes and incubated for 2 hours at 42oC: 
 
Linear DNA  (~1 µg/µL)     5 µL 
5x Transcription buffer     10 µL 
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1 M DTT       2 µL 
RNasin (20 units)      1 µL 
rNTP mix (25 mM each: rATP, rCTP, rGTP, rUTP)  6 µL 
SP6/T7 polymerase      2 µL 
ddH2O        24 µL 
 
Synthesised RNA was precipitated by adding 0.1 volumes of 3M NaOAc (pH 5.2) and 3 
volumes 100% ethanol and incubating on ice for 10 minutes.  This was then centrifuged at 
13,400 rpm for 10 minutes.  The supernatant was discarded and the pellet washed with 250 
µL 70% ethanol and centrifuged for a further 10 minutes at 13,400 rpm.  The supernatant 
was again discarded and the pellet was re-suspended in 50 µL ddH20, which was then 
aliquoted and stored at -80oC.  Small samples were removed and run on agarose gel (see 
Section 2.2.7) to confirm the RNA was the correct size. 
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2.5 In vitro translation methods 
2.5.1 S-30 bacterial cell extract preparation 
C41 cells from glycerol stocks were streaked out onto an antibiotic-free agar plate and 
incubated overnight (~16 hours) at 37oC.  From this 2 individual colonies were picked and 
grown in separate 5 mL LB-broth cultures overnight (~16 hours).  The next day these were 
used to inoculate separate 500 mL cultures of SOC media (see Section 2.1.2 for details of 
all the buffers used in this preparation).  The cells were incubated at 37oC in a shaking 
incubator and grown until they reached mid-log phase, A600 = 0.8.  Once this was reached 
the cultures were added to 1 litre of ice and then centrifuged at 7,000 rpm for 10 minutes at 
4oC.  The supernatant was then discarded and the pellet re-suspended in 100 mL of Buffer 
1 and then centrifuged again at 7,000 rpm for 10 minutes at 4oC.  The supernatant was 
discarded and the pellet re-suspended in 100 mL Buffer 1 and again centrifuged at 7,000 
rpm for 10 minutes at 4oC.  After removal of the supernatant the wet cell mass was 
weighed and the pellet was re-suspended in Buffer 2 at a concentration of 0.5 g/mL.  
Lysozyme was then added to a final concentration of 1 mg/mL and the cells then passed 
twice through a French Press at 8,000 psi.  The extract was then centrifuged at 15,000 rpm 
for 30 minutes at 4oC before transferring the supernatant to a fresh tube and again 
centrifuging at 15,000 rpm for 30 minutes at 4oC.  The supernatant was again retained and 
incubated at 26oC for 70 minutes with 0.15 volumes of Run-out premix.  Following this the 
extract was dialysed 3 times in Buffer 3, for a minimum of 1 hour each, using a Slide-A-
Lyzer Dialysis Cassette 3,500 MWCO.  Following this the extract was centrifuged at 
14,000 rpm for 10 minutes at 4oC and then aliquoted, snap frozen and stored at -80oC. 
 
2.5.2 Translation reactions 
2.5.2.1 E.coli in vitro transcription-translation reactions 
Standard 25 µL translation reactions were set up as follows, although volumes could be 
altered accordingly depending on the final volume.  Note full radiation protection 
procedures were followed for all reactions containing 35S-labelled methionine. 
 
Linear DNA  (~1 µg/µL)     2.5 µL 
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Translation premix      10 µL 
1 mM each L-amino acid (except methionine)  2.5 µL 
S-30 extract       7.5 µL 
[35S] methionine       10 µCi 
5 µg/µL anti-ssrA oligonucleotide     1 µL 
(5’-TTAAGCTGCTAAAGCGTAGTTTTCGTCGTTTGCGACTA-3’) 
 
Reactions were incubated at 37oC for 30 minutes and then chilled on ice for 5 minutes to 
stop translation.  Translation products were then assayed as detailed in sections: 2.3.3 - 
2.3.6. 
 
2.5.2.2 Wheat Germ translation reactions 
Wheat Germ translation reactions were carried out using the Promega Wheat Germ Extract 
kit.  50 µL reactions were set up as follows, although larger translations could be 
performed by adjusting the volumes accordingly:   
 
Wheat Germ Extract      25 µL 
1 mM each L-amino acids (except methionine)  4 µL 
RNA  (~1 µg/µL)      10 µL 
Potassium acetate      3.5 µL 
[35S] methionine      10 µCi 
ddH2O        Final volume 50 µL   
 
Standard reactions were incubated at 25oC for 60 minutes and then chilled on ice for 5 
minutes to stop translation.  As for the E.coli translation reactions, Wheat Germ translation 
products were then assayed as detailed in the following sections: 2.3.3 - 2.3.5. 
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2.5.3 CTABr precipitation assays 
2.5.3.1 SecM constructs 
After the 5 minute incubation on ice the translation products were mixed with 10 volumes 
of 2% (w/v) CTABr and 10 volumes of 0.5M NaOAc (pH 4.7) and incubated on ice for a 
further 15 minutes before being centrifuged at 13,400 rpm for 10 minutes at room 
temperature.  Pellet and supernatant fractions were separated, the pellets were washed with 
500 µL cold acetone whilst the supernatant was incubated with 10% TCA on ice for 10 
minutes before being centrifuged at 14,000 rpm for 10 minutes at 4oC.  TCA pellets were 
then washed with 1 mL cold acetone and both pellets were then centrifuged at 14,000 rpm 
for 10 minutes at 4oC.  The supernatants were then discarded and all pellets dried in a 
centrifugal evaporator at 14,000 rpm for 15 minutes.  The pellets were then re-suspended 
in 2x sample buffer and analysed by SDS-PAGE (See section 2.4.1).  
 
2.5.3.2 AAP and TnaC constructs 
As above (Section 2.3.3.1) except following CTABr precipitation and centrifugation the 
pellet is re-suspended in 15 µL 1 mg/mL RNaseA in ddH2O and incubated at room 
temperature for 10 minutes.  Following this 15 µL 2x sample buffer is added and the 
sample analysed by resolving on tricine gels (see Section 2.4.1).  The supernatant is treated 
the same as previously stated. 
 
2.5.4 Pegylation assays 
2.5.4.1 Pegylation assay as a test for nascent chain compaction in the exit tunnel 
50 µL in vitro transcription-translation reactions were carried out (see Section 2.3.2.1) with 
volumes altered accordingly.  Once translation reactions were chilled on ice for 5 minutes 
they were then overlaid onto a 100 μL sucrose cushion (0.5 M sucrose, RNC buffer) and 
centrifuged for 6 minutes at 100,000 rpm at 4oC using a Beckmann TLA-100 rotor.  Pellets 
were then re-suspended on ice in 60 µL PEG buffer before being divided in half.  To one 
30 µL sample was added 30 µL PEG buffer containing 2 mM PEG-mal (final PEG-mal 
concentration 1 mM) whilst to the control was added 30 µL PEG buffer.  These were then 
incubated on ice for 2 hours before the reaction was terminated by addition of 100 mM 
83 
 
DTT and incubation for 10 minutes.  Samples were then CTABr precipitated by addition of 
600 μL (10 volumes) 0.5 M NaOAc (pH 4.7) and 600 μL (10 volumes) 2% CTABr and 
incubated on ice for 15 minutes.  They were then centrifuged at 13,400 rpm for 15 minutes, 
the supernatant was discarded and the pellet was re-suspended in 15 μL 1 mg/ml RNaseA 
in ddH2O, followed by incubation at room temperature for 10 minutes.  15 μL 2x sample 
buffer was then added and samples were analysed by SDS-PAGE (see Section 2.4.1). 
 
2.5.4.2 Pegylation RNaseA assay to test for nascent chain structure formation and 
cysteine protection. 
100 µL in vitro transcription-translation reactions were carried out (see Section 2.3.2.1) 
with volumes altered accordingly.  Translation reactions were chilled on ice for 5 minutes 
and then overlaid onto a 100 μL sucrose cushion (0.5 M sucrose, RNC buffer) and 
centrifuged for 6 minutes at 100,000 rpm at 4oC using a Beckmann TLA-100 rotor.  Pellets 
were then re-suspended on ice in 60 µL PEG buffer before being divided in half.  To one 
30 µL sample was added 30 µL PEG buffer containing 1mg/ml RnaseA whilst to the other 
was added 30 µL PEG buffer.  These samples were incubated at room temperature for 10 
minutes before again being split in half.  To one 30 µL sample was added 30 µL PEG 
buffer containing 2 mM PEG-mal (final PEG-mal concentration 1 mM) whilst to the 
control was added 30 µL PEG buffer.  These were then incubated on ice for 2 hours before 
the reaction was terminated by addition of 100 mM DTT and incubation for 10 minutes.  
Samples were then CTABr precipitated by addition of 600 μL (10 volumes) 0.5 M NaOAc 
(pH 4.7) and 600 μL (10 volumes) 2% CTABr and incubated on ice for 15 minutes.  They 
were then centrifuged at 13,400 rpm for 15 minutes and following this the pellet and 
supernatant fractions were split into separate eppendorf tubes.  The pellets were washed 
with 500 µL cold acetone whilst the supernatant was incubated with 10% TCA on ice for 
10 minutes before being centrifuged at 14,000 rpm for 10 minutes at 4oC.  TCA pellets 
were then washed with 1 mL cold acetone and both pellets were then centrifuged at 14,000 
rpm for 10 minutes at 4oC.  The supernatants were then discarded and all pellets dried in a 
speedy vacuum at 14,000 rpm for 15 minutes.  The pellets were then re-suspended in 2x 
sample buffer and analysed by SDS-PAGE (See section 2.4.1).  
 
 
84 
 
2.5.5 Puromycin release assays 
Following translation (Sections 2.3.2.1 and 2.3.2.2) and incubation on ice for 5 minutes, 
the sample was divided in half, and to one was added puromycin to a final concentration of 
1 mM whilst the other acted as a control.  These were then incubated at 37oC for E. coli S-
30 extracts or 25oC for Wheat Germ extracts for 15 minutes.  Following incubation, they 
were placed on ice for 5 minutes before addition of an equal volume of 2x sample buffer 
and analysed by resolving on tricine gels (See section 2.4.1). 
 
2.5.6 Ribosome nascent chain (RNC) stability assays 
100µL translation reactions were performed as described previously in Sections 2.3.2.1 
with volumes altered accordingly.  The reactions were then stored at 4oC with aliquots 
taken at 0, 5, 24, 48 and 120 hours.  Two assays were performed, samples were either 
overlaid onto 100 μL sucrose cushion (0.5 M sucrose, RNC buffer) and centrifuged for 6 
minutes at 100,000 rpm at 4oC in a Beckmann TLA-100 rotor and pellets then re-
suspended in 30 µL 2x sample buffer and analysed by SDS-PAGE (see Section 2.4.1).  
Alternatively the samples were precipitated by CTABr precipitation (see Section 2.3.4.1) 
and analysed by SDS-PAGE.   
 
 
 
 
 
 
 
 
 
 
85 
 
2.6 General biochemical methods and analysis  
2.6.1 Gel Electrophoresis 
Larger proteins (MW >15 kDa) were separated by mass on 12.5% SDS-PAGE gels whilst 
smaller proteins (MW <15 kDa) were resolved on tricine gels.  Resolving and stacking 
solutions for SDS gels and separating, spacer and stacker solutions for tricine gels are 
outlined in Section 2.1.  Following addition of 2x sample buffer the protein samples were 
heated at 95oC for 10 minutes.  Samples were loaded alongside Pre-stained Protein Marker 
(New England Bioscience) on SDS gels or SeeBlue Pre-stained Standard (Invitrogen) on 
tricine gels.  Gels were run at 100 volts for 20 minutes to allow proteins to pass through the 
stacking gel and then at 200 volts for the remainder until the proteins had separated 
sufficiently and the dye-front nearly reached the bottom of the gel.  Once run, the gels 
were removed from the gel apparatus and soaked in destain solution (see Section 2.1.2) for 
1 hour whilst shaking. 
 
2.6.2 Autoradiography 
Following gel electrophoresis and destaining, protein samples containing radiolabelled 35S-
methioine could be visualised by autoradiography.  Gels were dried on a gel drier for 
approximately 1 hour at 65oC and then placed in a lightproof cassette, exposed to X-ray 
film for a period of time and then processed in a Kodak X-Omat processor. 
 
2.6.3 Image J analysis  
Following exposure of the gel to X-ray film, the processed films were scanned onto 
computer using a HP Scanjet 4850 scanner and the band intensity quantified using Image J 
software. 
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3 Sequence specificity of the SecM arrest motif 
3.1 Introduction 
Translational stalling peptides interact with the ribosome exit tunnel during synthesis and 
arrest their own translation, which in turn modulates the expression of downstream genes.  
It has been established that the interaction of the amino acids with the ribosome exit 
tunnel, and not the mRNA encoding it, which is responsible for arrest (Fang et al., 2000; 
Nakatogawa and Ito, 2002).  The variability in the amino acid arrest sequences indicates 
that whilst achieving the same goal of ribosome stalling, methods of arrest and interaction 
within the exit tunnel differ for each peptide.  Whilst there appears to be no overall 
sequence specificity there are some general similarities which can be seen in some, though 
not all, stalling peptides.   
 
For instance, many stalling peptides such as SecM, AAP and TnaC contain a tryptophan 
residue 11-12 amino acids from the C-terminus that is essential for stalling (Freitag et al., 
1996; Gong and Yanofsky, 2002; Nakatogawa and Ito, 2002).  Upon translation arrest this 
residue is located close to the constriction point of the exit tunnel and is therefore thought 
to play an important role in communicating with the ribosome (Bhushan et al., 2011; 
Seidelt et al., 2009).  Several peptides such as SecM and TnaC also contain a C-terminal 
proline residue which is located in the peptidyl transferase centre (PTC) upon stalling.  A 
proline present in the ribosome A site upon arrest increases the stability of the peptidyl-
tRNA complex (Woolhead et al., 2006), whilst the rigid nature and intrinsic properties of 
proline residues make formation of peptide bonds slower and would therefore further aid 
stalling (Pavlov et al., 2009).  These patterns show that through the course of evolution 
there are some commonalties between stalling peptides, although they are not uniform, 
indicating that the combination of interactions that takes place between each peptide and 
the exit tunnel are unique.  This chapter will specifically investigate the stalling sequence 
of SecM, a general introduction of which was given in Chapter 1. 
 
Briefly, SecM is a 170 amino acid peptide which undergoes translation elongation arrest at 
Proline-166, 4 residues prior to the termination point.  At this point tRNA-Pro166 is 
situated in the A site, however, a peptide bond does not form between Gly-165 and Pro-
166 therefore the proline is not incorporated into the peptide (Muto et al., 2006).  The 
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presence of the proline in the A site is still essential for translation arrest.  The essential 
arrest motif of SecM is highlighted in Figure 3.1.  Studies have shown that whilst the key 
arrest motif residues are critical for stalling in vivo, alterations to the arrest motif can be 
compensated for through multiple mutations of flanking residues in vitro, with Yap and 
Bernstein (2009) demonstrating that Arg-163 forms crucial interactions with the ribosomal 
exit tunnel that are required to induce stalling.  This was supported by molecular-dynamics 
flexible fitting (MDFF) modelling data, which showed it is the key interaction of R163 
with the ribosomal RNA (rRNA) nucleotide A2062 that is essential for stalling.  This 
interaction results in a potential relay communication between the SecM nascent chain and 
the PTC to induce stalling, whist the other key residues function to stabilise this interaction 
through positioning of the nascent chain within the exit tunnel (Gumbart et al., 2012).   
 
The secondary interactions between SecM and the exit tunnel were shown by cryo-EM to 
include key interactions in the upper tunnel with 23S rRNA nucleotides A2062, U2585 and 
U2609 and in the mid-tunnel with A751 (Bhushan et al., 2011).  Indeed insertion of an 
additional adenine residue within the 5 consecutive adenine residues A749-A753 abolished 
SecM stalling, highlighting that this area plays a function in nascent chain positioning 
(Nakatogawa and Ito, 2002).  The path of the SecM nascent chain through the ribosome 
exit tunnel, and its position in relation to selected ribosomal proteins and rRNA residues, is 
shown in Figure 3.2. 
 
The structure of the SecM nascent chain within the ribosome exit tunnel is critical to 
stalling as previous work has shown that compaction of the nascent chain upon arrest is 
essential for translation arrest (Woolhead et al., 2006).  This paper also demonstrated that 
this movement of the nascent chain and its ability to adapt and interact with the exit tunnel 
is mediated by the amino acid sequence of the nascent chain as mutation of non-essential 
C-terminus residues S157, Q158 and Q160 to proline prevented compaction which in turn 
abolished stalling.   
 
 
 
 
 
Figure 3.1 C-terminal 44 residues of SecM.  Schematic diagram illustrating the portion of SecM required 
for optimal stalling, with the essential arrest motif residues highlighted in red.  The arrest point at P166 is 
indicated by the arrow. 
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Figure 3.2 MDFF modelling of the SecM nascent chain indicating its path through the ribosome exit 
tunnel.  SecM is shown in red cartoon with stick form overlaid (blue – basic residue; green – hydrophilic; 
and white – hydrophobic).  Also shown are the key ribosomal rRNA nucleotides, L4/L22 proteins forming 
the constriction point and A- and P-tRNAs. Diagram reproduced from Gumbart et al., (2012). 
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Proline residues play an important role in the structure of the nascent chain as they restrict 
the flexibility of the nascent chain and therefore affect its movement within the exit tunnel 
(Schimmel and Flory, 1968).  The P153A mutation is important because Proline-153 is a 
non-essential residue which upon stalling and compaction of the nascent chain is situated 
at a key site within the exit tunnel, close to the constriction point 20-35Å from the PTC 
(Bhushan et al., 2011).  Whilst the cyclic structure of the proline side chain creates a rigid 
conformation, mutation to alanine, which has a small methyl side group (-CH3), increases 
the flexibility of the nascent chain.  Woolhead et al., (2006) demonstrated that whilst wild 
type SecM could not undergo translation arrest in mutant ribosomes possessing expanded 
exit tunnels (Δ82-84 L22), incorporation of the P153A mutation recovered arrest of SecM 
peptides.  The restoration of key interactions between the nascent chain and the ribosome 
exit tunnel re-enabled compaction of the nascent chain and subsequent translational 
stalling. 
 
It has previously been shown that whilst SecM150-166 encompasses the essential arrest 
motif, when truncated constructs are translated SecM140-166 is more efficient at stalling 
than the shorter SecM150-166 minimum stalling sequence (Nakatogawa and Ito, 2002).  
This suggests that the residues further away from the C-terminus, whilst not forming 
essential interactions with the exit tunnel still play an important role in positioning the 
residues further up the nascent chain closer to the PTC, in particular Arg163.  Therefore, it 
remained to be explored whether increased freedom of movement out with the essential 
arrest motif, could also influence positioning of the key residues at the C-terminus of the 
SecM nascent chain.   
 
The purpose of this work is to further investigate the sequence specificity of the SecM 
arrest motif, in particular what properties of these amino acids are essential for their 
interaction with the exit tunnel to enable their role in positioning Arg-163.  To do this the 
essential arrest residues were individually mutated to alanine and also to conservative 
amino acids (see Table 3.1 for structures) in order to determine what affect this has on 
translation arrest.  Following this, in order to study the influence of nascent chain 
flexibility on stalling, double mutants containing alteration of a non-essential proline 
residue to alanine at positions within (P153A) and outwith (P146A) the key arrest motif 
were created and analysed. 
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Table 3.1 Molecular structures of the amino acid residues that were altered in the SecM mutant 
constructs.   
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3.2 Results 
In this chapter the specificity of the SecM stalling sequence will be examined through 
analysis of SecM mutants by CTABr (Cetyltrimethylammonium bromide) precipitation.  
Details of the constructs and mutants used in this section can be found in Appendix 3.  The 
expression and stalling of these constructs was analysed through in vitro coupled 
transcription-translation assays, containing radiolabelled methionine, followed by CTABr 
precipitation, see Section 2.3.3 for methods.  CTABr binds to and precipitates RNA and by 
association, RNA-protein complexes.  Therefore in these experiments CTABr precipitates 
SecM that is stalled on the ribosome, due to its covalent attachment to the tRNA-Gly, 
(Gilmore et al., 1991).   By performing these assays containing a radiolabelled tracer 
amino acid, translation products can be purified, separated by SDS-PAGE and visualised 
by autoradiography, see Section 2.4.  
 
Point mutations were introduced into the SecM constructs by site-directed mutagenesis, 
see Section 2.2.5.3.1, and were confirmed by DNA sequencing, see Section 2.2.11.  The 
amino acid residues mutated to alanine are shown schematically in Figure 3.3A.  To 
confirm the importance of these arrest motif residues, as identified by Nakatogawa and Ito 
(2002) by alanine scanning mutagenesis in an in vivo experimental system, initial CTABr 
precipitation experiments were carried out on SecM constructs containing single alanine 
mutations (Figure 3.3B).  The results for wild type SecM are shown in Lanes 1 & 2, with 
the majority of the translation product in the pellet fraction.  This represents the arrested 
SecM as it migrated further than the full-length SecM, of which there is a small amount 
present in both the pellet and supernatant fractions.  The individual mutant SecM peptides 
had different translation capabilities, as seen by the varying total intensities on the gel 
(Figure 3.3B; Lanes 3-20), this is natural variation due to the efficiency of translation of 
each mutant construct.   
 
The results shown in Figure 3.3B support the ability to reproduce the Nakatogawa and Ito 
(2002) findings in vitro by confirming the importance of the essential arrest motif residues, 
as only G165A was able to maintain any degree of stalling (Figure 3.3B; Lane 17).  This 
residue is located in the ribosome P site upon stalling and therefore, unlike the other 
residues, which are located within the exit tunnel, may be able to accommodate the minor 
glycine to alanine mutation more effectively whilst still being an essential residue for 
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efficient stalling.  The effect of the P153A mutation was also examined and it was 
confirmed that this mutation has no effect on stalling, with the levels of arrested peptide 
remaining the same as wild type SecM (Figure 3.3B; Lane 5).   
 
The next step was to examine the effect of an increase in the freedom of movement of the 
SecM nascent chain to accommodate the mutation of essential residues.  To do this the 
P153A mutation was introduced into the single alanine mutant constructs, to create 
constructs containing double mutations.  The results of the CTABr experiments are shown 
in Figure 3.3C and all the results are summarised in Figure 3.4.  The data indicate that, 
with the exception of R163A and G165A, increased flexibility of the nascent chain 
allowed alanine mutations of the essential arrest motif residues to be better accommodated.  
In particular the highest level of stalling was reintroduced when F150A or G161A 
mutations were coupled with P153A (Figure 3.3C; Lanes 3 & 9).  These results indicate 
that residue 165, which is located in the ribosome P site is important for arrest but is not 
influenced by the positioning of the SecM nascent chain within the exit tunnel, as an 
increase in flexibility has no further increase in stalling (Figures 3.3B & C; Lanes 17 & 15 
respectively).  These results also highlight that the proximity of the alanine mutation to 
P153A is not a factor, with G161A/P153A (Figure 3.3C; Lane 9) having greater stalling 
than either W155A/P153A or I156A/P153A (Figure 3.3C; Lanes 5 & 7 respectively).  The 
only alanine mutation that cannot be accommodated regardless of an increase in the 
flexibility of the nascent chain is R163A (Figures 3.3B & C; Lanes 15 & 13 respectively).  
This supports previous work by Yap and Bernstein (2009), which indicated that R163 is 
the sole essential residue with the other key arrest motif residues responsible for its correct 
positioning, enabling it to interact with rRNA nucleotide A2062 and initiate translation 
arrest. 
 
These results are representative of multiple experiments and the double mutant 
I162A/P153A consistently ran at a higher molecular weight.  For these calculations the 
higher top band was taken as the full length and the lower band as the arrested, despite it 
running at the same weight as the full length peptide in the other lanes.  This higher 
molecular weight could be due to altered processing of the peptide causing it to run at a 
higher molecular weight.  However, further tests such as mass spectrometry would need to 
be carried out to confirm this is the correct product that is present. 
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Figure 3.3 Stalling of single and double SecM alanine mutants. A. Schematic diagram of the mutations made to individual SecM constructs.  B. Single and C. Double alanine SecM 
mutants were translated in vitro and CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and resolved by SDS-PAGE. SecM arrest was quantified by Image J 
software and calculated as a percentage of [Arrested/ (Arrested + Total full length)] with each value adjusted for background.  Wild type SecM was taken as 100% and all percentage 
values were taken as a proportion to this.  Results are representative of multiple experiments. 
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Figure 3.4 Summary of stalling of single and double SecM alanine mutants.  Illustration of the effects of individual alanine mutations both on their own and in tandem with the 
P153A mutation based on the percentage stalling in the CTABr experiments shown in Figure 3.3B & C.  Solid circles indicate the residues which were mutated and the key indicates the 
shading corresponding to the percentage arrested. 
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The key properties of the essential arrest motif amino acids were then investigated by 
individually mutating these residues to conservative amino acids, see Figure 3.5A, to 
identify whether the size or properties of the amino acid were critical to its involvement in 
translation arrest.  The stalling capabilities of these mutants were analysed by CTABr 
precipitation as before (Figure 3.5B).  Mutants of P166 were not made as it was previously 
shown by Nakatogawa and Ito (2002), and supported by the results in Figure 3.3B, that this 
proline is an essential residue required for stalling to occur.  An illustration of the 
structures of the amino acids that were altered in these experiments are given in Table 3.1 
for reference. 
 
These results indicate that G165S retains levels of stalling analogous to wild type SecM 
(Figure 3.5B; Lane 17).  This indicates that the properties of a serine residue can substitute 
for glycine and that despite having a larger side chain, this is not detrimental to stalling.  
F150Y and I156L (Figure 3.5B; Lanes 3 & 7) maintained levels of stalling of 
approximately 50% to that of wild type SecM (Figure 3.5B; Lane 1).  When these residues 
are replaced with alanine, SecM stalling is abolished (Figure 3.3B; Lane 3 & 9), this 
suggests that the structure of these side chains is important for their function.   
 
W155Y, G161S and A164G stalling is approximately 20% to that of wild type SecM 
(Figure 3.5B; Lanes 5, 9 & 15 respectively), whilst I162L and R163K have the lowest 
stalling capability (Figure 3.5B; Lanes 11 & 13 respectively), which is equivalent to that of 
their respective alanine mutants (Figure 3.3B; Lanes 13 & 15 respectively).  These results 
support previous work that identified R163 as the key residue for translation arrest as both 
its presence and exact position were critical (Yap and Bernstein, 2009).  In addition these 
results show that the residues surrounding R163 cannot tolerate mutation, even to 
conservative amino acids, as efficiently as residues further away.   
 
Following this, the P153A mutation was incorporated into the single conservative mutant 
constructs to examine whether an increase in the freedom of movement at this region of the 
nascent chain could further accommodate the conservative mutations, thus allowing further 
examination of what properties of these amino acids are necessary for stalling.  The results 
of these CTABr experiments are shown in Figure 3.5C and all results are summarised in 
Figure 3.6.  The data show that increased flexibility in the lower region of the arrest motif 
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Figure 3.5 Stalling of single and double SecM conservative mutants.  A. Schematic diagram of the mutations made to individual SecM constructs.  B. Single and C. Double SecM 
conservative mutants were translated in vitro and CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and resolved by SDS-PAGE. SecM arrest was quantified by 
Image J software and calculated as a percentage of [Arrested/ (Arrested + Total full length)], with each value adjusted for background.  Wild type SecM was taken as 100% and all 
percentage values were taken as a proportion to this.  Results are representative of multiple experiments. 
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Figure 3.6 Summary of stalling of single and double SecM alanine and conservative mutants.  Illustration of the effects of individual alanine and conservative mutations both on 
their own and in tandem with the P153A mutation based on the percentage stalling in the CTABr experiments shown in Figures 3.3B & C and 3.5B & C.  Solid circles indicate the 
residues which were mutated and the key indicates the shading corresponding to the percentage arrested. 
98 
 
within the exit tunnel has no further effect on the level of stalling of the G165S construct 
(Figure 3.5C; Lane 17).  Likewise for W155Y, R163K and A164G it did not result in 
significant changes in levels of arrest (Figure 3.5C; Lanes 5, 13 & 15 respectively).   The 
constructs which did show an increase in arrest with the double mutation were F150Y, 
I156L, G161S and I162L (Figure 3.5C; Lanes 3, 7, 9 & 11 respectively).  As can be seen in 
the schematic diagram in Figure 3.5A, these residues are spaced apart on the nascent chain 
and not necessarily close to the P153A mutation, indicating that it can have a far ranging 
influence.  
 
These results establish the importance of increased flexibility of the nascent chain in 
allowing the arrest essential amino acid residues to re-position and interact with the exit 
tunnel and in turn compensate for the mutation of key residues.  To further investigate this, 
the influence of increased freedom of movement in the nascent chain, outwith the arrest 
motif, was examined by mutating the proline residue at position 146 to alanine, as 
illustrated in Figure 3.7A.    This residue is situated 4 amino acids upstream from the last 
residue of the arrest sequence, F150, and according to the study of Bhushan et al., (2011) is 
located beyond the exit tunnel constriction site upon compaction and stalling.  CTABr 
precipitation assays show that, like the P153A mutation, the proline at position 146 can be 
mutated to alanine with no effect on the arrest efficiency of SecM (Figure 3.7B; Lane 3).   
 
Coupled in vitro transcription-translation assays were then carried out using a ribosome 
extract derived from cells harbouring a deletion of residues 82-84 in the conserved β-
hairpin of the L22 protein.  This mutation results in ribosomes with expanded exit tunnels 
but has no significant effect on translation (Chittum and Champney, 1994; Gabashvili et 
al., 2001).  Previous experiments examining SecM translation arrest in these mutant 
ribosomes have shown that arrest is severely impeded, however, when combined with the 
P153A mutation, arrest was restored (Woolhead et al., 2006).  The increased flexibility of 
the nascent chain is believed to enable correct positioning of the key amino acid residues in 
the expanded ribosome exit tunnel.  The results of CTABr experiments to observe the 
effect of the P146A mutation in these ribosomes are shown in Figure 3.7C.  Whilst the 
P153A mutation restores stalling capability (Figure 3.7C; Lane 7), these experiments 
indicate that SecM P146A (Figure 3.7C; Lane 5) has equivalent levels of stalling to wild 
type SecM (Figure 3.7C; Lane 3) suggesting that an increase in flexibility further from the 
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C-terminus and out with the arrest motif is unable to sufficiently influence the positioning 
of the residues within it.   
 
To confirm this, further experiments were performed in which the P146A mutation was 
introduced into three of the conservative mutation constructs: F150Y, I156L and G161S, 
as well as into the double mutants: F150Y/P153A, I156L/P153A and G161S/P153A.  
These conservative mutants were selected as they have been shown to increase stalling 
when combined with the double mutation of P153A (Figure 3.5C; Lanes 3, 7 & 9 
respectively).  In addition to this a double mutant containing P146A/P153A was also 
created and tested and, as with the separate proline to alanine mutations, the level of 
stalling was analogous to wild type SecM (Figure 3.8; Lane 3).  When the double P146A 
mutants were translated in vitro and CTABr precipitated the levels of stalling were lower 
than single conservative mutations (Figure 3.8; Lanes 5, 7 & 9).  Whilst the F105Y and 
I156L reductions were not significant the G161S/P146A mutation appears to abolish 
stalling.  Further experiments would need to be carried out to confirm why this occurs but 
it may be that freedom of movement in the 146 region of the nascent chain results in 
misplacement of the peptide chain further up the exit tunnel.  When combined with P153A 
in a triple mutation (Figure 3.8; Lanes 11, 13 & 15) levels of stalling were comparable 
with that of the P153A double mutation (Figure 3.5; Lanes 3, 7 & 9) indicating that P153A 
can compensate and rescue stalling.  The results are summarised in Figure 3.9 and they 
support the previous results of this chapter that show that increased flexibility out with the 
arrest motif does not enable repositioning of residues closer to the C-terminus and 
therefore cannot compensate for mutation of the key arrest motif residues. 
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Figure 3.7 Stalling of selected SecM peptides in mutant ribosome exit tunnels. A. Schematic diagram indicating the position of the P146A and P153A mutations introduced into 
SecM constructs.  The key arrest residues are highlighted in bold and underlined and the arrest point, Proline-166, is indicated by an arrow.  B. SecM WT, P146A and P153A were 
translated in vitro and CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and resolved by SDS-PAGE.  C. The constructs indicated were translated in coupled in 
vitro transcription-translation assays containing wild type E.coli S30 cell extract or cell extract derived from E.coli strains containing ribosomal deletion mutations of residues 82-84 of 
the L22 protein, which results in an expanded exit tunnel.  The reactions were precipitated by CTABr, separated into pellet (P) and supernatant (S) fractions and resolved by SDS-
PAGE.  All gels are representative of multiple experiments. 
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Figure 3.8 Stalling of double and triple SecM conservative mutants.  SecM WT, P146A/P153A double mutant, double conservative mutations coupled with P146A and triple 
conservative mutations coupled with both P146A and P153A mutations were translated in vitro and CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and 
resolved by SDS-PAGE.  The percentage of arrested SecM was quantified by Image J software and calculated as a percentage of [Arrested/(Arrested + Total full length)], with each 
value adjusted for background.  These values were then normalised to wild type SecM to calculate proportion arrested.  All gels and percentages are representative of multiple 
experiments. 
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Figure 3.9 Full summary of the stalling results of all the SecM mutants in this study.  Summary of the results of the CTABr precipitation experiments for all alanine and 
conservative mutations of the key arrest residues shown in Figures 3.3B & C, 3.5B & C and 3.8.  Solid circles indicate the residues which were mutated and the key indicates the 
shading corresponding to the percentage arrested.
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3.3 Conclusion 
The results of the single alanine SecM mutants assayed in this study (Figure 3.3B) support 
the results of the alanine scanning mutagenesis conducted by Nakatogawa and Ito (2002), 
with some slight differences.  Nakatogawa and Ito (2002) showed that Pro-166 and Arg-
163 residues are essential; whilst Trp-155, Ile-156 and Gly-165 are important; and Phe-
150, Gly-161, Ile-162 and Ala-164 are partially required for stalling.  However, the results 
presented here show that G165A is the only alanine mutant able to maintain any degree of 
stalling, with nearly half the level of stalling relative to wild type SecM (Figure 3.3B; Lane 
17).  Both studies assayed SecM stalling by CTABr precipitation with the experiments 
presented here were carried out in vitro using E.coli cell extract whilst Nakatogawa and Ito 
(2002) conducted their experiments in vivo in E.coli.  By performing the same assays but 
in coupled transcription-translation systems in the absence of any intrinsic factors, it 
appears to augment the effect of the mutations. 
 
Upon stalling, interactions between the SecM nascent chain and the ribosome exit tunnel 
result in the P site tRNA adopting an altered conformation within the PTC; hindering 
peptide bond formation between Glycine-165 and Proline-166 in the A site (Bhushan et al., 
2011).  The ability of SecM to maintain a degree of stalling with the G165A mutation may 
be accounted for due to the fact that glycine (-H) to alanine (-CH3) is a relatively simple 
exchange as there is no loss or gain of a major side chain.  It could be speculated that in 
order to maintain stalling then the tRNA-Ala may also be capable of undergoing a similar 
ratcheting motion to tRNA-Gly, however, this cannot be confirmed from this study.  The 
glycine residue also appears to be able to tolerate alteration more effectively in the PTC 
than when it is located in the exit tunnel at residue G161.  In this situation the amino acid 
may be responsible for interacting with the tunnel wall or positioning the nascent chain 
within the tunnel, as the Glycine-161 to alanine modification has major implications on the 
stalling capability of the SecM peptide (Figure 3.3B; Lane 11).  These results also indicate 
that when the SecM nascent chain is arrested residue 165, situated in the ribosome P site, is 
not influenced by the positioning of the nascent chain within the exit tunnel, as an increase 
in flexibility at P153A has no further increase in levels of stalling (Figures 3.3B & C; 
Lanes 17 & 15 respectively).  As stated previously, the importance of G165 is in the shift 
the tRNA undertakes which prevents the formation a peptide bond with Proline-166 upon 
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stalling, this appears to be due to alterations within the PTC and cannot be optimised by 
the positioning of the nascent chain within the exit tunnel. 
 
However, an increase in the flexibility of the nascent chain does increase stalling for some 
of the other SecM mutants, most notably, F150A and G161A.  These residues are located 
apart on the arrest motif (see Figure 3.3A), upon stalling F150 is situated close to the L22 
constriction site whilst G161 is positioned just below the rRNA nucleotide A2062, which 
forms important interactions with R163 (Bhushan et al., 2011).  As noted previously, these 
residues are not concentrated in a small area of the nascent chain, indicating that this 
increased freedom of movement of P153A enables the repositioning of the essential amino 
arrest motif portion of the SecM nascent chain.  There are, however, still some of the 
double mutants, W155A/P153A and I156A/P153A, which do not recover stalling 
effectively (Figure 3.3C; Lanes 5 & 7).  These residues form an important contact with 
rRNA nucleotide A751 (Bhushan et al., 2011), which may require highly specific 
interactions with the wild type amino acids that in the case of the mutants cannot be 
compensated for by the ability to adapt the structure of the nascent chain. 
 
The respite to stalling provided by the introduction of P153A is notable but the 
improvements are not complete as stalling is not restored to wild type levels, see Figure 3.4 
for summary.  This is likely to be because, despite the potential repositioning of the 
nascent chain provided by this increase in flexibility, the alanine in place of the key arrest 
residue is still lacking the vital properties required to interact with the exit tunnel and 
induce efficient stalling.  To explore further what these properties might be, for example 
the shape or charge of the amino acid, the CTABr experiments were performed using 
SecM constructs with conservative mutations of the key arrest residues.  The results of 
these experiments are shown in Figures 3.5B & C and summarised in Figure 3.6.  
 
Despite the G165S mutation involving the addition of a larger serine side chain (-CH2-
OH), in place of the simple glycine (-H) side chain, this was the only construct capable of 
maintaining levels of translation arrest analogous to wild type SecM.  There is genetic 
evidence for a serine residue at position 165 in SecM variants of other species, including 
Mannheimia succiniciproducens, which may account for its ability to maintain wild type 
levels of stalling in E.coli SecM.  Also this P site tRNA undergoes a 2 Å shift in the ester 
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linkage upon stalling (Bhushan et al., 2011), therefore it is the ratcheting motion of the 
tRNA and impediment of peptide bond formation, as opposed to the direct properties of the 
amino acid side chain, which appear important for stalling at this position. 
 
A164 is the last residue to be located in the exit tunnel upon stalling and translation arrest 
is reduced by ~75% in A164G SecM mutants in comparison to wild type SecM (Figure 
3.5B; Lanes 15 & 1 respectively).  Despite both alanine (-CH3) and glycine (-H) having 
small side chains, the methyl group of the alanine residue must still have an important role 
in translation arrest and the communication of the stalling signal to the PTC.  As might be 
expected, increased flexibility further down the tunnel at P153A has no effect on the 
stalling capability of this mutant (Figure 3.5C; Lane 15).  A164 is located above the critical 
R163 in the exit tunnel and upstream alterations serve to position R163 correctly but do not 
appear to be able to compensate for alterations above this. 
 
Alteration of R163 to another similar basic amino acid still abolishes stalling (Figure 3.5B; 
Lane 13) therefore it remains unknown what are the critical elements about arginine that 
are required to induce translation arrest.  Interaction between arginine and the ribosome 
exit tunnel does not appear to be transient as it is so highly specific, instead it suggests that 
the arginine residue may bind within a specific rRNA pocket; interacting with rRNA 
nucleotide A2062, to induce structural changes that signal to the PTC leading to the 
ratcheting of the tRNA moiety and ultimately translational stalling (Bhushan et al., 2011).  
Having such a highly specific location and amino acid requirement is critical as this 
reduces the chances of similar peptides wrongly inducing translation arrest. 
 
Interaction with A2062 has also been shown to be a key factor in translation arrest for 
several other stalling peptides such as the erythromycin resistance gene ermC (Vazquez-
Laslop et al., 2010; Vazquez-Laslop et al., 2008).  However, despite being conserved 
amongst SecM homologs, arginine is not conserved at this position in other stalling 
peptides.  For instance the residue -2 from the PTC, and a critical factor for stalling in 
ErmAL1 and ErmCL, is alanine and phenylalanine respectively (Ramu et al., 2011).  It is 
interesting to note that these inducible stalling peptides require the presence of 
erythromycin for stalling and the binding of this antibiotic occurs at this region and acts to 
bring the nascent chain in close proximity to the A2062 residue (Vazquez-Laslop et al., 
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2008).  Therefore other factors can enable different amino acids to function in this position 
and form the necessary interactions with A2062 to induce stalling. 
 
The specificity of the nascent chain is complex as the same conservative mutations have 
different degrees of influence on stalling depending on where in the nascent chain they 
occur.  For instance, I162, which is located beside the critical R163 and may also have 
subsidiary interactions with A2062 (Bhushan et al., 2011), does not tolerate conservative 
mutation to leucine and cannot be greatly compensated for by an increase in flexibility at 
P153A (Figures 3.5B & C; both Lane 11).  However, further down the nascent chain I156L 
has relatively high levels of stalling for the same amino acid modification (Figures 3.5B & 
C; both Lane 7) and likewise G161S and G165S have greatly different effects (Figures 
3.5B & C; Lanes 9 & 17 respectively).  This illustrates the complex picture of interactions 
which take place within the exit tunnel and highlights that it is not necessarily the 
properties of the amino acids that are key but also where they are located within the exit 
tunnel; with those residues closer to R163 having higher specificity. 
 
Both W155 and I156 have both been shown to make contact with the exit tunnel at rRNA 
nucleotide A751 (Bhushan et al., 2011) and insertion of additional nucleotides here also 
abolishes stalling (Nakatogawa and Ito, 2002).  However, it is the tryptophan which 
appears to be the more essential residue, with low stalling when it is mutated to 
phenylalanine and no great increase in stalling with the additional P153A mutation 
(Figures 3.5B & C; both Lane 5) despite the close proximity of these residues to each other 
in the nascent chain (Figure 3.5A).  I156 meanwhile still maintains approximately 50% 
stalling when mutated to leucine and this can be further enhanced by the increase in 
flexibility at P153A (Figures 3.5B & C; both Lane 7).  This correlates with previous data 
which has shown that a tryptophan residue 11-12 amino acids from the PTC is an essential 
feature which is conserved amongst other stalling peptides such as TnaC (Gong and 
Yanofsky, 2002). 
 
It is perhaps not surprising that the residue furthest from R163 has the greatest scope for 
alteration, with F150Y the most accommodating of the conservative mutations, with over 
50% stalling compared to wild type SecM, which increases to ~80% with the P153A 
double mutation (Figures 3.5B & C; both Lane 3).  This also highlights how 
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rearrangements in the lower part of the arrest motif can influence stalling despite this 
predominantly being based on the positioning of residues (R163) further up the exit tunnel 
near the PTC. 
 
The recovery of stalling function enabled by the P153A mutation indicates this can 
compensate for the alteration of key arrest residues by improving the flexibility of the 
nascent chain and enabling it to reposition within the ribosome exit tunnel.  The next step 
was to examine if an increase in flexibility further from the C-terminus, and outwith the 
arrest motif, could also influence the positioning of the essential amino acid arrest residues.  
The next proline residue in the SecM sequence is P146, but whilst removal of this 
restrictive proline residue for alanine had no detrimental effect on stalling (Figure 3.7B; 
Lane 3), it had no ability to recover stalling in SecM mutants (Figure 3.8).  This is most 
likely due to the fact the P146 residue is located beyond the ribosome exit tunnel 
constriction point (Bhushan et al., 2011), which appears to null any ability to influence 
SecM nascent chain positioning closer to the PTC.  Therefore an increase in flexibility of 
the nascent chain is only beneficial in the region within the arrest motif which is located in 
the upper tunnel upon arrest. 
 
Finally, these results have shown that a combination of both nascent chain flexibility 
within the arrest motif, and amino acid specificity are required for SecM stalling.  The 
SecM nascent chain is highly dynamic within the exit tunnel and is able accommodate 
mutations of essential residues to varying degrees.  Some residues are more important than 
others in particular those located close to, and including, the essential R163 residue.  
Outwith R163, this work highlights that it is not necessarily how an individual residue 
behaves on its own, but how the C-terminus of SecM as a whole combines to position the 
key R163 residue.  The ability of the P153A mutation to recover stalling of some mutants 
indicates that these SecM peptides must position themselves differently within the tunnel 
to allow the more effective communication of the stalling signal to the reach the PTC.  To 
confirm what repositioning each mutant undergoes it would be necessary to undertake 
cryo-EM for each mutant, this would be highly beneficial as it may reveal common 
rearrangements or exit tunnel connections to identify which of the contacts are key for the 
correct positioning of R163. 
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4. Compaction of the SecM nascent chain upon 
translation arrest 
4.1 Introduction 
With a length of approximately 100 Å from the peptidyl transferase centre (PTC) to the 
exit on the base of the large subunit, and a width ranging from 10-20 Å, the dimensions of 
the ribosome exit tunnel potentially allow attainment of a limited degree of secondary 
structure of the nascent chain during translation and passage through the large subunit (Ban 
et al., 2000; Nissen et al., 2000).   In addition to this, the ribosome exit tunnel also provides 
a favourable environment for secondary structure formation as the conditions entropically 
stabilise alpha helix formation (Ziv et al., 2005).  Indeed, studies have confirmed that the 
formation of alpha helices can occur at various points within the exit tunnel (Bhushan et 
al., 2010a; Lu and Deutsch, 2005a, b; Woolhead et al., 2004).  However, formation of 
other secondary structure such as β-sheets, or more advanced tertiary structures, is 
restricted by the size constraints of the exit tunnel and has only been shown to occur at the 
distal end of the ribosome exit tunnel (Gilbert et al., 2004; Kosolapov and Deutsch, 2009; 
Robinson et al., 2006; Tu et al., 2014).  Although the conditions are favourable, different 
peptides behave and interact uniquely within the exit tunnel and so not all peptides will 
form secondary structure.  For instance, FRET-based experiments demonstrated that the 
transmembrane segment of a nascent membrane protein compacted within the ribosome 
exit tunnel whilst the secreted pre-prolactin protein (PPL) traversed the exit tunnel in an 
extended conformation (Woolhead et al., 2004).   
 
Formation of secondary structure within the ribosome is relevant to translation arrest as 
studies have revealed that some stalling peptides, such as E. coli SecM and CGS1 in 
Arabidopsis thaliana, undergo compaction in the exit tunnel upon translation arrest (Onoue 
et al., 2011; Woolhead et al., 2006).  This compaction acts to position key residues within 
the exit tunnel allowing interactions to take place between the nascent chain and the tunnel 
walls, thus enabling stalling signals to be transmitted to the PTC.  For instance, in the case 
of SecM, the positioning of R163 is critical for translation arrest to occur (Gumbart et al., 
2012; Woolhead et al., 2006; Yap and Bernstein, 2009).  It is termed compaction as folding 
is not necessarily fully alpha helical and does not occur throughout the length of the 
nascent chain within the ribosome exit tunnel, (Woolhead et al., 2006). Only some stalling 
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peptides rely on compaction to achieve the correct positioning of key residues and this is 
not a uniform occurrence as some stalling peptides, such as E.coli TnaC and N.crassa 
AAP, have been shown to remain in an extended conformation upon stalling (Seidelt et al., 
2009; Wu et al., 2012).   
 
Previous studies by Woolhead et al., (2006) using FRET assays have revealed that the 
SecM peptide undergoes compaction at the C-terminus upon translation arrest and this 
compaction is essential for stalling.  This arrest occurs through a series of reciprocal 
interactions between the nascent chain and the exit tunnel, which are triggered by the  
addition of Proline-166 to the PTC A site, and functions to correctly position the key arrest 
residues to enable translation stalling (Woolhead et al., 2006).   Molecular-dynamics 
flexible fitting (MDFF) modelling has further refined this initial discovery to reveal that 
this compaction occurs between residues W155 and R163, shortening the distance between 
the two residues from the ~31 Å that would be expected if the peptide was in an fully 
extended conformation to 24 Å.  This compaction was shown to locate and stabilise R163 
in the vicinity of the 23S nucleotide A2062, the residue responsible for communicating 
stalling signals to the PTC (Gumbart et al., 2012).   
 
Compaction of SecM upon translation arrest was further investigated in this study using a 
pegylation assay, a technique which has been modified from that previously described by 
Lu and Deutsch (2005a & b).  These assays employ methoxy-polyethylene glycol 
maleimide (PEG-mal), which has a molecular weight of 5 kDa and binds covalently to the 
thiol groups of cysteine residues and results in an increase in the apparent molecular 
weight of the protein when separated on an SDS gel, see Figure 4.1A.  These assays 
involve performing coupled in vitro transcription-translation, containing radiolabelled 
methionine, to produce stalled ribosome-nascent chain complexes.  Exposed cysteine 
residues of the stalled nascent chains in these complexes are then mass-tagged with PEG-
mal and detected by gel shift assay.  PEG-mal is too large a molecule to enter the ribosome 
exit tunnel and therefore only cysteine residues on stalled nascent chains that are located 
outside of the ribosome exit tunnel will be exposed to pegylation (Lu and Deutsch, 2001), 
see Figure 4.1B.  As SecM contains no native cysteine residues it can be selectively 
mutated to include single cysteine residues that are specifically located near to the end of 
the ribosome exit tunnel when the peptide stalls, see Figure 4.1C. 
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Figure 4.1 Pegylation as an assay for measuring nascent chain compaction within the ribosome exit 
tunnel. A. Structure of the PEG-mal functional group which covalently binds to the thiol group of cysteine. 
B. Diagrammatic representation illustrating the protection of cysteine residues located within the ribosome 
exit tunnel upon stalling in comparison to the pegylation of exposed cysteine residues located outside the 
ribosome exit tunnel. C. The sequence of the C-terminus of the SecM nascent chain highlighting the residues 
individually mutated to cysteine in red and the arrest motif underlined, with the essential residues highlighted 
in blue. 
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Based on the theory that a fully extended nascent chain would occupy 3.0-3.4 Å per amino 
acid residue, and an alpha helix would occupy 1.5 Å per amino acid residue, then it was 
hypothesised that a fully extended peptide would take ~28 residues to traverse the 100 Å 
length of the exit tunnel, whilst a partially alpha helical chain would take ~34-40 residues.  
This pegylation assay is ideal for measuring nascent chain compaction as the extent of 
pegylation is a representation of the length of peptide contained within the ribosome exit 
tunnel and therefore reflects the structure of the nascent peptide within the tunnel. 
 
The aim of this chapter was to extend the initial discovery of SecM compaction upon 
translation arrest made by Woolhead et al., (2006) and analyse the compaction of 3 
conservative SecM mutants selected from Chapter 3, both individually and in tandem with 
the additional P153A mutation.  The results in Chapter 3 highlighted that it was not 
necessarily the properties of the amino acid that are important for translation arrest but also 
where they are located within the exit tunnel upon stalling.  Therefore these experiments 
would reveal what influence these mutations had on compaction of the SecM nascent chain 
and how this is influenced by the increase in flexibility due to the additional P153A 
mutation.  The mutants selected were F150Y, I156L and G161S as these retained the 
greatest degree of stalling in comparison to wild type SecM, which increased when 
combined with the double mutation of P153A (Figure 3.5B & C). 
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4.2 Results 
4.2.1 Pegylation as an assay to study SecM compaction upon translation arrest 
As in the previous Chapter, SecM mutants were created by site-directed mutagenesis (see 
Section 2.2.5.3.1) and correct mutations were confirmed by DNA sequencing (see Section 
2.2.11), these constructs are detailed in Appendix 3.  The SecM residues for chosen for 
mutation to cysteine were selected as they cross the opening of the exit tunnel and ranged 
from SecM D120 to SecM T145.  Upon ribosome stalling and SecM translation arrest, 
residue G165 is situated in the P-site of the PTC and therefore D120C will be located 46 
amino acid residues from the PTC whilst T145C will be only 21 residues away.  Based on 
these distances, upon stalling, D120C would be expected to have traversed the length of 
the large ribosome subunit and be exposed outside the exit tunnel, whilst T145C would 
still be contained within it.   
 
These constructs were then analysed in coupled in vitro transcription-translation assays 
containing radiolabelled methionine, followed by CTABr precipitation (see Section 2.3.3 
for details).  The results are shown in Figure 4.2 and indicate that all the single cysteine 
SecM constructs translated efficiently, retaining levels similar to wild type SecM.  In terms 
of translation arrest, SecM D120C, L125C and G130C constructs maintained levels 
analogous to wild type SecM (Figure 4.2A; Lanes 1-8), whilst a small proportion of SecM 
K135C, D140C and T145C appears to be released as full length peptide (Figure 4.2A; 
Lanes 9-14, upper bands).  Despite this all the SecM peptides created were suitable for 
assaying in pegylation experiments as translation levels were high and the protocol was 
designed to isolate only the stalled ribosome-nascent chain complexes by centrifuging the 
translation products at high velocity through a sucrose cushion and obtaining the pellet.  
 
To demonstrate the suitability of PEG-mal for these experiments, and ensure it labelled 
only exposed cysteine residues and not those contained within the ribosome exit tunnel, 
two constructs, SecM D120C and SecM T145C were first tested.  Of the six SecM cysteine 
mutant constructs created these two constructs contain cysteine residues located furthest 
apart on the nascent chain and are separated by 25 amino acids (Figure 4.1C).  Constructs 
were first translated in vitro as described previously and then assayed for nascent chain 
compaction by pegylation (see Section 2.3.4.1).  The products were then separated by SDS  
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Figure 4.2 SecM cysteine mutants analysed by CTABr precipitation and initial test pegylation assay.  
A. SecM peptides indicated were translated in vitro, CTABr precipitated and separated into pellet (P) and 
supernatant (S) fractions and separated by SDS-PAGE.  Wild type SecM is shown in Lanes 1 & 2 and all 
cysteine modified SecM peptides are shown in comparison (Lanes 3-14).  B. SecM WT, D120C and T145C 
were translated in vitro  and stalled ribosome-nascent chain complexes were isolated by ultracentrifugation 
through a 0.5 M sucrose cushion, divided in two and then incubated with 1mM PEG-mal (Lanes 1-3) or 
without (Lanes 4-6).  Pegylation of cysteine residues is indicated by a mass shift (1) of ~10 kDa in 
comparison to unpegylated translation product (2).  Gels are representative of multiple experiments.   
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gel electrophoresis and visualised by autoradiography (see Section 2.4).  These results 
confirmed that the exposed D120C residues were stably tagged with PEG-mal and resulted 
in a ~10 kDa shift when the products were separated by SDS-PAGE (Figure 4.2B; Lane 2).  
However, if there was no cysteine present, as in wild type SecM, or the cysteine residue 
was still protected inside the ribosome exit tunnel, as in SecM T145C, then no pegylation 
occurred and there was no mass shift (Figure 4.2B; Lanes 1 & 3 respectively). 
 
An additional control was performed to determine the degree of cysteine pegylation 
achieved in the absence of the ribosome and associated factors.  This was done by 
incubating the translation product with 1mg/ml RNaseA prior to incubation with PEG-mal 
to degrade any RNA present, thereby releasing the nascent chain from the ribosome (see 
Section 2.3.4.2 for details).  Two constructs were analysed, SecM G130C and D140C were 
selected as results in Figure 4.5B, which have yet to be discussed, show that these two 
peptides traverse the opening of the ribosome exit tunnel, with G130C (Figure 4.5B; Lane 
4) located outside the ribosome and therefore accessible to pegylation, and D140C (Figure 
4.5B; Lane 6) remaining protected within the exit tunnel and therefore shielded from 
pegylation.  The results of this RNaseA control experiment also serve to highlight the 
importance of the CTABr precipitation step in the isolation of the synthesised peptide as 
the presence of pegylated protein in the supernatant fraction indicates that a portion of 
stalled peptide is released from the ribosome during the time frame of the PEG-mal 
incubation (Figure 4.3; Lanes 2 & 4).  If not separated and removed from the final product 
these released peptides would give a false result as to the level of pegylated stalled peptide 
bound to the ribosome.  These results indicate that, under the normal pegylation protocol, 
30.9% of translation arrested SecM G130C undergoes pegylation (Figure 4.3; Lane 1); 
whilst of the released SecM G130C in the supernatant fraction 42.6% is pegylated (Figure 
4.3; Lane 2).  Meanwhile stalled SecM D140C in the pellet fraction, which is still 
contained within the ribosome exit tunnel, only undergoes 3.8% pegylation (Figure 4.3; 
Lane 3) whilst released SecM D140C peptide isolated in the supernatant fraction 
undergoes 33.8% pegylation (Figure 4.3; Lane 4).     
 
When treated with 1mg/ml RNaseA prior to incubation with PEG-mal, to degrade any 
RNA present and therefore release all peptides from the ribosome, all the translation 
product is recovered in the supernatant fraction following CTABr precipitation, as no 
tRNA is present to precipitate any attached peptide, (Figure 4.3; Lanes 10, 12, 14 & 16). 
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Figure 4.3 RNaseA nascent chain release control. Prior to incubation with 1mM PEG-mal, SecM G130C and D104C were translated in vitro and half of the sample incubated in the 
absence of RNaseA (Lanes 1-8) and the other half incubated with 1mg/ml RNaseA (Lanes 9-16).  Samples were halved again, with half incubated with 1 mM PEG-mal (Lanes 1-4 and 
9-12) and the other half acting as a control without (Lanes 5-8 and 13-16).  Final products were isolated by CTABr precipitation and separated into pellet (P) and supernatant (S) 
fractions and resolved by SDS-PAGE.  Pegylation of cysteine residues is indicated by a mass shift of ~10 kDa (1) in comparison to unpegylated full length (2) and arrested (3) 
translation product. % pegylation was calculated as a percentage of [pegylated/(unpegylated+pegylated)] adjusted for background. 
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The results indicate that in the absence of the ribosome and any associated factors, 100% 
pegylation of the nascent chain is still not achieved with SecM G130C undergoing 46.1% 
pegylation (Figure 4.3; Lane 10) and SecM D140C undergoing 42.6% pegylation (Figure 
4.3; Lane 12).  This indicates that the cysteine residues are being protected from PEG-mal 
modification, most likely due to folding of the peptide into secondary or possibly tertiary 
structure, however, it is unknown from these assays whether this is a structured or 
disordered folding of the nascent chain outside the exit tunnel.  Disordered folding is likely 
as a result of hydrophobic amino acid residues seeking to avoid contact with water 
molecules by shielding within the nascent chain but as there are no chaperones to assist 
this process it may not have a determined structure. 
 
4.2.2 Pegylation of compacted and extended SecM peptides stalled on the ribosome 
The next step was to assay all SecM cysteine mutants (D120C-T145C) to define at which 
point the stalled nascent chain is exposed from the ribosome exit tunnel by determining the 
degree of pegylation across multiple points.  Figure 4.4A illustrates the position of the 
cysteine mutations made to individual SecM constructs, also indicating their distance away 
from the PTC.  As seen in the previous experiment (Figure 4.2B; Lane 1), wild type SecM 
does not undergo pegylation as it does not contain any native cysteine residues to bind 
PEG-mal (Figure 4.4B; Lane 1), whilst SecM cysteine mutants D120C, L125C and G130C 
undergo pegylation of ~40-50% (Figure 4.4B; Lanes 2-4 respectively).  There is a dramatic 
reduction in pegylation at K135C to 8.4% and this continues to decrease the nearer the 
cysteine residue is situated to the C-terminus, with 6.0% pegylation at D140C and only 
1.7% at T145C (Figure 4.4B; Lanes 5-7 respectively).  These results indicate that residues 
K135C, D140C and T145C are still contained within the ribosome exit tunnel upon stalling 
and compaction of the SecM nascent chain and is summarised diagrammatically in Figure 
4.4D.  
 
To enable comparisons to be drawn between compacted and extended SecM nascent 
chains, the SecM Q158P mutation was utilised.  Residue Q158 is a non-essential amino 
acid located within the arrest motif and situated close to the essential R163 residue (see 
Figure 4.4A).  Whilst not an essential amino acid for arrest it has been shown to interact 
the 23S rRNA nucleotide A752 (Gumbart et al., 2012).  Due to the restrictive nature of 
proline, mutation to this residue prevents compaction and results in a loss of translation  
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Figure 4.4 Pegylation assays of wild 
type SecM and SecM Q158P.  
A. Schematic diagram of the mutations 
made to individual SecM constructs.  
Mutated cysteine residues are shown in 
red; Q158P in orange; and the arrest 
motif is underlined with the essential 
residues shown in blue.  B. Wild type 
SecM and C. SecM Q158P containing 
single cysteine mutations were translated 
in vitro and divided in half, with one half 
a control and the other incubated with 1 
mM PEG-mal before being CTABr 
precipitated and resolved by SDS-PAGE. 
Pegylation of cysteine residues is 
indicated by a mass shift of ~10 kDa (1) 
in comparison to unpegylated translation 
 
A. 
 
 
B. 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
D.  SecM WT   E.  SecM Q158P     
 
 
 
 
 
 
 
 
product (2). % pegylation was calculated as a percentage of [pegylated/(unpegylated+pegylated)] adjusted 
for background.  Results are representative of multiple experiments.  D & E. Schematic diagram of 
pegylation results for D. wild type SecM and E. SecM Q158P, indicating the first exposed cysteine residue 
which undergoes pegylation, G130C and D140C respectively. 
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stalling (Woolhead et al., 2006).  As this peptide no longer undergoes translation arrest, to 
obtain stalled ribosome-nascent chain complexes it was necessary to use truncated linear 
DNA lacking a stop codon and containing Proline-166 as the terminal residue, in the in 
vitro transcription-translation assays.  In the absence of a stop codon mRNA remains 
associated with the ribosome, as there is no signal to initiate termination, allowing stalled 
ribosome-nascent chain complexes to be obtained. 
 
These results indicate that the extended SecM Q158P undergoes pegylation at residues 
D120C – D140C (Figure 4.4C; Lanes 2-6), whilst T145C remains unpegylated (Figure 
4.4C; Lane 7), indicating only residue T145C remains within the ribosome exit tunnel 
upon stalling, see Figure 4.4E for summary.  The overall percentage of pegylation is 
reduced in comparison to wild type SecM with the highest level of pegylation being 51.3% 
in wild type SecM (Figure 4.4B; Lane 2), compared to 36.3% in SecM Q158P (Figure 
4.4C; Lane 3).  This is most likely due to differences in the secondary or tertiary structure 
of the nascent chain outside the exit tunnel, which in the case of SecM Q158P results in the 
cysteine residue being more protected and therefore consequently decreasing the 
accessibility of PEG-mal, resulting in a reduced overall rate of pegylation.  Despite this 
there is still a clear segregation in the level of pegylation between residues outside of the 
exit tunnel and those protected within it, as pegylation of SecM Q158P at residue T145C 
reduces to only 0.9% (Figure 4.4C; Lane 7).   
 
Hypothetically, an extended nascent chain has 3.5 Å per amino acid and would therefore 
requires ~28 residues to traverse the 100 Å length of the ribosome tunnel (Figure 4.5A), 
whilst a fully alpha helical nascent chain has 1.5 Å per amino acid and would therefore 
require ~67 residues to traverse the ribosome exit tunnel (Figure 4.5D) (Lu and Deutsch, 
2005a).  However, previous studies have shown that nascent chains traversing the exit 
tunnel do not form complete alpha helices throughout its full length, with certain parts of 
the exit tunnel more favourable to secondary structure formation than others (Bhushan et 
al., 2010a; Lu and Deutsch, 2005a; Woolhead et al., 2006).  Therefore it is hypothesised 
that a partially alpha helical chain with 10 amino acids forming an alpha helix, with the 
remainder fully extended, would require ~34 residues to traverse the exit tunnel (Figure 
4.5B1), whilst a partially alpha helical chain with 20 amino acids in the helix with the 
remainder fully extended would require ~40 residues to traverse the exit tunnel (Figure 
4.5C).  The previous studies indicated that compaction occurred within defined areas of the 
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Figure 4.5 Length of nascent chain contained within the ribosome exit tunnel dependant on the level of 
compaction. A. A fully extended nascent chain.  B1. Partially alpha helical nascent chain tightly compacted 
within a 10 amino acid region or B2. Loosely compacted along the length of the nascent chain.  C. Partially 
alpha helical nascent chain tightly compacted within a 20 amino acid region. D. Fully alpha-helical nascent 
chain throughout the length of the ribosome exit tunnel.  E.  Compacted wild type SecM is initially pegylated 
at G130C indicating that 31-35 residues are contained within the exit tunnel.  F.  Extended SecM mutants are 
first pegylated at D140C indicating that only 21-25 residues are contained within the ribosome exit tunnel. 
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exit tunnel, however, the pegylation assay does not discriminate between a tight 
compaction in one area of the nascent chain and an overall looser compaction of the full 
nascent chain throughout the length of the exit tunnel (Figure 4.5B1 & B2 respectively). 
 
These results indicate that wild type SecM has between 31 and 35 residues contained 
within the exit tunnel upon stalling and compaction, whilst the extended SecM Q158P 
peptide has between 21 and 25 residues protected by the exit tunnel, a difference of ~10 
amino acids (Figure 4.5E & F).  These values are close to the hypothesised values which 
estimate that a fully extended peptide would require ~28 residues to traverse the exit tunnel 
whilst a partially alpha helical chain would take ~34-40 residues.  The slight differences 
may be due to PEG-mal being able to access and pegylate residues at the very end of the 
exit tunnel where it widens slightly, however, these results still indicate that the difference 
in pegylation between extended and compacted SecM is representative of a partially alpha 
helix compaction of the SecM nascent chain upon stalling.   
 
The compaction of truncated SecM constructs has previously been assayed through FRET 
analysis by Woolhead et al., (2006), in which they established that SecM does not undergo 
compaction until the full arrest motif including Proline-166 has been synthesised.  To 
further explore the pegylation rates of extended and compacted SecM peptides additional 
pegylation assays were performed using truncated SecM 1-166 and 1-165 single cysteine 
constructs, the results of which are shown Figures 4.6A & B respectively.  The pegylation 
of SecM 1-166 is analogous to wild type SecM, with these results indicating that the 
percentage pegylation of SecM 1-166 is between 40.2-31.0% at residues D120C, L125C 
and G130C (Figure 4.6A; Lanes 2-4 respectively), with a sudden decrease to 5.8% 
pegylation at K135C (Figure 4.6B; Lane 5).  This further decreases to 2.2 and 0.5% at 
D140C and T145C respectively (Figure 4.6B; Lanes 6 & 7 respectively).  These results 
again indicate that when SecM compacts upon stalling the nascent chain crosses the 
opening of the exit tunnel between residues G130C and K135C.  In contrast, the extended 
SecM peptide is protected within the exit tunnel only at residue T145C, with only 2.9% of 
the peptide undergoing pegylation (Figure 4.6B; Lane 7), and the other peptides, D120C – 
D140C undergoing between 24.4 and 17.2% pegylation (Figure 4.6B; Lanes 2-6 
respectively).  These results support the previous data in Figure 4.4B & C that compacted 
SecM has between 31 and 35 residues contained within the exit tunnel upon stalling and 
compaction, whilst extended SecM has between 21 and 25 residues.  These results are 
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Figure 4.6. Pegylation assays of truncated SecM constructs.  A. SecM 1-166 and B. SecM 1-165 single 
cysteine constructs were translated in vitro as previously described, divided in half, with one half a control 
and the other incubated with 1 mM PEG-mal before being CTABr precipitated and resolved by SDS-PAGE. 
Pegylation of cysteine residues is indicated by a mass shift of ~10kDa (1) in comparison to unpegylated 
translation product (2).  % pegylation was calculated as a percentage of [pegylated/(unpegylated+pegylated)] 
adjusted for background.  Results are representative of multiple experiments. C. Summary of the pegylation 
results of compacted SecM (WT and 1-166) and extended SecM (Q158P and 1-165) indicating the number of 
residues contained within the ribosome exit tunnel upon stalling. 
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summarised diagrammatically in Figure 4.6C.  The results of the truncated SecM 1-165 
constructs in Figure 4.6B also highlight that reduced pegylation of the exposed residues in 
extended SecM peptides in comparison to those of compacted SecM is a recurring 
commonality.  This supports the theory that extended SecM peptides adopt secondary or 
tertiary structure outside the exit tunnel, which results in a more protected cysteine 
residues and therefore lower degrees of pegylation.   
 
4.2.3 Analysis of compaction of selected single SecM mutants 
From these initial experiments the next step was to assay the compaction of several 
selected SecM mutants to identify the effect of altering key arrest motif residues on the 
ability of the SecM nascent chain to undergo compaction upon translation arrest.  The first 
SecM mutant to be assayed was SecM P153A, as work in the previous chapter had shown 
that this alteration of the restrictive proline residue for an alanine plays an important role in 
the ability of SecM mutants to regain stalling ability.  This recovery of stalling function is 
thought to be due to the ability of the SecM nascent chain to reposition the key R163 
residue and the work in this chapter further expands on this to examine what role 
compaction of the nascent chain has in this process.  Previous work has shown that the 
P153A mutation does not affect stalling (Figure 3.3B; Lane 5) and additionally, Woolhead 
et al., (2006) employed a FRET assay to show that compaction between the two FRET 
probes at residues 135 and 159 of the SecM nascent chain was unaffected by this mutation.   
 
Therefore, initial pegylation experiments were carried out to confirm the overall degree of 
compaction of SecM P153A within the full-length of the ribosome exit tunnel in 
comparison to wild type SecM.  The assay focused on the 3 cysteine mutants G130C, 
K135C and D140C as from the previous results, these have been identified as the residues 
spanning the opening of the exit tunnel (Figure 4.4 and 4.6).  The results of SecM P153A 
compaction and pegylation are shown in Figure 4.7A and indicate that this mutation has no 
effect on nascent chain compaction upon stalling in comparison to wild type SecM.  
G130C undergoes an average of 31.2% pegylation (Figure 4.7A; Lane 1) which reduces to 
an average of 6.5% and 5.0% at K135C and D140C respectively (Figure 4.7A; Lanes 2 and 
3) indicating that, like wild type SecM, the nascent chain compacts and protects residues 
K135C and D140C within the ribosome exit tunnel.   The graph in Figure 4.7B summarises 
these results, highlighting the differences in the pegylation of residues G130C, K135C and 
123 
 
A. 
 
 
 
 
 
 
 
 
 
B. 
 
 
Figure 4.7 Pegylation of SecM P153A and summary of extended and compacted SecM controls.  
A. SecM P153A single cysteine constructs G130C, K135C and D140C were translated in vitro as previously 
described, divided in half, with one half a control and the other incubated with 1 mM PEG-mal before being 
CTABr precipitated and resolved by SDS-PAGE. Pegylation of cysteine residues is indicated by a mass shift 
of ~10 kDa (1) in comparison to unpegylated translation product (2).  % pegylation was calculated as a 
percentage of [pegylated/(unpegylated+pegylated)] adjusted for background.  B. Summary of the average 
percentage pegylation of SecM constructs: WT, 1-165, Q158P and P153A. All average percentage pegylation 
values are calculated from an n of 3.  Error bars indicate standard deviation. 
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D140C, in extended SecM Q158P and 1-165 in comparison to wild type SecM and SecM 
P153A which undergo compaction.   
 
Following this, the compaction and stalling of 3 conservative SecM mutations: F150Y, 
I156L and G161S were assayed.  These constructs have been shown in Chapter 3 to 
maintain the highest level of stalling of the conservative mutations studied with ~50% 
stalling in F150Y and I156L and ~25% stalling in G161S (Figure 3.5B; Lanes 3, 7 & 9 
respectively).  The work in this chapter examined what effect these mutations had on the 
compaction of the SecM nascent chain and whether this is linked to the level of translation 
arrest undergone by the peptide. 
 
Whilst the average pegylation rates of residues G130C and D140C of SecM F150Y (Figure 
4.8A; Lanes 1 & 3) remain relatively similar to that of wild type SecM (Figure 4.4B; Lanes 
4 & 6), the increased pegylation of SecM F150Y at residue K135C (Figure 4.8A; Lane 2) 
in comparison to wild type (Figure 4.4B; Lane 5) indicates that this peptide adopts a less 
compact structure within the exit tunnel upon stalling, resulting in increased exposure of 
K135C from the exit tunnel and hence increased pegylation.  These results indicate that 
only 26-30 residues of SecM F150Y are contained within the ribosome exit tunnel upon 
stalling, in comparison to 31-35 residues of wild type SecM.  This suggests that there is 
still partial folding or helix formation as a fully extended SecM had only 21-25 residues 
contained within the exit tunnel (see Figure 4.6C).  SecM G161S undergoes a similar 
degree of compaction as SecM F150Y with residue D140C (Figure 4.9B; Lane 3) 
remaining protected by the ribosome exit tunnel whilst increased pegylation of K135C 
indicates increased exposure of the residue from the exit tunnel again implying a more 
extended conformation of this SecM mutant upon stalling (Figure 4.9B; Lane 2).   
 
Of the three conservative mutants, I156L adopts the most extended conformation upon 
stalling, comparable to a fully extended SecM peptide (Figure 4.9A; Lanes 1-3) with 
pegylation present at all 3 cysteine residues (G130C – D140C) indicating all 3 residues are 
exposed and only 21-25 residues remain within the exit tunnel.  Also, as seen with the 
extended peptides, SecM Q158P and truncated SecM 1-165, the overall rates of pegylation 
are lower than wild type SecM, with SecM I156L having a highest average pegylation at 
G130C of 24.5% (Figure 4.9A) in comparison to wild type SecM which has 40.4% (Figure  
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Figure 4.8 Pegylation of conservative SecM F150Y mutant.  A. Schematic diagram of the C-terminus of 
SecM, the conservative mutations made to separate SecM constructs are highlighted in green.  Additional 
mutations were made to these constructs as described in the text including: G130C, K135C and D140C 
mutations which are shown in red.  The Q158P mutation is indicated in orange.  The arrest motif is 
underlined with the essential residues shown in blue.  B. Pegylation results for SecM F150Y single cysteine 
constructs G130C, K135C and D140C.  These peptides were translated in vitro as previously described, 
divided in half, with one half a control and the other incubated with 1 mM PEG-mal before being CTABr 
precipitated and resolved by SDS-PAGE.  Pegylation of cysteine residues is indicated by a mass shift of ~10 
kDa (1) in comparison to unpegylated translation product (2). % pegylation was calculated as a percentage of 
[pegylated/(unpegylated+pegylated)] adjusted for background.  Average percentage pegylation is calculated 
from an n of 3. 
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Figure 4.9 Pegylation of conservative SecM I156L and G161S mutants.  Pegylation results for A. SecM 
I156L and B. SecM G161S single cysteine constructs G130C, K135C and D140C.  These peptides were 
translated in vitro as previously described, divided in half, with one half a control and the other incubated 
with 1 mM PEG-mal before being CTABr precipitated and resolved by SDS-PAGE. Pegylation of cysteine 
residues is indicated by a mass shift of ~10 kDa (1) in comparison to unpegylated translation product (2). % 
pegylation was calculated as a percentage of [pegylated/(unpegylated+pegylated)] adjusted for background.  
Average percentage pegylation is calculated from an n of 3. 
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4.4B; Lane 4).  This indicates that I156L also undergoes similar secondary or tertiary 
structure outside the exit tunnel as the other extended peptides SecM Q158P and SecM 1-
165, reducing access of PEG-mal to the cysteine residues of the extended peptide. 
 
4.2.4 Analysis of compaction of selected conservative SecM mutations coupled with 
P153A 
Work in Chapter 3 showed that introduction of the P153A mutation into the conservative 
SecM mutants resulted in a recovery of translation arrest (see Figure 3.5C).  This increase 
in stalling was attributed to the increased flexibility of the nascent chain provided by the 
removal of the restrictive proline residue, resulting in more efficient placing of the nascent 
chain to position R163 correctly to initiate stalling.  Further to this, the next aim of these 
experiments was to examine what effect this increased flexibility had on the compaction of 
the SecM nascent chain, to explore what influence this has on the recovery of stalling.   
 
The results of compaction of the SecM F150Y/P153A double mutant are shown in Figure 
4.10A and indicate that incorporation of the P153A mutation results in increased 
compaction of the nascent chain.  Whilst G130C pegylation remains high at an average of 
30.5% indicating it is positioned outside the exit tunnel and exposed to PEG-mal binding 
(Figure 4.10A; Lane 1), average pegylation of K135C decreases from 23.1% in SecM 
F150Y (Figure 4.8B; Lane 2) to an average of 10.0% when combined with the P153A 
mutation (Figure 4.10A; Lane 2).  Meanwhile D140C remains protected by the exit tunnel 
and undergoes an average of 8.1% pegylation (Figure 4.10A; Lane 3).  This indicates that 
compaction of the nascent chain is restored when combined with the P153A mutation, 
indicated by the withdrawing of the K135C residue further into the exit tunnel protecting it 
from PEG-mal binding.  The pegylation of SecM F150Y and F150Y/P153A mutants are 
compared to wild type SecM and extended SecM Q158P in Figure 4.10B, with this graph 
illustrating that the presence of the P153A mutation returns compaction to levels analogous 
to wild type, restoring the 31-35 residues contained within the exit tunnel. 
 
Of the three SecM mutants examined the I156L single mutant has been shown to be the 
most extended upon stalling (Figure 4.9A), with levels of pegylation analogous to 
extended SecM Q158P (Figure 4.4C), however, incorporation of the P153A mutation  
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Figure 4.10 Analysis of pegylation and compaction of SecM F150Y and SecM F150Y/P153A mutants. 
A. SecM F150Y/P153A single cysteine constructs G130C, K135C and D140C were translated in vitro and 
divided with one half a control and the other half incubated with 1 mM PEG-mal before being CTABr 
precipitated and resolved by SDS-PAGE.  Pegylation of the cysteine residues is indicated by a mass shift of 
~10 kDa (1) in comparison to unpegylated translation product (2).  B. Average percentage pegylation of 
SecM F150Y and SecM F150Y/P153A constructs at G130C, K135C and D140C in comparison to SecM WT 
and extended mutant SecM Q158P.  All % pegylation values were calculated as a percentage of 
[pegylated/(unpegylated + pegylated)] adjusted for background.  Average percentage pegylation is calculated 
from an n of 3.  Error bars indicate standard deviation. 
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restores compaction of the SecM nascent chain (see Figure 4.11A).  Pegylation of the 
exposed G130C residue of the SecM I156L/P153A double mutant increased to an average 
of 36.2% (Figure 4.11A; Lane 1) which is analogous to wild type SecM which undergoes 
40.4% pegylation (Figure 4.4C; Lane 4).  In addition to this average pegylation of K135C 
and D140C reduced to 13.1% and 8.7% respectively (Figure 4.11A; Lanes 2 &3 
respectively) indicating that these residues are now protected within the exit tunnel upon 
stalling and compaction.  These results are summarised in Figure 4.11B which highlights 
the difference in overall pegylation between the extended and compacted SecM nascent 
chains.  These results also further indicate that there must be a difference in secondary or 
tertiary structure formation of the extended peptide outside the exit tunnel to account for 
the lower rates of pegylation of these peptides. 
 
The final SecM mutation examined was G161S, which of the 3 conservative mutations had 
the lowest recovery of stalling from ~20% (Figure 3.5B; Lane 9) to ~40% when combined 
with the P153A mutation (Figure 3.5C; Lane 9).  The results of the pegylation assays of 
the G161S/P153A double mutant show that G130C had an average of 23.4% pegylation 
(Figure 4.12A; Lane 1) which, although lower than wild type SecM at 40.4% (Figure 4.4; 
Lane 4), indicated that this residue was located outside the exit tunnel upon stalling.  
Meanwhile pegylation at residues K135C and D140C reduced to an average of 5.9% and 
2.1% respectively (Figure 4.12A; Lanes 2 & 3 respectively), indicating these residues are 
protected within the ribosome exit tunnel (see Figure 4.12B for summary).  These results 
show that whilst the single mutant had a more extended conformation upon stalling with 
only 26-30 residues contained within the exit tunnel, in combination with the P153A 
double mutation, partial alpha helix structure of the nascent chain was again restored, with 
21-25 residues contained within the exit tunnel upon stalling and compaction. 
 
These results indicate that conservative mutations of the key amino acid arrest residues 
affect compaction of the SecM nascent chain upon stalling to differing degrees, which does 
not correlate with the level of translation arrest that these mutants attain.  For instance, 
SecM I156L maintains a greater degree of stalling than SecM G161S with ~50% of the 
peptide arrested in comparison to ~20% (Figure 3.5B; Lanes 7 & 9 respectively), however, 
pegylation results reveal that it is in a more extended conformation upon stalling (Figure 
4.9A & B respectively).  Increased freedom of movement of the nascent chain by mutation 
of the restrictive Proline-153 to alanine results in restoration of compaction to levels 
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Figure 4.11 Analysis of pegylation and compaction of SecM I156L and SecM I156L/P153A mutants.  
A. SecM I156L/P153A single cysteine constructs G130C, K135C and D140C were translated in vitro and 
divided with one half a control and the other half incubated with 1 mM PEG-mal before being CTABr 
precipitated and resolved by SDS-PAGE.  Pegylation of the cysteine residue is indicated by a mass shift of 
~10 kDa (1) in comparison to unpegylated translation product (2).  B. Average percentage pegylation of 
SecM I156L and SecM I156L/P153A constructs at G130C, K135C and D140C in comparison to SecM WT 
and extended mutant SecM Q158P.  All % pegylation values were calculated as a percentage of 
[pegylated/(unpegylated + pegylated)] adjusted for background.  Average percentage pegylation is calculated 
from an n of 3.  Error bars indicate standard deviation. 
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Figure 4.12 Analysis of pegylation and compaction of SecM G161S and SecM G161S/P153A mutants. 
A. SecM G161S/P153A single cysteine constructs G130C, K135C and D140C were translated in vitro and 
divided with one half a control and the other half incubated with 1 mM PEG-mal before being CTABr 
precipitated and resolved by SDS-PAGE.  Pegylation of the cysteine residues is indicated by a mass shift of 
~10 kDa (1) in comparison to unpegylated translation product (2).  B. Average percentage pegylation of 
SecM G161S and SecM G161S/P153A constructs at G130C, K135C and D140C in comparison to SecM WT 
and extended SecM Q158P mutant.  All % pegylation values were calculated as a percentage of 
[pegylated/(unpegylated + pegylated)] adjusted for background.  Average percentage pegylation is calculated 
from an n of 3.  Error bars indicate standard deviation. 
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analogous to wild type SecM for all three conservative mutant constructs studied (see 
Figures 4.10, 4.11 & 4.12).  The increase in the levels of translation arrest are due to the 
increased freedom of movement of the nascent chain within the exit tunnel which enables 
the repositioning of key amino acid arrest residues.  The resulting increase in translation 
arrest indicates that the interactions between the nascent chain and the ribosome exit tunnel 
are a key mediator in the level of translation arrest.  However, although the additional 
P153A mutation increases the level of stalling of the F150Y, I156L and G161S mutants, 
these results indicate that recovery of full compaction of the SecM nascent chain does not 
result in a full recovery of translation arrest, see Figure 4.13 for an overall summary of the 
results. 
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Figure 4.13 Combined summary of translation arrest and degree of compaction for the selected conservative SecM mutants studied.  Highlighted in red are the three 
conservative SecM mutations which were investigated in the pegylation assay to determine number of residues contained within the ribosome exit tunnel, and therefore the degree of 
compaction of the SecM nascent chain upon translation arrest. 
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4.3 Conclusion 
4.3.1 Analysing SecM stalling and compaction by cysteine pegylation 
Cysteine modification by PEG-maleimide is a technique that has previously been exploited 
to detect nascent peptide conformation within the ribosome exit tunnel and this technique 
has been utilised here to assay the level of SecM compaction upon translation arrest.  
SecM compaction had previously been established by Woolhead et al., (2006) through use 
of a FRET assay, however, it was only possible to define the extent of folding between the 
position of the two FRET probes at residues 135 and 159 due to the limitations of having 
to place the probes at these positions so as not to affect the essential arrest motif amino 
acids.  The pegylation assay described here is advantageous as it allowed the full degree of 
compaction within the whole length of the ribosome exit tunnel to be measured, and from 
this, comparisons to be drawn between wild type SecM and several SecM mutants. 
 
To determine if exposed cysteine residues outside of the ribosome exit tunnel undergo 
complete pegylation, SecM nascent chain release was induced by RNaseA degradation of 
the ribosome prior to incubation with PEG-mal (see Figure 4.3).   In the absence of the 
ribosome and associated factors the SecM peptide does not achieve complete pegylation, 
with the results showing that less than 50% pegylation is achieved (Figure 4.3; Lanes 10 & 
12).  This indicates that the inability to undergo complete pegylation cannot be accounted 
for by any protection provided by the ribosome or associated factors but instead could be 
due to folding of the SecM nascent chain resulting in a shielding of the cysteine residue.  
This appears to be evident in all the extended SecM peptides in this study, with the overall 
percentage of pegylation seen with both the extended control peptides, SecM Q158P and 
1-165, and also the extended SecM I156L peptide when stalled on the ribosome, reduced 
in comparison to wild type SecM.  As this was not an isolated occurrence and all extended 
SecM peptides examined showed a similar pattern of lower pegylation, it is most likely 
accounted for due to differences in secondary or tertiary structure outside the ribosome exit 
tunnel, resulting in protection of the cysteine residue and therefore a reduction in the 
overall rate of pegylation.   
 
Although not necessary for the scope of these experiments, it may be possible to confirm 
this theory by using NMR spectroscopy to examine the structure of stalled SecM attached 
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to the ribosome.  The structure of proteins attached to the ribosome has previously been 
studied using by NMR analysis by using the SecM C-terminus to anchor other proteins to 
the ribosome (Cabrita et al., 2009; Hsu et al., 2007).  Therefore, using these established 
techniques it would be possible to study the folding of the full-length SecM nascent chain 
of both wild type SecM, and an extended SecM peptide, whilst stalled on the ribosome. 
 
4.3.2 Influence of single conservative mutations on compaction of SecM nascent chain 
The structure of the SecM nascent chain within the exit tunnel appears to be dynamic and 
mutations of key arrest motif residues can be compensated for by increased freedom of 
movement of the nascent chain, as this enables re-positioning of the nascent chain upon 
stalling thus enabling accommodation of mutations of key amino acid residues, see 
Chapter 3 for details.  The focus of this chapter was to examine SecM compaction by 
studying selected mutations of key arrest motif residues and also to examine the influence 
of a further P153A mutation in the restoration of stalling capability of these peptides.  As 
stated previously the 3 conservative mutations studied in this Chapter were selected due to 
their ability to retain the greatest degree of stalling which is further increased when 
combined with the additional P153A mutation.  The results in this chapter reveal that of 
the three conservative SecM mutants studied, F150Y and G161S underwent only slight 
compaction upon stalling, not equivalent to the partially alpha helical structure of wild type 
SecM, whilst SecM I156L remained in an extended conformation.  Despite this loss of 
compaction SecM F150Y and I156L maintain stalling capability of ~ 55% whilst SecM 
G161S is ~20%, see Figure 4.13 for a summary of these results.   
 
The timing of compaction was shown to occur once the synthesis of the arrest motif was 
complete, with the SecM nascent chain remaining in an extended conformation until this 
time (Woolhead et al., 2006).  Molecular-dynamics flexible fitting (MDFF) modelling 
revealed that compaction of the SecM nascent chain upon stalling occurs between residues 
W155 and R163, and results in a shortening of the distance between these residues from 
~31 Å in a fully extended conformation to 24 Å (Gumbart et al., 2012).  Loss of 
compaction will therefore affect the positioning of the residues downstream from R163, 
and although this residue will remain in the vicinity of rRNA nucleotide A2062 (Bhushan 
et al., 2011) it is still dependant on downstream contacts with the ribosome exit tunnel to 
position it correctly to ensure correct interaction with A2062 and initiate stalling. 
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Previous experiments using truncated constructs to generate ribosome-nascent chain 
complexes have shown that the SecM nascent chain still underwent compaction when 
selected key arrest motif amino acid residues were mutated to alanine, despite these 
mutations resulting in stalling being abolished in full-length constructs (Woolhead et al., 
2006).  This is believed to be due to the importance of these residues and their function in 
interacting with the ribosome exit tunnel and the subsequent positioning of residue R163, 
to enable it to interact correctly with the rRNA nucleotide A2062.  The question remains 
what are these key interactions between the SecM nascent chain and the ribosome exit 
tunnel, and how do they vary between different stalling peptides?  It has already been 
established that different stalling peptides have little amino acid sequence similarity 
suggesting that each one forms different interactions with the exit tunnel to induce 
translation arrest (Ito et al., 2010).  Evidence here indicates that different interactions can 
be formed by mutants of the same stalling peptide, as the mutated SecM nascent chains 
compact differently from wild type SecM yet are still able to maintain a degree of stalling.  
This suggests that in order to achieve this the SecM nascent chain must utilise the time 
taken between synthesis of the arrest motif and ratcheting of the glycine-tRNA in the P site 
to achieve a conformation which enables translation arrest to be maintained, through 
correct positioning of R163 with rRNA nucleotide A2062.  Although some mutants 
achieve this, not all peptides of the same mutant are successful, hence why stalling is not 
100% effective, and in these instances the SecM nascent chain continues to be synthesised 
and is released. 
 
Previous evidence showed that constriction of the nascent chain backbone by mutation of 
non-essential residues 157-160 to proline prevented compaction and in doing so abolished 
arrest (Woolhead et al., 2006).  However, in these experiments SecM I156L has shown that 
an extended SecM nascent chain can still undergo arrest, see Figure 4.13 for summary.  
This indicates that a SecM peptide that is extended but not constrained is still able to utilise 
its movement within the exit tunnel to shift and potentially allow it to sample a range of 
structures to find one capable of forming suitable interactions that enable stalling.  It must 
do so through potentially forming new interactions or by alternative residues being able to 
form these key interactions with the ribosome exit tunnel as the loss of compaction 
resulting in an extended nascent chain upon stalling would results in different positioning 
of the key arrest amino acids upstream from R163. 
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As stated previously, the main interaction between the SecM nascent chain and the 
ribosome exit tunnel that is responsible for translation arrest occurs at rRNA nucleotide 
A2062, however, there are other interactions between the nascent chain and exit tunnel 
which occur near the L4/L22 constriction point that are also important but appear less 
essential (Gumbart et al., 2012).  In particular in this region residue W155 of SecM has 
been shown to base stack with nucleotide A751 of 23S rRNA.  As I156L is directly beside 
W155 and this SecM mutant remains in an extended conformation, this suggests that 
mutation of this residue to Leucine prevents base stacking between W155 and A751, 
resulting in the extended conformation of SecM I156L upon stalling.  The loss of base 
stacking at A751 due to the proximity of the I156L mutation would explain why F150Y 
and G161S mutations, which are further away, affect compaction to a lesser degree.  
Despite this the level of extension or compaction, does not correlate with the level of 
stalling, as SecM I156L has the highest level of translation arrest out of the three 
conservative mutations studied.  This suggests that compaction of the SecM nascent chain 
does not directly determine the stalling capability of the peptide, instead stalling appears to 
be based on a more refined ability of the nascent chain to position the key R163 residue 
correctly within the ribosome exit tunnel.  For wild type SecM this is achieved through 
compaction of the nascent chain, however, these results show that SecM mutants can be 
accommodated by alternative positioning and interactions of the nascent chain within in 
the exit tunnel.  In turn, this accounts for the high level of variation in the sequence and 
behaviour of other stalling peptides which do not rely on nascent chain compaction to 
achieve translation arrest, such as AAP (Wu et al., 2012).   
 
Of the 3 conservative mutations examined SecM I156L would be the most interesting to 
examine further as it maintains the highest rate of stalling at ~55% (Figure 3.5B; Lane 7) 
yet this peptide is in the most extended conformation upon translation arrest (Figure 
4.10B).  In wild type SecM, I156 is located near the L4/L22 constriction point and both 
I156 and W155 make contact with the exit tunnel at rRNA nucleotide A751 (Bhushan et 
al., 2011).  W155 is a highly conserved residue and as stated previously many stalling 
peptides such as SecM, AAP and TnaC contain a tryptophan residue 11-12 amino acids 
from the C-terminus which is essential for stalling (Freitag et al., 1996; Gong and 
Yanofsky, 2002; Nakatogawa and Ito, 2002).  Closer examination of the positioning of the 
SecM I156L nascent chain within the ribosome exit tunnel would need to be performed, 
potentially through cryo-EM, to examine the structure of this stalled peptide and observe 
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how it overcomes the loss of these key interactions and indeed to examine what new 
interactions it forms that can compensate for this.   
 
4.3.3 Influence of additional flexibility of the nascent chain resulting from P153A 
mutation on compaction of SecM mutants 
Mutation of P153A alone does not affect the efficiency of SecM stalling in comparison to 
wild type (Figure 3.3B; Lane 5), neither does it have any effect on the overall compaction 
of SecM upon stalling (Figure 4.7).  However, when combined with single conservative 
mutations it resulted in a return of nascent chain compaction to levels analogous to that of 
wild type SecM, for all 3 conservative mutations studied.  This also correlated with an 
increase in translation arrest, however, unlike nascent chain compaction, the levels of 
translation arrest do not return to that of wild type SecM, see Figure 4.13 for an overall 
summary.  Although not possible to conclude from these experiments, the close proximity 
of P153A to the W155 residue may account for the observed recovery of stalling in the 
peptides containing the additional P153A mutation.  The increased flexibility of the SecM 
nascent chain adjacent to the base stacking of W155 with rRNA nucleotide A751 appears 
to enable accommodation of the conservative mutations and return compaction of the 
nascent chain to that of wild type levels.  However, although the results indicate that the 
increased flexibility of the SecM nascent chain restores the levels of compaction to that of 
wild type SecM, it is unable to completely compensate for the loss of the essential amino 
acid residues, despite their mutation to closely related conservative amino acids.  The 
restoration of compaction in these conservative mutants when provided with increased 
nascent chain flexibility, reinforces again that compaction of SecM upon stalling provides 
the optimum positioning of R163.   
 
The P146A mutation that was examined in Chapter 3 (see Figure 3.8) which, unlike the 
P153A, resulted in no improvement to the rate of translation arrest is most likely due to 
this mutation being unable to restore compaction, as the distance between P146A and 
W155 is too great to provide effective alternative positioning of the SecM nascent chain at 
this critical point to accommodate the conservative mutations and enable restoration of 
base stacking.  These conclusions would need to be confirmed by further experiments 
which would be hypothesised to show that the additional P146A mutation had no effect on 
nascent chain compaction. 
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4.4.4 Overall conclusions and scope for future investigations 
This study has utilised a cysteine pegylation assay to establish the length of the SecM 
nascent chain contained within the ribosome exit tunnel when both extended and 
compacted upon translation arrest.  Furthermore it has identified differences in compaction 
of the SecM nascent chain with selected conservative mutations, and also the influence of 
an increase in the flexibility of the nascent chain on this compaction.  The work here has 
shown that whilst compaction is not reliant on the detection of a completely accurate arrest 
motif complete stalling capability is.   
 
In terms of the importance of individual residues, of the 3 conservative mutations studied 
in this chapter it appears that G161 forms the most important interactions as it has the least 
toleration for mutation most likely due to its close proximity to the essential R163 residue 
(see Figure 4.13).  Conversely F150Y, appears to be the most tolerated mutation as this 
residue is furthest away from R163, and also outside of the compaction zone between 
W155 and R163, as identified by Gumbart et al., (2012).  These results have shown that 
increased flexibility of the SecM nascent chain results in recovery of the compaction of 
SecM mutants.  However, whilst the P153A mutation is sufficient to return SecM 
compaction to wild type levels the pegylation assay does not reveal any details on the exact 
structure adopted by the SecM nascent chain within the exit tunnel, and how it may be 
individually adapted so as to position the R163 residue most effectively.  Therefore, future 
routes of study could involve the cryo-EM analysis of these mutants as this, combined with 
the knowledge of their stalling abilities, could identify the key interactions required for 
positioning of R163 and translation arrest. 
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5. Specificity of translation arrest motifs in non-native 
ribosomes (prokaryotic vs. eukaryotic) 
5.1 Introduction 
Peptides capable of undergoing translation arrest, and subsequent control of the expression 
of downstream genes, occur in both prokaryotic and eukaryotes, however, these peptides 
share little homology in both length and amino acid stalling sequence, indicating that each  
has a relatively unique arrest mechanism (Ito et al., 2010).  Previous work has shown 
variations in the species dependency of stalling sequences, with some showing stricter 
requirements for native ribosomes than others.  Non-specific examples include the fungal 
arginine attenuator peptide (AAP) which undergoes stalling in fungi, plants and animals 
(Fang et al., 2004) and human cytomegalovirus (hCMV) gp48 upstream open reading 
frame 2 (uORF2) which can undergo stalling in Wheat Germ ribosomes (Bhushan et al., 
2010b).  Meanwhile, prokaryotic stalling peptides E.coli SecM and Bacillus subtilis MifM 
appear to be species-specific (Chiba et al., 2011), however, this is not universal for all 
bacterial stalling peptides, with others such as the Proteus vulgaris TnaC peptide capable 
of undergoing stalling in E.coli ribosomes (Cruz-Vera et al., 2009).  In addition, as 
discussed in previous chapters, amino acid stalling sequences can be modified extensively 
and still function (Yap and Bernstein, 2009).  It was therefore sought to firmly establish 
whether stalling peptides could instigate translation arrest in ribosome systems from 
different domains, for example whether a prokaryotic stalling peptide can stall translation 
of a eukaryotic ribosome and vice versa.   
 
Eukaryotic cytoplasmic ribosomes are composed of a large 60S subunit (50S in 
prokaryotes) and a small 40S subunit (30S in prokaryotes) which combine to form the 
complete 80S ribosome (70S in prokaryotes) upon translation initiation.  This is composed 
of 80 ribosomal proteins (79 in yeast) and four rRNA chains (25S, 5.8S, and 5S in the 
large subunit and 18S in the small subunit) (Wilson and Cate, 2012).  Of these ribosomal 
proteins, 46 are eukaryote-specific (18 in the 40S subunit and 28 in the 60S subunit) and 
have no bacterial homologs, whilst in the prokaryotic 70S ribosome, 20 ribosomal proteins 
are bacteria-specific (6 in the 30S subunit and 14 in the 50S subunit) (Melnikov et al., 
2012).  Despite these differences genetic data and structural models of prokaryotic and 
eukaryotic ribosomes indicate that they share a common core structure containing 
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evolutionarily conserved protein and ribosomal RNA.  In addition to this core structure, 
eukaryotic ribosomes contain eukaryotic-specific extensions to conserved proteins and 
additional proteins which account for it being ~40% larger than prokaryotic ribosomes.  
Those proteins that are unique to either domain tend to be located on the surface of the 
ribosome, enabling them to be accessible to interacting factors such as translation factors 
and chaperones which may act to regulate translation allosterically (Ben-Shem et al., 
2011).  Meanwhile studies have shown that the ribosomal interface between the large and 
small subunits, the area around the mRNA entry site and the ribosome exit tunnel, are 
highly conserved, with structural studies revealing that the length and dimensions of the 
exit tunnel are universal between prokaryotes and eukaryotes (Ban et al., 2000; Ben-Shem 
et al., 2011; Klinge et al., 2011; Nissen et al., 2000).  Both eukaryotic and prokaryotic 
ribosome exit tunnels contain a constriction site approximately 20 Å from the PTC formed 
by the L4 and L22 (formally named L17 in eukaryotes) proteins, although due to insertions 
in the L4 protein in eukaryotes this constriction is slightly narrower (Klinge et al., 2011).  
In addition to the L4 and L22 proteins the bacterial ribosome exit tunnel contains bacteria-
specific extensions of L23, whilst in eukaryotes these contributions are replaced by L39e 
(Ban et al., 2000; Ben-Shem et al., 2011; Klinge et al., 2011).  Also, in comparison to 
prokaryotic ribosomes, eukaryotic ribosomes contain additional inter-subunit bridges 
formed predominantly by eukaryotic-specific proteins.  These bridges appear to aid in the  
rotation of the head domain of the small subunit during translation which aids translocation 
of mRNA and tRNA through the ribosome (Ben-Shem et al., 2010).  The diagram in 
Figure 5.1 provides a comparison of prokaryotic and eukaryotic ribosomes and highlights 
the proteins involved in lining the exit tunnel.  
 
Despite the relative conservation between prokaryotic and eukaryotic ribosomes the 
variation in size and complexity between the two systems also correlates with a difference 
in the speed of translation.  Prokaryotic ribosomes translate at a 10-fold faster rate than 
eukaryotes, with prokaryotic ribosomes capable of synthesising peptides 15-20 amino 
acids per second whilst eukaryotes synthesise at a rate of 2 amino acids per second 
(Lafontaine and Tollervey, 2001; Netzer and Hartl, 1997).  Despite this, and whilst the 
translation initiation process in eukaryotes is more complex than prokaryotes, the 
conservation of the PTC between all domains suggests that the process of elongation is 
relatively conserved (Klinge et al., 2011).   
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A.                                                                     B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Molecular structures of prokaryotic and eukaryotic large ribosomal subunits indicating the 
path of the exit tunnel.  A. Prokaryotic and B. Eukaryotic ribosomes with the path of exit tunnel through the 
large subunit shown by a dashed line.  Diagram reproduced from Yusupova and Yusupov (2014). 
 
To explore the specificity of translation arrest motifs in ribosomes of different domains, 
the in vitro stalling capabilities of selected stalling peptides were examined in two different 
systems, prokaryotic E.coli cell extract systems and eukaryotic Wheat Germ cell-free 
systems.  Three stalling peptides were selected for study: prokaryotic E.coli SecM, leader 
peptide of the SecA operon; prokaryotic E.coli TnaC, leader peptide of the tryptophanase 
operon; and eukaryotic upstream open reading frame (uORF) fungal N.crassa arginine 
attenuator peptide (AAP).  These stalling peptides were selected to give a broad 
representation of different arrest mechanisms with SecM being an intrinsic stalling peptide 
whilst TnaC and AAP are inducible, only undergoing stalling in the presence of high 
concentrations of their signal molecules tryptophan and arginine respectively.  These 
signal molecules are believed to bind to the ribosome near the PTC site, with tryptophan 
believed to induce arrest of TnaC by causing conformational alterations to the ribosome 
resulting in the inability to complete translation termination (Cruz-Vera et al., 2006; Wu et 
al., 2012) whilst arginine has been shown to induce a conformational change in AAP 
within the ribosome exit tunnel resulting in prevention of translation termination (Wu et 
al., 2012).  Additionally SecM is a translation elongation stalling peptide and undergoes 
arrest 4 amino acids from the stop codon, whilst AAP and TnaC are both translation 
termination stalling peptides, undergoing arrest when the stop codon is located in the 
ribosome P site.  The essential amino acid stalling motifs of these peptides are compared in 
Table 5.1.  Whilst there are some shared amino acid residues this comparison highlights 
the lack of any strong sequence similarity between stalling peptides either within the same 
domain or across different domains. 
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Intrinsic  P 
site 
A 
site 
 
[1] SecM E.coli … Q A K F S T P V W I S Q A Q G I R A G P 
[2] TnaC E.coli … I C V T S K W F N I D N K I V D H R P * + Tryptophan 
[3] AAP N.crassa … S V F T S Q D Y L S D H L W R A L N A * + Arginine 
Distance from ribosome P site -19 -18 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 +1  
 
 
 
 
Table 5.1. Comparison of the C-terminus amino acid sequences of the translational stalling peptides SecM, TnaC and AAP.  Essential stalling residues are highlighted in red and 
bold with non-essential residues in black.  Residues shaded green are conserved between the stalling peptides as indicated whilst those highlighted in orange are similar but non-
identical residues.  Residues occupying the ribosome A and P sites are shown on the right of the table.  An asterisk (*) is used where peptides stall with the stop codon in the ribosome 
A site.  Arrest sequences from [1] Nakatogawa and Ito (2002); [2] Cruz-Vera et al., (2008); and [3] Spevak et al., (2010).
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To obtain optimal translation it was necessary to take into account the different translation 
initiation systems present in both prokaryotes and eukaryotes, therefore separate constructs 
were made for each system with Shine-Dalgarno sequences engineered into the prokaryote 
specific constructs and Kozak sequences in the eukaryotic constructs.  Details of the 
plasmids and constructs used in this study can be found in Appendix 3.  This removes any 
issues of ineffective peptide translation and places the focus on the peptides’ ability to 
interact with the ribosome exit tunnel and undergo translation arrest.  As both E. coli TnaC 
and N. crassa AAP are only 24 amino acids in length, considerably shorter than SecM 
which is 170 amino acids, adapted constructs were created in order to study these stalling 
peptides effectively.  To clearly visualise these peptides on a gel, modified constructs were 
created by attaching these peptides at the C-terminus of the 62 N-terminal residues of 
SecM (see Figure 5.2A).  The constructs were additionally point-mutated within the SecM 
region to include a further 3 methionine residues as the original constructs produced too 
weak a signal in initial experiments.  The N-terminus of SecM is responsible for peptide 
targeting to the membrane and has no role in translation arrest (Chiba et al., 2011), 
therefore it can be employed in these constructs without effecting the results of these 
assays.  Whilst other unrelated proteins could have been selected to serve as an N-terminus 
attachment to these constructs, further studies would have been required to establish that 
any folding of these additional peptides outside of the ribosome exit tunnel did not result in 
a pull on the nascent chain which could artificially release stalling.   
 
In addition to SecM-AAP and SecM-TnaC, constructs were also made containing the last 4 
amino acids of SecM (QRLT) at the C-terminus of both AAP and TnaC, to establish 
whether truncated TnaC or AAP functions efficiently or if an additional mRNA ‘tail’ has a 
role in providing stability within the ribosome beyond the translation pause site, Figure 
5.2B.  Finally an additional control AAP construct was created containing the D12N 
mutation which has previously been shown to eliminate arginine specific regulation of 
AAP thus preventing stalling in vitro (Freitag et al., 1996; Wang and Sachs, 1997), Figure 
5.2C.  A full list of the constructs used in this chapter, including details of how they were 
generated, can be found in Appendix 3. 
 
AAP and TnaC undergo translation arrest in the presence of high concentrations of inducer 
molecule, arginine and tryptophan respectively.  Although the location of inducer molecule 
was unable to be visualised by cryo-EM (Bhushan et al., 2010b; Seidelt et al., 2009), the  
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SecM-AAP 
 
SecM-TnaC 
 
 
SecM-AAP+4 
 
SecM-TnaC+4 
 
 
SecM-AAP D12N 
 
 
SecM-AAP D12N+4 
 
 
 
 
 
A. 
 
 
 
 
B. 
 
 
 
 
C. 
 
 
 
 
 
 
 
 
 
Figure 5.2 The generated AAP and TnaC constructs employed in this chapter.  A. SecM-AAP and 
SecM-TnaC constructs, B. SecM-AAP and SecM-TnaC constructs containing the additional 4 C-terminal 
residues of SecM (QRLT) and C. Control SecM-AAP D12N and SecM-AAP D12N+4 construct.  Note the 
three additional methionine residues introduced into the SecM portion of each of the above constructs by 
point mutation to provide a stronger signal when labelled with radio-labelled methionine.  
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inducer molecule is believed to bind close to the PTC to induce stalling (Cruz-Vera et al., 
2006).  Therefore the AAP and TnaC constructs were synthesised in in vitro prokaryotic 
E.coli cell extract systems and eukaryotic Wheat Germ cell-free systems in both the 
presence of high inducing concentrations (1 mM or 2 mM) or low non-inducing 
concentrations (0.01 mM) of their respective inducer molecules.  Two assays were then 
implemented to investigate peptide stalling, the previously described CTABr precipitation 
and also a Puromycin release assay.  Puromycin is an aminonucleoside antibiotic with part 
of it analogous to the 3’ end of tyrosyl-tRNA (Yarmolinsky and de la Haba, 1961) (see 
Figure 5.3A & B).  Due to this structural similarity, puromycin is able to enter the 
ribosome A site and covalently attach to the carboxyl terminus of the polypeptide chain, 
preventing further chain elongation and resulting in premature release of the peptide from 
the ribosome (Figure 5.3C).   This assay has previously been utilised to illustrate that, 
when arrested, stalling peptides undergo alterations within the PTC which results in them 
no longer being susceptible to release by puromycin (Gong et al., 2001; Wei et al., 2012; 
Woolhead et al., 2006).  Therefore, by using truncated mRNA to artificially stall peptides 
on the ribosome at the point of the proposed arrest, only those which have undergone 
changes in the PTC induced by actual translation arrest will remain bound in the presence 
of puromycin, whilst those peptides attached to the ribosome solely through the use of 
truncated mRNA will be released (see Figure 5.3 D).  This is detected when the translation 
products are resolved on a gel, by the presence or absence of the higher molecular weight 
band of the stalled tRNA-peptide. 
 
Each of the stalling peptides SecM, TnaC and AAP have been visualised by cryo-EM, 
which shows that they appear to undergo separate interactions within the ribosome exit 
tunnel upon translation arrest (Bhushan et al., 2010b; Gumbart et al., 2012; Seidelt et al., 
2009).  Chapter 1 contains a comprehensive summary, briefly however, due to the 
similarities between prokaryotic and eukaryotic ribosome exit tunnels the nascent peptides 
appear to interact within similar areas of the exit tunnel including ribosomal RNA 
nucleotides U2585, A2062, A2058 and A751, and the extensions of ribosomal proteins L4 
and L22 (L17).  This suggests it may be feasible for eukaryotic stalling peptides to arrest in 
prokaryotic ribosomes and vice versa and therefore investigating the specificity of arrest 
sequences will be the focus of this chapter.  
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A.            B. 
 
 
 
 
 
 
C. 
 
 
 
 
 
D. 
 
 
 
 
 
 
 
 
 
Figure 5.3 Summary of puromycin release assay. A. Chemical structure of puromycin, which resembles 
the 3’ end of tyrosyl-tRNA. Circled in red is the amide group which differs from the ester group of tRNA 
(circled in B.) and is responsible for the prevention of further chain elongation.  B. Under normal 
circumstances aminoacyl-tRNA attacks the peptidyl-tRNA as indicated by the curly arrows, resulting in 
chain elongation.  C.  Diagrammatic representation of chain elongation during translation, transfer of amino 
acid to the growing nascent chain occurs under normal conditions, however, in the presence of puromycin, 
this molecule is incorporated into the nascent chain resulting in translation termination and premature release 
of the peptide from the ribosome.  D. In the puromycin release assay, truncated mRNA is used to artificially 
stall ribosomes, however, only those containing fully arrested peptides will remain bound to the ribosome in 
the presence of puromycin, whilst artificially arrested, non-stalling peptides will be released from the 
ribosome by the addition of puromycin. 
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5.2 Results 
5.2.1 SecM  
To examine the ability of stalling peptides to undergo translation arrest in alternative 
ribosome systems initial CTABr experiments were conducted on E.coli SecM to examine 
the ability of this peptide to undergo stalling in eukaryotic ribosomes.  SecM is an ideal 
model stalling peptide for in vitro studies in eukaryotic translation systems as the results 
can be compared to the robust stalling ability of this peptide in its native prokaryotic E.coli 
system.  SecM undergoes a high level of arrest in E.coli, with the majority of the peptide 
isolated as the shorter (166 amino acids) translation elongation-arrested peptide in the 
CTABr pellet fraction (Figure 5.4; Lane 1), and only a small amount of full length peptide 
is released and isolated in the CTABr supernatant fraction (Figure 5.4; Lane 2).  Although 
the SecM peptide is sufficiently well translated in eukaryotic Wheat Germ ribosomes, 
stalling does not occur, as the majority of the peptide is full-length (170 amino acids) and 
recovered in the CTABr supernatant fraction (Figure 5.4; Lane 4).  There is no lower band 
present in the pellet fraction indicating an absence of stalled peptide (Figure 5.4; Lane 3). 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Stalling of E.coli SecM in prokaryotic E.coli and eukaryotic Wheat Germ translation 
systems.  SecM WT was translated in vitro in both E.coli cell extract and a Wheat Germ cell-free translation 
system before being CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and resolved 
by SDS-PAGE.   Results are representative of multiple experiments. 
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5.2.2 TnaC and TnaC+4  
5.2.2.1 TnaC and TnaC+4 stalling in prokaryotic E.coli ribosomes 
Following this, E.coli TnaC was synthesised in vitro using E.coli cell extract in the 
presence of several different tryptophan concentrations (initially: 0.01, 1 and 2 mM) with 
stalling expected to occur only in the presence of high concentrations of inducer molecule.  
The two constructs, SecM-TnaC and SecM-TnaC+4, were synthesised and the results are 
shown in Figure 5.5.  In comparison to wild type SecM stalling in E.coli cell extract, TnaC 
undergoes a lower level of overall stalling even at high tryptophan concentrations, 
resulting in a strong band present in the supernatant fraction of all the samples indicating 
released peptide (Figure 5.5A; even numbered lanes).  This lower level of stalling of TnaC 
in comparison to SecM is not believed to be due to lack of inducer molecule, as previous 
studies have established the optimum levels of tryptophan for efficient stalling (Gong et 
al., 2001; Gong and Yanofsky, 2001).  Instead this difference may be due to the 
inefficiency of tryptophan binding and therefore inducible stalling in this in vitro 
translation system.  Also, affecting interpretation of these results is the presence of a higher 
band at ~40 kDa in the pellet fraction (Figure 5.5A; denoted by asterix *), which previous 
studies have identified as being SecM-TnaC-tRNAPro (Gong and Yanofsky, 2001).  
Removal of this band was achieved by incubation with RNaseA prior to separating on a 
tricene gel, concentrating the stalled peptides within the one lower band in the CTABr 
pellet fraction (Figure 5.5 B).  This enabled calculation of the percentage of translation 
arrest of TnaC at different tryptophan concentrations, with the results indicating that there 
appeared to be a basal level of TnaC stalling even at low concentrations of tryptophan 
inducer (Figure 5.6A; Lane 1).  Interestingly this basal level of stalling was higher for 
TnaC+4 peptides (Figure 5.6A; Lane 7).  Both peptides displayed increasing levels of 
arrest with increasing tryptophan concentrations (Figure 5.6A; Lanes 3 & 9), with TnaC+4 
also achieving a higher maximum overall percentage of arrest (Figure 5.6A; Lane 11) in 
comparison to TnaC (Figure 5.6A; Lane 5).   
 
The average percentage of arrest for the TnaC and TnaC+4 peptides are shown in Figure 
5.6B.  This graph highlights that although the TnaC+4 construct had an overall greater 
level of stalling at high concentrations of inducer (2 mM tryptophan) this was countered by 
a higher initial level of stalling at low tryptophan concentrations (0.01 mM).  It appears 
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A. 
 
 
 
 
 
 
 
B. 
Figure 5.5 Stalling of SecM-
TnaC and SecM-TnaC+4 in a 
prokaryotic E.coli translation 
system.  A. SecM-TnaC and 
SecM-TnaC+4 were 
synthesised in E.coli cell 
extract in vitro transcription-
translation assays containing 
0.01 mM, 1 mM or 2 mM 
tryptophan (inducer molecule).  
Products were CTABr 
precipitated, separated into 
pellet (P) and supernatant (S) 
fractions and resolved on 
tricene gels.  An asterix (*) 
indicates SecM-TnaC-tRNAPro 
whilst the arrow indicates the 
band representing the TnaC 
peptide.  B. SecM-TnaC and 
SecM-TnaC+4 were 
synthesised as previously with 
an additional incubation with 1 
mg/ml RNaseA, prior to 
separating on tricine gels. 
RNaseA treatment removes 
tRNAPro resulting in one band 
representing total translated 
TnaC peptide and indicated on 
the gel by arrow. All gels are 
representative of multiple 
experiments. 
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A. 
 
 
 
 
 
 
 
B.
Figure 5.6 Stalling of SecM-
TnaC and SecM-TnaC+4 in 
an E.coli translation system 
with RNaseA incubation.  A. 
SecM-TnaC and SecM-
TnaC+4 were synthesised in 
E.coli cell extract in vitro 
transcription-translation assays 
containing 0.01 mM, 1 mM or 
2 mM tryptophan (inducer 
molecule).  Translation 
products were CTABr 
precipitated, separated into 
pellet (P) and supernatant (S) 
fractions and incubated with 1 
mg/ml RNaseA prior to being 
resolved on tricene gels.  The 
arrow indicates total translated 
TnaC peptide.  The percentage 
of arrested TnaC was 
quantified by Image J software 
and calculated as a percentage 
of [Arrested/(Arrested + 
Released)], with each value 
adjusted for background.  Gel 
is representative of multiple 
experiments. 
B.  Average percentage arrest 
of SecM-TnaC and SecM-
TnaC+4 peptides at 0.01 mM, 
1 mM and 2 mM tryptophan 
concentrations. Average is 
calculated from an n of 3.  
Error bars indicate standard 
deviation. 
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that the additional 4 residues at the C-terminus of TnaC+4 does have a role in aiding arrest 
and more will be discussed on this later with relation to the AAP+4 construct. 
 
5.2.2.2 TnaC and TnaC+4 stalling in eukaryotic Wheat Germ ribosomes 
After establishing the level of TnaC translation arrest in native E.coli ribosomes the 
stalling capabilities of these peptides were then tested in eukaryotic Wheat Germ 
ribosomes.  Similar to the results in the prokaryotic system, there was a higher level of 
basal stalling for TnaC+4 (Figure 5.7; Lane 5) than TnaC (Figure 5.7; Lane 1) at low 
tryptophan concentrations (0.01 mM).  These levels of basal stalling were similar to that 
seen in E.coli ribosomes at the same concentrations of tryptophan (0.01 mM) with ~8% for 
TnaC (Figure 5.6A & 5.7; both Lane 1) and ~16% for TnaC+4 (Figure 5.6A & 5.7; Lane 7 
and 5 respectively).  However, unlike in the prokaryotic system, there was no further 
increase in the level of arrest at high concentrations of inducer molecule (2 mM 
tryptophan) for either TnaC (Figure 5.7; Lane 3) or TnaC+4 (Figure 5.7; Lane 7).  This 
indicates that the TnaC peptide is only able to undergo increased levels of induced stalling 
in native E.coli ribosome systems. 
 
To confirm these results, further experiments were carried out to examine translation arrest 
using the puromycin release assay.  Truncated mRNA was used for these assays to 
artificially stall the nascent chain on the ribosome therefore only SecM-TnaC, and not 
SecM-TnaC+4, could be investigated using this assay.  Stalled TnaC peptidyl-tRNAPro is 
indicated by the presence of the higher molecular weight band (Gong et al., 2001) which in 
the absence of puromycin is seen at both low (0.01 mM) and high (2 mM) concentrations 
of tryptophan in both E.coli (Figure 5.8, Lanes 1 & 2) and Wheat Germ systems (Figure 
5.8, Lanes 5 & 6).  Addition of puromycin results in the loss of artificially induced stalling 
caused by the use truncated mRNA constructs, which is indicated by the absence of the 
higher weight molecular band.  These results show that in E.coli cell extract, at low 
tryptophan concentrations (0.01 mM) addition of puromycin relieves the artificial stalling 
induced by truncated mRNA (Figure 5.8, Lane 3).  However, arrest is maintained after the 
addition of puromycin in the presence of high concentrations (2 mM) of tryptophan (Figure 
5.8, Lane 4).  This stalling is not reflected in eukaryotic ribosome systems with the 
abolishment of the higher molecular weight peptidyl-tRNAPro band at both low (0.01 mM) 
and high (2 mM) tryptophan concentrations in the presence of puromycin (Figure 5.8, Lane  
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Figure 5.7 Stalling of SecM-TnaC and SecM-TnaC+4 in eukaryotic Wheat Germ cell-free translation 
system with RNaseA incubation.  SecM-TnaC and SecM-TnaC+4 were synthesised in Wheat Germ cell 
extract in vitro translation assays containing 0.01 mM or 2 mM tryptophan (inducer molecule).  Translation 
products were CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and incubated with 
1 mg/ml RNaseA prior to being resolved on tricene gels. The percentage of arrested TnaC was quantified by 
Image J software and calculated as a percentage of [Arrested/(Arrested + Released)], with each value 
adjusted for background.  Arrow indicates translated TnaC peptide.  Gel is representative of multiple 
experiments. 
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Figure 5.8 SecM-TnaC stalling in prokaryotic E.coli and eukaryotic Wheat Germ translation system 
detected by Puromycin release assay.  Truncated SecM-TnaC mRNA lacking a stop codon was translated 
in vitro in E.coli and Wheat Germ cell extract, in the presence of either 0.01 mM or 2 mM tryptophan 
(inducer molecule).  Reactions were divided in half with 1 mM puromycin added to one whilst the other 
served as a control.  After incubation the products were resolved on tricine gels.  The asterix (*) indicates 
TnaC peptidyl-tRNAPro whilst the arrow indicates released SecM-TnaC peptide.  Gel is representative of 
multiple experiments. 
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7 & 8).  This confirms the previous CTABr precipitation results which indicated that TnaC 
undergoes stalling at high inducer concentrations in native E.coli ribosomes but is not able 
to emulate this stalling in eukaryotic Wheat Germ ribosomes.  Instead the basal stalling 
seen in the CTABr precipitation assays at low inducer concentrations in the E.coli cell 
extract system (Figure 5.6A; Lanes 1 and 7) and both low and high inducer concentrations 
in eukaryotic Wheat Germ ribosomes (Figure 5.7; Lanes 1, 3, 5 and 7) is indicative of the 
peptide undergoing a translational pause without obtaining full translational arrest.  The 
significance of this will be discussed further in Section 5.3. 
 
5.2.3 AAP and AAP+4  
5.2.3.1 AAP and AAP+4 stalling in eukaryotic Wheat Germ ribosomes 
CTABr precipitation assays were carried out to assess the stalling capability of the 
eukaryotic N.crassa stalling peptide AAP, in both eukaryotic Wheat Germ and prokaryotic 
E.coli translation systems.  Previous work has shown that this peptide has the ability to 
stall in fungal, plant and animal ribosomes (Fang et al., 2004), therefore it was first sought 
to establish the stalling of these SecM-AAP and SecM-AAP+4 peptides in eukaryotic 
Wheat Germ ribosome systems.  The results indicate that at low arginine concentration 
(0.01 mM) there is minimal basal stalling of wild type AAP (Figure 5.9A; Lane 1), whilst 
high arginine concentrations (2 mM) activated AAP stalling (Figure 5.9A; Lane 3).  This is 
similar to AAP+4, however, as with TnaC+4, the basal rate of stalling was slightly higher 
(Figure 5.9A; Lane 5) and in turn the stalling under inducing arginine concentrations was 
also higher (Figure 5.9A; Lane 7).  There is a noticeable difference in the lengths of the 
stalled AAP+4 peptides in the pellet fraction (Figure 5.9A; Lane 7) to the released peptides 
isolated in the supernatant fraction (Figure 5.9A; Lane 8) due to the stalled peptide not 
having translated the additional 4 C-terminal residues at the point of arrest.  Also of note 
was that the basal level of AAP+4 stalling was higher than that seen for the AAP D12N+4 
peptide (Figure 5.9A; Lane 13).  As expected neither of the mutant AAP D12N peptides 
underwent stalling at low (0.01 mM) or high (2 mM) arginine inducer concentrations 
(Figure 5.9A; Lanes 11 & 15). 
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B. 
 
 
 
 
 
 
Figure 5.9 AAP stalling in eukaryotic Wheat Germ and prokaryotic E.coli translation systems.  Peptides were synthesised in A. Wheat Germ and B. E.coli in vitro transcription-
translation assays containing 0.01 mM or 2 mM arginine (inducer molecule). Products were CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and incubated 
with 1 mg/ml RNaseA prior to being resolved on tricene gels. The percentage of arrested AAP was quantified by Image J software and calculated as a percentage of [Arrested/(Arrested 
+ Released)], with each value adjusted for background.  1. Released (full length) and 2. Stalled AAP peptide.  Gels are representative of multiple experiments. 
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5.2.3.2 AAP and AAP+4 stalling in prokaryotic E.coli ribosomes 
Further to this, the stalling of AAP in prokaryotic E.coli ribosomes was then investigated, 
with the results showing that both AAP and AAP+4 undergo a high level of basal stalling 
at low (0.01 mM) arginine inducer concentrations (Figure 5.9B; Lanes 1 & 5).  This 
stalling is far greater than the level observed in the eukaryotic translation system and is 
more analogous to the induced arrested state seen in Wheat Germ ribosomes at high (2 
mM) arginine inducer concentrations (Figure 5.9A; Lane 7).  However, stalling remained 
at this level in the E.coli translation system and did not increase at high (2 mM) 
concentrations of the arginine inducer molecule (Figure 5.9B; Lane 3).  There was also no 
difference seen with the presence of the four additional (QRLT) SecM C-terminus residues 
(Figure 5.9B; Lane 7).  Similarly the AAP D12N and AAP D12N+4 mutants also had a 
high level of stalling in low (0.01 mM) arginine inducer conditions (Figure 5.9B; Lanes 9 
& 13 respectively) which did not increase any further even in the presence of high (2 mM) 
concentrations of arginine (Figure 5.9B; Lanes 11 & 15 respectively).  Although in the 
E.coli ribosome system the AAP D12N mutation no longer completely abolished stalling, 
there was still a slight influence with stalling of this mutant overall slightly decreased 
compared to wild type AAP (Figure 5.9B). 
 
To enable better interpretation of these results, puromycin release assays were also 
performed on the AAP peptide in the prokaryotic E.coli ribosome system.  As previously, 
truncated mRNA constructs were used to obtain artificially stalled ribosomes, if translation 
arrest has occurred then these peptides will be resistant to puromycin whilst simulated 
stalled peptides will be released from the ribosome.  The results indicate that in the 
absence of puromycin, truncated mRNA results in a population of the peptides stalled as 
peptidyl-tRNAAla for both AAP WT and AAP D12N peptides at both low (0.01 mM) and 
high (2 mM) arginine concentrations (Figure 5.10; Lanes 1-2 & 5-6).  However, the 
addition of puromycin causes stalling to be released for both AAP WT and AAP D12N, as 
indicated by the absence of the higher molecular weight band of peptidyl-tRNAAla, 
regardless of the presence of high concentrations of arginine inducer molecule (Figure 
5.10; Lanes 3-4 & 7-8).  This indicates that these peptides are only stalled on the ribosome 
initially because of the truncated mRNA lacking a stop codon and AAP and AAP D12N do 
not undergo functional translation arrest in prokaryotic E.coli ribosomes.   
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This makes the interpretation of the CTABr precipitation results in Figure 5.9B very 
interesting as the high level of basal stalling does not correspond to stably arrested peptide 
and instead, similar to the TnaC peptide,  suggests that the AAP peptide undergoes a 
translational pausing which is independent of the small molecule inducer arginine.  This 
will be discussed further in Section 5.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Stalling of SecM-AAP and SecM-AAP D12N in prokaryotic E.coli translation system 
detected by puromycin release assay.  Truncated SecM-AAP and SecM-AAP D12N constructs lacking a 
stop codon were synthesised in E.coli cell extract in vitro transcription-translation assays containing 0.01 
mM or 2 mM arginine (inducer molecule).  Reactions were divided in half with 1 mM puromycin added to 
one whilst the other served as a control.  After incubation the products were resolved on tricine gels.  The 
asterix (*) indicates AAP peptidyl-tRNAAla whilst the arrow indicates released SecM-AAP/SecM-AAP 
D12N peptide. Gel is representative of multiple experiments. 
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5.2.4 Summary  
The overall results of this chapter are summarised in Table 5.2 and indicate that 
prokaryotic E.coli stalling peptides SecM and TnaC can only undergo full translation arrest 
in prokaryotic ribosome systems and vice versa for eukaryotic stalling peptide N.crassa 
AAP.  There does, however, appear to be a degree of translational pausing which can be 
undergone by the inducible stalling peptides TnaC and AAP in the absence of inducer 
molecule in their native systems and also independently of their inducer molecules in the 
alternative ribosome systems.  The lack of full arrest of stalling peptides in alternative 
ribosome systems highlights the complexity of the ribosome and the uniqueness of the 
interactions which occur to induce stalling of different translation arrest peptides.   
 
 
 
 
 
 
 
Table 5.2 Summary of SecM, TnaC and AAP stalling in alternative ribosome systems.  The combined 
results from both CTABr and puromycin release assays for the three stalling peptides SecM, TnaC and AAP 
in both prokaryotic and eukaryotic ribosome systems.  
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5.3 Conclusion 
5.3.1 Inducible translation arrest peptides can undergo translational pausing, but not 
arrest, in alternative ribosome systems 
Firstly, from these results translation arrest of the inducible stalling peptides AAP and 
TnaC appears to be less efficient than the intrinsically stalling SecM peptide, as both 
undergo lower levels of arrest.  However, it should be noted that this may be a result of the 
in vitro translation system and may not reflect the in vivo levels of stalling achieved by 
these peptides.  This is because whilst SecM stalling continues in vivo until the stalled 
nascent chain is subject to a pulling force from the translocon resulting in its release 
(Butkus et al., 2003), AAP and TnaC stalling is controlled by the presence of the bound 
inducer molecule, arginine and tryptophan respectively.  The stability of the inducer 
molecule binding is experimentally undetermined, as is how this binding is affected in 
vitro, and therefore it is possible that potential instability of inducer molecule in vitro may 
result in a more transient stalling process than occurs in vivo.  In addition, previous studies 
have shown that when multiple AAP arrest sequences are engineered in tandem into the 
same construct, whilst stalling occurs temporarily, at some point translation arrest is 
overcome and translation continues along the transcript resulting in multiple stalled 
intermediates and full length peptides (Fang et al., 2004).  Therefore the stalling rates of 
~30% obtained for AAP and TnaC in these assays at high (2 mM) inducer concentrations 
(Figure 5.9 and 5.6 respectively) appears to be consistent in comparison to published in 
vitro translation systems. 
 
These results are very interesting as the cross-domain stalling of TnaC and AAP in 
alternative ribosome systems, indicated by the results of the CTABr precipitation assays 
(Figure 5.7 & 5.9B respectively), does not withstand puromycin addition (Figure 5.8 & 
5.10 respectively).  The release of this stalling by puromycin indicates that the results of 
the CTABr experiments are not reflective of full stalling, but instead that these peptides 
must be undergoing a translational pausing.  Translational pausing is a well-documented 
occurrence which has been under research for some time (Wolin and Walter, 1988), it can 
serve several regulatory functions, examples include aiding the co-translational folding of 
nascent peptides on the ribosome (Thanaraj and Argos, 1996; Zhang et al., 2009), and also 
to delay completion of translation to allow correct cellular localisation of the peptide upon 
release (Yanagitani et al., 2011).  TnaC also appears to undergo a similar pausing in native 
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E.coli ribosomes at low tryptophan inducer concentrations (Figure 5.6; Lane 1), which is 
also abolished by puromycin addition (Figure 5.8; Lane 3).  The results indicate that 
translational pausing occurs in the absence of inducer molecule and is therefore dependent 
upon synthesis of the arrest motif residues and the subsequent interactions of the nascent 
chain within the exit tunnel.  To increase the efficiency of inducer molecule binding to the 
ribosome it is logical that inducible peptides may undergo a pause after the translation of 
the arrest motif.  The peptide can then undergo full stalling only if the inducer molecule 
binds correctly and promotes the necessary changes within the ribosome.  Indeed previous 
studies have shown that arginine can bind after the synthesis of the peptide and still induce 
a change in the PTC to induce stalling (Wei et al., 2012), supporting the theory that 
pausing provides additional time to enable the efficient binding of the inducer. 
 
Whilst pausing of the TnaC peptide in eukaryotic Wheat Germ ribosomes was equivalent 
to un-induced levels in native E.coli ribosomes, in contrast, AAP pausing in E.coli 
ribosomes was equivalent to induced levels of stalling of AAP+4 in eukaryotic Wheat 
Germ ribosome systems.  In the prokaryotic E.coli system AAP and AAP+4 peptides 
underwent ~32-34% arrest (Figure 5.9; Lanes 1-7), whilst even the AAP D12N mutant, 
which abolishes arrest in native eukaryotic ribosomes had only slightly reduced the levels 
of pausing in prokaryotic E.coli ribosomes compared to wild type AAP at ~28-30% 
(Figure 5.9; Lanes 9-16).  The high level of translational pausing of the D12N mutants in 
the prokaryotic E.coli ribosome system indicate that this residue is no longer critical to 
AAP stalling.  These results are striking as they reveal that arginine-independent 
translational pausing in the prokaryotic ribosome system is equivalent to the levels of full 
translation arrest observed in native eukaryotic ribosome system, however, despite this the 
AAP peptide is missing an essential impetus required to achieve full arrest.  This will be 
discussed further in the following section 5.3.2.   
 
In contrast, no stalling of SecM was observed in eukaryotic ribosomes (Figure 5.4, Lane 
4), this is most likely due to differences in the properties of intrinsic and inducible stalling 
peptides.  Intrinsic arrest peptides do not require any external influences and are dictated 
by their interactions within the ribosomal exit tunnel and the PTC.  It appears that in cross-
domain translation if these do not occur efficiently, then stalling will not occur.  
Meanwhile inducible stalling peptides that rely on both the presence of an inducer 
molecule and interactions within the ribosome exit tunnel are able to undergo translational 
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pausing which may be part of a natural two-step process on the way to complete translation 
arrest, however, due to the cross-domain differences are unable to undergo full translation 
arrest. 
 
5.3.2 Translation arrest in alternative ribosome systems 
There is a range of evidence present that illustrates that stalling peptides maintain the 
ability to arrest outwith their native species, for example, as stated previously, AAP is 
capable of undergoing stalling in a range of eukaryotic ribosomes including fungi, plants 
and animals (Fang et al., 2004) whilst Proteus vulgaris TnaC peptide is capable of 
arresting in E.coli ribosomes (Cruz-Vera et al., 2009).  Also due to the conservation 
between prokaryotic and eukaryotic ribosome exit tunnels, stalling peptides appear to 
interact within similar areas of the exit tunnel, including ribosomal RNA nucleotides 
U2585, A2062, A2058, A751 and the protein extensions L4 and L22 (L17) (Bhushan et al., 
2010b; Gumbart et al., 2012; Seidelt et al., 2009).  Therefore, in theory, it would be 
reasonable to suggest that full translation arrest of prokaryotic peptides may be able to 
occur in eukaryotic systems and vice versa.   
 
However, the results in this chapter show that cross-stalling over different domains does 
not occur.  SecM is unable to undergo translation arrest in eukaryotic ribosomes as shown 
by the CTABr precipitation assays in which only full-length SecM peptide was produced 
(Figure 5.4; Lane 4).  Likewise, TnaC and AAP peptides are unable to undergo full 
translation arrest in their alternative eukaryotic and prokaryotic ribosome systems 
respectively, as confirmed by puromycin release assays (Figures 5.8 and 5.10 
respectively).  A potential explanation for this could be that, despite the conservation in the 
ribosome exit tunnels, x-ray crystallography studies show that the head domain of the 
eukaryotic ribosome small subunit goes through global conformational changes during 
translation.  This large-scale rotation of the head domain of the small subunit serves to 
enable translocation of the tRNA and mRNA along the large and small ribosome subunit 
interface (Ben-Shem et al., 2011).  This is enhanced by the fact that eukaryotic ribosomes 
contain additional intersubunit bridges at the large and small subunit interface, which 
nearly double the surface area between them in comparison to prokaryotic ribosomes and 
play an important function in the rotation of the subunits (Yusupova and Yusupov, 2014).  
Studies also indicate that there is a difference in tRNA positioning during translocation 
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between prokaryotes and eukaryotes with the elbow domains of A and P site tRNAs 10 Å 
further apart in eukaryotic ribosomes than prokaryotic ribosomes, whilst the P and E site 
ribosomes are 16 Å closer in eukaryotes (Budkevich et al., 2011), see Figure 5.11 for an 
overview. 
 
These differences in structure will have a considerable impact on the process of translation 
arrest of stalling peptides, for instance, interactions of the SecM nascent chain with the exit 
tunnel cause it to arrest due to a subsequent shift in the position of the peptidyl-tRNAGly, 
with this ratcheting preventing the nucleophilic attack of the aminoacyl-tRNAPro thus 
resulting in a stalled nascent chain (Bhushan et al., 2011).  A large scale movement of the 
small subunit upon translocation and the difference in tRNA-positioning within the A and 
P sites in eukaryotic ribosomes may negate this relatively subtle shift causing the loss of 
translation arrest and resulting in complete translation of the SecM peptide.  Conversely 
for AAP stalling, whilst the peptide is able to interact with the exit tunnel of prokaryotic 
ribosomes sufficiently to undergo a translational pause, the difference in subunit 
movement and tRNA positioning upon translocation may account for the loss of full 
translation arrest of this peptide even in the presence of high concentrations of arginine 
inducer molecule.  This would explain how N.crassa AAP is not specific within eukaryotic 
ribosomes and can maintain stalling function in fungal, plant and animal ribosomes (Fang 
et al., 2004) but does not, as shown in this study, undergo full translation arrest in 
prokaryotic ribosomes.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Comparison of tRNA positions within the PTC of prokaryotic and eukaryotic ribosomes.  
The differences in tRNA positioning are highlighted with the eukaryotic A, P and E site tRNAs shown in 
pink, green and yellow respectively whilst prokaryotic tRNA positioning is shown in grey.  Figure 
reproduced from Budkevich et al., (2011). 
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It is not possible to determine from these experiments if the interactions within the exit 
tunnel have been maintained across prokaryotic and eukaryotic domains.  However, if so 
then this highlights that whilst the interactions within the exit tunnel may be important for 
initiating translation arrest and relaying messages to the PTC to induce stalling, the 
subsequent interactions within the PTC are vital to uphold stalling.  In addition to this, 
whilst intrinsic stalling peptides rely on their interactions within the exit tunnel to initiate 
stalling, correct inducer molecule binding in alternative ribosomes may also be a factor for 
inducible peptide stalling, however, this is unable to be determined from these 
experiments.   
 
5.3.3 Influence of additional +4 C-terminus residues 
As the open reading frame (ORF) for stalling peptides are located upstream on the mRNA 
from their downstream cistrons, SecM-AAP and SecM-TnaC constructs containing an 
additional four C-terminal residues (QRLT) were created to determine whether additional 
mRNA beyond the stop codon had a role in providing stabilisation of the mRNA within the 
PTC and therefore influencing levels of translation arrest.  These residues were selected as 
they are the four C-terminal residues of SecM beyond the Proline-166 translation arrest 
point and are known to enable stalling to occur without causing any interference.  The 
results indicated that the additional residues had a dual effect, resulting in higher basal 
translational pausing at low inducer concentrations (0.01 mM) of both AAP (Figure 5.8A) 
and TnaC (Figure 5.5A) in their native eukaryotic and prokaryotic ribosome systems 
respectively, and subsequently increased levels of stalling in the presence of high 
concentrations (2 mM) of the relevant inducer molecule.  In ribosome systems of the 
opposite domain the effect of the +4 residues in AAP was negated (Figure 5.8B) whilst the 
effect on TnaC was the same as in the prokaryotic system (Figure 5.6).   
 
Prokaryotes contain an inbuilt rescue system, transfer-messenger RNA (tm-RNA), to 
alleviate stalled ribosomes by tagging the C-terminus of stalled peptides and in doing so 
marking them for destruction by cellular proteases (Keiler et al., 1996).  The additional 
four C-terminal residues would result in occupancy of the ribosome A site thus preventing 
the identification of the stalled ribosome by tm-RNA, however, the observed results are not 
likely to be due to delaying cellular recycling of stalled ribosomes by tm-RNA as the 
coupled in vitro transcription-translation systems employed in these assays were 
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purposefully designed to include anti-ssrA oligonucleotide to bind and sequester tm-RNA 
to prevent this issue.   Therefore the increased level of translational pausing and stalling 
seen in the peptides with the additional mRNA tail is most likely due to stabilising the 
mRNA within the ribosome PTC and delaying mRNA drop off. 
 
5.3.4 Overall conclusions 
The ribosome is a hugely complex processing system responsible for the synthesis of all 
cellular proteins, which must then in turn leave through the ribosome exit tunnel.  Despite 
the increasing number of stalling peptides which have been identified, their high specificity 
explains how ribosomes are able to support stalling peptides by making their interactions 
niche so that multiple factors must be correct to induce full translation arrest thereby 
minimising the occurrence of aberrant, and subsequently detrimental, ribosome stalling. 
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6 Final Discussion 
6.1 Stalling peptide nascent chain interactions with the 
ribosome exit tunnel  
The aim of this thesis was to investigate the interactions between stalled translation arrest 
peptides and the ribosome exit tunnel.  This work sheds light on the key interactions that 
occur during translation arrest that are responsible for enabling this small niche of peptides 
to stall on the ribosome, a process that, if it were to occur aberrantly, would be highly 
detrimental to the cell.  Initially this work focussed on one particular stalling peptide, 
SecM, an ideal protein of interest as much research has already been carried out on 
elucidating its method of stalling and identifying the important contacts it makes within the 
ribosome exit tunnel.  Through the study of selected SecM mutants this thesis has revealed 
further insights into the interactions of the SecM nascent chain with the ribosome exit 
tunnel and also the influence of these interactions in the compaction of the SecM nascent 
chain upon translation arrest.  In particular highlighting the importance of the flexibility of 
the SecM nascent chain to enable positioning of the key interactions required for efficient 
translation arrest.  
 
As discussed earlier, Nakatogawa and Ito (2002) identified the key amino acids that are 
essential for SecM stalling, and it was these particular residues that were the focus of the 
first part of thesis.  In particular, determining what the key properties of these amino acids 
are for promoting translation arrest and what alterations they can undergo whilst still 
functioning to maintain stalling.  It was previously identified by Yap and Bernstein (2009) 
that Arg-163 was the sole essential residue required for SecM translation arrest, whilst the 
function of the other key arrest amino acids is to position this residue correctly within the 
ribosome exit tunnel.  Subsequent visualisation of the stalled SecM nascent chain within 
the ribosome exit tunnel by cryo-EM supported this, as Arg-163 appears to form the 
essential communication network with rRNA nucleotide A2062 to enable signalling to the 
PTC to induce stalling (Bhushan et al., 2011; Gumbart et al., 2012).  From the work in this 
thesis it has been established that the ability of the SecM peptide to tolerate mutation of the 
other key arrest residues to conservative amino acids is dependent on their distance from 
R163.  It appears that, with the exception of W155, the further away from residue R163 the 
greater the adaptability to mutation appears to be.  The lower tolerance of residue W155 to 
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mutation is most likely due to its location at the constriction site of the ribosome exit 
tunnel upon stalling (Bhushan et al., 2011). 
 
As Gly-165 is located in the P site of the ribosome upon stalling, the important role of this 
residue in SecM arrest is mediated through the movement of the tRNA-Gly in preventing 
peptide bond formation upon translation arrest (Bhushan et al., 2011), and not the 
properties of the amino acid itself.  Therefore of the key arrest motif residues, it is able to 
withstand mutation most effectively and can be mutated to serine without impacting 
stalling, with the peptide maintaining levels of arrest analogous to wild type SecM (refer to 
Figure 3.9 for reference).  I162 which is situated just below R163 in the exit tunnel is the 
least tolerant to mutation as it is in closest proximity to this key residue.  Meanwhile one 
residue further down at G161 has slightly more adaption to mutation which is improved 
with increased flexibility of the nascent chain provided by the P153A mutation.  Indeed, 
the greater the distance from R163, the more effectively mutations can be tolerated, with 
increased flexibility of the SecM nascent chain further counter acting the loss of stalling 
caused by the initial mutation.  This indicates the highly accurate nature of the placement 
of residue R163 with the rRNA nucleotide A2062, and indicates how accidental stalling is 
kept to a minimum as the interactions at this point are so specific.   
 
Further to this, it appears that the properties of specific amino acids have differing 
importance depending on where they are positioned within the SecM nascent chain, again 
the closer to the essential R163 the less tolerance there is for alteration.  For instance, an 
isoleucine to leucine mutation at residue 156 can be tolerated more effectively than one at 
position 162.  Likewise, glycine to serine, when located at residue 165 at the ribosome P 
site upon stalling, has far greater scope for modification than the same mutation at position 
161 which is located within the exit tunnel. 
 
As discussed previously, increased flexibility of the SecM nascent chain by mutation of a 
restrictive proline residue to an alanine at residue 153, provided improved ability to adapt 
to mutation of the key arrest motif amino acid residues.  This is believed to be because it 
enables the repositioning of the SecM nascent chain within the ribosome exit tunnel 
allowing it to compensate for mutations to varying extents, except R163 as previously 
stated.  This better flexibility must come from within the essential arrest motif, as 
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increased movement provided by mutation of another proline residue outwith the essential 
motif, at P146, had no effect on improving stalling of SecM mutants.  The P146 residue is 
located beyond the constriction point of the ribosome exit tunnel (Bhushan et al., 2011), 
indicating that to influence SecM nascent chain positioning improvements in flexibility 
must be able to influence the residues in the upper portion of the exit tunnel where the key 
interactions take place.   
 
Another feature of SecM stalling that was investigated in this thesis was the compaction of 
the nascent chain upon translation arrest, a process that has previously been established as 
being required for SecM arrest (Woolhead et al., 2006).  These results expand this work 
further to reveal that conservative mutations of key arrest motif residues affect SecM 
nascent chain compaction but do not completely abolish stalling (see Figure 4.13 for 
summary).  This is in contrast to the effect of alanine mutations to key arrest residues 
which have previously been shown, by FRET assays, to maintain compaction but abolish 
stalling (Woolhead et al., 2006).  This indicates that whilst conservative mutations affect 
the placement of SecM within the exit tunnel, resulting in a more extended conformation, 
the nascent chain can adapt to these mutations by forming new interactions which enable 
the correct positioning of the key R163 residue, maintaining a degree of stalling.  
Tolerance to mutation can be further enhanced through increased flexibility of the SecM 
nascent chain provided by the P153A mutation.  This mutation results in recovery of the 
compaction of SecM mutants to levels analogous to wild type SecM, correlating with a 
further increase in the levels of translation arrest obtained by the peptide.  Despite this, the 
levels of arrest do not reach that of wild type SecM, indicating that whilst compaction is 
not reliant on the detection of a completely accurate arrest motif, complete stalling 
capability is.   
 
Further work in this area would ideally involve the elucidation of the specific interactions 
occurring within the ribosome exit tunnel of a range of these SecM mutants, particularly 
SecM I162L, which has an extended conformation yet can maintain a relatively high level 
of stalling.  It would be highly interesting to discover if these mutants undergo different 
interactions with the ribosome exit tunnel to enable initiation of stalling and how these 
compensate for the loss of the original connections.  Also, these studies could explore 
whether enabling the SecM conservative mutants additional freedom through mutation of 
P153A enables the nascent chain to revert back to the original interactions or if they also 
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form an altered compacted structure.  Cryo-EM would be an ideal method to study this as 
it would enable direct visualisation of the SecM nascent chain within the ribosome exit 
tunnel.  Additionally photo-crosslinking would be a suitable alternative or as a 
supplementary analysis, by enabling the use of crosslinkers to biochemically map the 
interactions of the SecM nascent chain within the ribosome exit tunnel.  Although in 
comparison to cryo-EM, which can map the full path of the nascent chain through the exit 
tunnel, crosslinking only provides a snap-shot of the interactions at the location selected 
for the placement of the crosslinking probes within the nascent chain.  However, photo-
crosslinking is advantageous as it does not depend on long term RNC stability, as 
experiments are able to be completed as soon as the stalled nascent chain complexes are 
generated, by light activation of the crosslinker, these products themselves are then also 
relatively stable with the chemical crosslinks permanently formed.  This removes any 
issues as to whether the time course of the experiment has altered the structure of the 
nascent chain within the exit tunnel as is a consideration with cryo-EM.  Also with cryo-
EM protocols it may be necessary to add additional proteins to the N-terminus of the 
protein of interest to enable pure samples to be obtained by affinity purification.  These are 
all factors which need to be taken into consideration when planning the best experimental 
course of action. 
 
6.2 Specificity of translation arrest peptides in non-native 
ribosomes 
This thesis also sought to establish the specificity of translation arrest of prokaryotic and 
eukaryotic stalling peptides in non-native ribosomes of other domains.  This study has 
revealed that whilst translation arrest peptides are unable to commit to full translational 
stalling in ribosomes from non-native domains, most likely due to the differences in the 
architecture of prokaryotic and eukaryotic ribosome exit tunnels, it has identified their 
ability to undergo translational pausing.  This step appears to only occur during stalling of 
inducible translation arrest peptides, which would benefit from a pause after synthesis of 
the arrest motif to allow efficient binding of the inducer molecule, thereby enabling 
instigation of full translation arrest.  It was not identified directly in native ribosome 
stalling systems of AAP and TnaC as nascent chain/ribosome compatibility results in 
attainment of full arrest.  The translational pause is likely to occur after recognition of the 
stalling sequence of the nascent chain, prior to binding by the inducer molecule.  The cryo-
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EM structures of the stalled ribosome-nascent chain complexes of AAP and TnaC 
currently available are in the absence of inducer molecule, yet they show the peptides 
forming distinct conformations within the exit tunnel, influencing the position of the key 
23S rRNA nucleotides, such as A2062 (Bhushan et al., 2010b; Seidelt et al., 2009).  From 
the results established in this study it can therefore be hypothesised that interaction of the 
nascent chain with the exit tunnel induces a structural change within the ribosome to 
establish ribosome pausing.  The purpose of the translational pause is to provide a 
reasonable time frame to allow for the binding of inducer molecule to occur (Figure 6.1C).  
If binding does not occur due to low concentrations of inducer molecule, then pausing will 
be released and full translation arrest will not be achieved (Figure 6.1D).  Conversely, this 
translational pause is not necessary in intrinsic stalling peptides, which do not rely on 
external stimuli for stalling, and therefore would not benefit from undergoing a 
translational pause prior to initiation of full translation arrest. 
 
This study was restricted in that it only assessed three stalling peptides, one intrinsic and 
two inducible, therefore to further validate if the occurrence of translational pausing occurs 
for all inducible peptides it would be necessary to assess a wider range of translation arrest 
peptides.  In addition, this would also enable determination of whether similar patterns 
hold true for all prokaryotic and eukaryotic stalling peptides.  For instance in this study, the 
prokaryotic peptide TnaC appeared to undergo translational pausing in eukaryotic Wheat 
Germ ribosomes at levels equivalent to un-induced levels of translational stalling in native 
E.coli ribosomes, whilst in contrast, eukaryotic AAP pausing in E.coli ribosomes was 
equivalent to induced levels of stalling in eukaryotic Wheat Germ ribosome systems.  
Further analysis on a wider range of peptides is required to assess if this occurrence was 
uniform across all prokaryotic and eukaryotic stalling peptides or varied for individual 
peptides. 
 
Although prokaryotic and eukaryotic ribosomes share a core structure, this work concludes 
that cross-domain stalling does not occur, however, it remains to be established how 
undiscriminating stalling peptides can be within their own domains.  At the moment there 
exists conflicting reports of the capability of stalling peptides to undergo translation arrest 
within the ribosomes of different species within the same domain, for instance as discussed 
previously, the AAP peptide is able to undergo stalling in fungi, plants and animals (Fang 
et al., 2004), whilst on the other hand E.coli SecM and Bacillus subtilis MifM appear to be
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Figure 6.1 Representation of translational pausing. A. Stop codon enters the 
ribosome A site and nascent chain interacts with the ribosome exit tunnel. B. Nascent 
chain interactions (Blue star) result in translational pausing and the formation of an 
inducer molecule binding site (White star) within the ribosome. C. Binding of 
inducer molecule (Red star) initiates ribosome alterations resulting in full 
translational stalling. D. In the absence of inducer molecule the translational pausing 
is transient, translation termination is completed resulting in release of the mRNA 
and leader peptide and subsequent recycling of the ribosome. 
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species-specific (Chiba et al., 2011).  However, not all SecM variants appear to be species-
specific, with distantly related SecM homologs from Haemophilus influenzae and 
Mannheimia succiniciproducens able to efficiently stall translation in E.coli ribosomes 
(Yap and Bernstein, 2011).  Perhaps, it may be that within the same domain, the ability of 
peptides to undergo stalling in foreign ribosomes varies on an individual peptide basis, 
dependant on the particular peptide and ribosomes being analysed and the interactions 
made within the ribosome exit tunnel.   
 
These conflicting reports of SecM stalling in alternative ribosomes indicate that this may 
be an area requiring further study.  Investigating the stalling ability of different SecM 
homologs within ribosomes of alternative bacterial species would reveal if there were 
specific shared features of the ribosome exit tunnel that enable cross-species stalling or 
whether certain SecM variants could adapt to maintain stalling function in different 
species.  If the individual SecM species can undergo adaptions to stall in different species 
of bacterial ribosome then establishing how that is achieved would be crucial to a better 
understanding of SecM stalling.  The investigation could also be expanded to examine the 
role of the mRNA sequence or potential auxiliary factors in mediating this cross species 
stalling.  
 
In addition, pegylation assays similar to those performed in this thesis would determine if 
all SecM homologs compact, and if so to what degree does this correspond between 
different species.  This in turn can be expanded to explore if compaction of a SecM peptide 
remains the same when translated in a different species or does it alter to provide adaption 
to the foreign exit tunnel and enable stalling to proceed in the different ribosomes.  This 
will provide a fascinating insight into how adaptable stalling peptides are to sense their 
environment and explore the interactions required to undergo translation arrest. 
 
6.3 Future directions 
The work presented in this thesis has further increased our knowledge on translation arrest 
peptides and their interactions within the ribosome exit tunnel upon stalling.  Following on 
from this work, several paths of future research can be pursued.  Firstly, there is still much 
to discover regarding the interactions of stalling peptides with the ribosome exit tunnel, in 
173 
 
particular how the signal to undergo translation arrest is transferred from these interactions 
to the PTC where stalling is induced and maintained.  Previous studies have suggested that 
ribosomal proteins and specific rRNA nucleotides are responsible for conveying signals to 
the PTC to induce subtle structural rearrangements within the PTC to induce stalling.  
However, it remains to be firmly established how this stalling signal is conveyed to PTC 
and if all stalling peptides communicate from the exit tunnel to the PTC through the same 
pathway.  With increasing refinement of cryo-EM techniques greater clarity can be gained 
into the stalling peptides interactions within the exit tunnel upon translation which may 
help to provide a better understanding of this process.  By comparing the structures of 
empty ribosomes and stalled ribosome-nascent chain complexes (RNCs) it will be possible 
to further assess the process undergone during translation arrest, providing molecular level 
detail.  Whilst various cryo-EM structures of translation arrest peptides have already been 
defined, drawbacks of the current structures for the inducible peptides TnaC and AAP are 
that both have been visualised in the absence of their respective inducer molecules 
tryptophan and arginine (Bhushan et al., 2010b; Seidelt et al., 2009).  It is critically 
important that structures are obtained with the inducer molecule present as this would 
ascertain that the current data from these previous studies is correct and also allow 
definitive establishment of the binding site of the inducer molecule and analysis of how it 
influences induction of stalling.  There is the distinct possibility that structures with the 
inducer molecule bound could reveal differences in either conformation of the peptide 
within the exit tunnel or alterations in the structure of the translation arrested ribosome. 
 
In addition to this path of research, it is also possible to take the knowledge that has been 
gathered from the study of translation arrest peptides and utilise it to generate hyper stable 
stalled-RNC complexes, using modified SecM stalling sequences that have been altered by 
selective mutation to gain increased stability.   Previous studies have attached the wild type 
SecM arrest motif at the C terminus of proteins of interest to create constructs capable of 
translating peptides that can stall on the ribosome (Cabrita et al., 2009; Evans et al., 2005; 
Schaffitzel and Ban, 2007), however, this can be further refined and Appendix 1 provides 
the ground work of such a study.  These high-stability constructs are highly beneficial for 
use in time-intensive experiments such as FRET, NMR, cryo-EM and X-ray 
crystallography.   
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This thesis focussed on the interactions of stalling peptides, in particular SecM, within the 
ribosome exit tunnel, however, little is known about the role of these peptides beyond the 
exit tunnel.  It is already known that the fate of SecM is to be rapidly degraded by tail-
specific proteases upon translocation to the periplasm (Nakatogawa and Ito, 2001), 
however, studies are now starting to explore if there are roles for the remainder of the 
SecM peptide in addition to its C-terminal arrest motif and N-terminal signal sequence.  
Indeed recently a role for residues 100-109 in export-coupled arrest release was discovered 
(Nakamori et al., 2014), which leaves the question of whether there are additional 
functions for the remainder of the SecM peptide. 
 
The study and further understanding of stalling peptides is crucial as they perform 
important functions in gene and protein expression through the regulation of transcription 
and translation of downstream genes on the same operon.  Additionally, as indicated in 
Appendix 1, a better understanding of stalling peptides enables them to be exploited more 
efficiently for uses in molecular biology techniques through the generation of hyper stable, 
stalled-ribosome nascent chain complexes of alternative proteins.  This enables the 
investigation of the behaviour and processes undertaken by natively non-stalling peptides 
whilst they are being translated by the ribosome to be examined. 
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Appendix 1: Applying SecM stalling to generate 
ribosome-nascent chain complexes to study the folding of 
proteins of interest arrested on the ribosome 
 
Further to the work already presented in this thesis, the knowledge gathered from the study 
of SecM stalling can be utilised to create constructs containing proteins of interest attached 
to the N-terminus of the SecM arrest motif, which are therefore capable of stalling on the 
ribosome.  The generation of these stable, stalled ribosome-nascent chain (RNC) 
complexes enables the timing and process of co-translational protein folding and exit from 
the ribosome exit tunnel to be studied.  Previous studies have employed the wild type 
SecM stalling sequence to obtain RNCs of proteins of interest stalled on the ribosome 
(Cabrita et al., 2009; Evans et al., 2005), however, whilst SecM stalling in vivo is strong it 
is not permanent, as this would be detrimental to the cell to have ribosomes sequestered 
too long.  Therefore, the results presented here expand this concept further to identify 
variants of the SecM arrest motif which can be exploited to obtain the most stable long-
term ribosome stalling.  The potential number of proteins that can be studied whilst stalled 
on the ribosome by attaching SecM is vast, however, for the purpose of this study, human 
beta-2 microglobulin (B2M) a component of MHC class 1 molecules was selected.  The 
human B2M is 119 amino acids in length and has been selected as it is a small, soluble 
protein with a known structure (Figure A1.1A).  It contains a single disulphide bond 
between Cys45 – Cys100 which connects the two β-sheets and stabilises the molecule.   
 
Several B2M constructs were created containing the SecM stalling sequence at the C 
terminus, to enable stalled ribosome-nascent chains displaying the B2M protein to be 
obtained for structural studies (Figure A1.1B).  Four test constructs were created to analyse 
the stability of the SecM arrest sequence with the B2M protein attached.  Each construct is 
161 amino acids in length and contains full length B2M at the N-terminus, 2 spacer 
residues (Ser, Arg) and the C-terminal 40 residues of SecM (or a variation of the SecM C-
terminus).  The length of the SecM portion of these constructs has been designed based on 
the pegylation data in Chapter 4 (Figure 4.4B), so that upon compaction of the SecM 
nascent chain during translation arrest, the C-terminus of the B2M protein will be 
positioned at the opening of the exit tunnel.  The constructs contain either wild type SecM 
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1                                                               119     130                                               170
B2M                         SecM 
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*
1                                                               119     130                                               170
B2M                         SecM P153A 
N- -C
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1                                                               119                 137                                  170
B2M                         5xPro SecM 
N- -C
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*
1                                                               119                137                                  170
B2M                         5xPro SecM P153A 
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A.                                                                B. 
 
 
 
 
 
 
 
 
 
 
C. 
M S R S V A L A V L A L L S L S G L E A I Q R T P K I Q V Y S R H P A E N G K S N F L N C Y V S G F H P S D I E V D L L K N G E R I E K V E H S D L S F S K D W S F Y 
L L Y Y T E F T P T E K D E Y A C R V N H V T L S Q P K I V K W D R D M Stop 
Figure A1.1 Structure of B2M and B2M-SecM constructs.  A. Structure of human beta-2 microglobulin (PDB: 1a1m) attached to the SecM C-terminus stalled on the ribosome, note 
diagram not to scale.  Shown in cyan are residues Cys 45 and 100 which form a disulphide bond. B. Schematic diagrams of the 4 B2M-SecM constructs created: B2M-SecM, B2M-
SecM P153A, B2M-Pro5x SecM and B2M-Pro5x SecM P153A. C. Full wild type Beta-2 microglobulin amino acid sequence, highlighted in cyan are Cys-45 and 100 which form a 
disulphide bond in the folded protein. 
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Full length wild type SecM =170 amino acids 
Arrested SecM = 165 amino acids   
Full length B2M-SecM = 161 amino acids  
Arrested B2M-SecM = 156 amino acids 
 
 
 
Figure A1.2 B2M-SecM test translations. SecM WT, B2M-SecM, B2M-SecM P153A, B2M-Pro5x SecM and B2M-Pro5x SecM P153A were translated in coupled in vitro 
transcription-translation assays before being CTABr precipitated, separated into pellet (P) and supernatant (S) fractions and resolved by SDS-PAGE. The percentage of arrested peptide 
was quantified by Image J software and calculated as a percentage of [Arrested/(Arrested + Total full length)], with each value adjusted for background, and then taken as a proportion 
of wild type SecM.  Results are representative of multiple experiments.
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or SecM P153A and in addition to this two of the constructs also contain a 5x proline 
repeat (Figure A1.1B).  Previous work has shown that a 5x proline repeat contained within 
the ribosome exit tunnel upon arrest increases the stability of ribosome-SecM nascent 
chain complexes (Woolhead, unpublished data).   A proline repeat forms a rigid helix 
structure (Cowan and McGavin, 1955) which, in this instance, will serve to promote the 
stability of the interactions between the SecM portion of the nascent chain and the 
ribosome exit tunnel.  The SecM P153A mutant was selected as it has been hypothesised 
from the work in Chapter 3 of this thesis that increased flexibility of the nascent chain 
within the ribosome exit tunnel, due to the mutation of a restrictive proline residue to 
alanine, could enable the nascent chain increased adaptability to gain the correct 
interactions within the exit tunnel.  It is thought that this will increase the stability of the 
stalled RNC over a longer time frame. 
 
Initial experiments were carried out to ensure the addition of B2M at the N-terminus did 
not impede SecM translation or arrest.  The results indicated that the additional B2M 
portion did not hinder translation and in fact resulted in all constructs having improved 
levels of arrest in comparison to wild type SecM (Figure A1.2).  Even B2M-SecM had an 
increased level of stalling in comparison to wild type SecM (Figure A1.2; Lane 3), this is 
possibly due to folded B2M outside the ribosome acting to stabilise the ribosome-nascent 
chain complex.  The additional P153A mutation further increased levels of arrest (Figure 
A1.2; Lane 5) with the 5x proline repeat further increasing it slightly more so (Figure 
A1.2; Lane 9). 
 
Following this, the longer term stability of the ribosome bound nascent chain complexes 
was assessed over a 120 hour period (Figure A1.3 and A1.4).  The constructs were 
synthesised in coupled in vitro transcription-translation assays for 30 minutes at 37oC 
before being stored at 4oC and aliquots were then taken at the time points 0, 5, 24, 48 and 
120 hours.  To assess the stability of the peptidyl-tRNA the samples were either 
centrifuged through a sucrose cushion to pellet the ribosome-nascent chain complexes 
(Figure A1.3) or CTABr precipitated (Figure A1.4).  The results indicated that at 24 hours 
all wild type SecM was released from the ribosome (Figure A1.3A; Lane 3 and A1.4A; 
Lane 5) whilst in comparison at 48 hours all of the B2M constructs still had some level of 
stalling (Figure A1.3A & B and A1.4B & C).  Similar to the test translation results, this 
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A. 
 
 
 
 
 
B. 
 
 
 
 
 
Figure A1.3 B2M-SecM stability time course with sucrose cushion assay.  A. SecM WT, B2M-SecM, B2M-SecM P153A and B. B2M-Pro5x SecM and B2M-Pro5x SecM P153A 
were translated in coupled in vitro transcription-translation assays before being stored at 4oC with aliquots taken at time points: 0, 5, 24, 48 and 120 hours.  These were then centrifuged 
through a sucrose cushion and the pellet resuspended in sample buffer and separated on an SDS gel. Results are representative of multiple experiments. 
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A. 
 
 
 
 
 
B. 
 
 
 
 
C. 
 
 
 
Figure A1.4 B2M-SecM stability time course with 
CTABr precipitation assay.  A. SecM WT B. B2M-SecM, 
B2M-SecM P153A and C. B2M-Pro5x SecM and B2M-
Pro5x SecM P153A were translated in coupled in vitro 
transcription-translation assays before being stored at 4oC 
with aliquots taken at time points: 0, 5, 24, 48 and 120 hours.  
These were then CTABr precipitated, separated into pellet 
(P) and supernatant (S) fractions and resolved by SDS-
PAGE.  Results are representative of multiple experiments. 
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stalling was further improved by the P153A mutation (Figure A1.3A; Lane 14 and A1.4B; 
Lane 17) and Pro5x repeat (Figure A1.3B; Lane 9 and A1.4C; Lane 17). 
 
Both stability assay methods identify B2M-Pro5x SecM P153A as the most stable stalled 
construct and this will therefore be taken forward for future work.  This work will include 
engineering the B2M portion of the construct to study various features such as protein 
folding during translation through methods including fluorescence resonance energy 
transfer (FRET) and pegylation assays.  Additionally, by maintaining the SecM stalling 
sequence but truncating or extending the length of the C-terminus of B2M it would be 
possible to study the timing of the folding of the peptide as it exits the ribosome tunnel.  
These assays require long term stable ribosome stalling to generate the highest possible 
yields of RNCs and therefore can be carried out more efficiently using the higher stability 
constructs identified in this study.  Indeed the optimisation of the SecM stalling sequence 
established in this study will be useful to any researchers carrying out time-intensive 
structural studies such as NMR, cryo-EM and X-ray crystallography where long term 
maintenance of the RNC complexes would increase experimental efficiency. 
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Appendix 2: Table of constructs 
A2.1 Chapter 3 constructs 
All constructs used in this chapter are in the pTrc99A plasmid 
 
Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM F150A  TTC GCC 
SecM P153A  CCC GCC 
SecM W155A TGG GCG 
SecM I156A  ATA GCA 
SecM G161A  GGC GCC 
SecM I162A  ATC GCC 
SecM R163A  CGT GCT 
SecM G165A  GGC GCC 
SecM P166A  CCT GCT 
Table A2.1 SecM single alanine mutants 
 
 
Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM F150A/ P153A See Table A3.1 For individual 
mutations 
SecM W155A/P153A   
SecM I156A/P153A    
SecM G161A/P153A   
SecM I162A/P153A   
SecM R163A/P153A   
SecM G165A/P153A   
Table A2.2 SecM alanine mutants with P153A double mutation 
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Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM F150Y  TTC TAC 
SecM W155Y TGG TAC 
SecM I156L  ATA CTA 
SecM G161S  GGC AGC 
SecM I162L  ATC CTC 
SecM R163K  CGT AAA 
SecM A164G  GCT GGT 
SecM G165S GGC AGC 
Table A2.3 SecM single conservative mutants 
 
 
Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM F150Y/P153A See Tables A3.1 
and A3.3 
For individual 
mutations 
SecM W155Y/P153A   
SecM I156L/P153A    
SecM G161S/P153A   
SecM I162L/P153A   
SecM R163K/P153A   
SecM A164G/P153A   
SecM G165S/P153A   
Table A2.4 SecM conservative mutants with P153A double mutation 
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Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM P146A CCA GCA 
SecM P146A/P153A See above and 
Tables A3.1 and 
A3.3 
For individual 
mutations 
SecM F150Y/P146A   
SecM I156L/P146A    
SecM G161S/P146A   
SecM F150Y/P146A/P153A   
SecM I156L/P146A/P153A   
SecM G161S/P146A/P153A   
Table A2.5 SecM conservative mutants with P146A and P153A double and triple mutations 
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A2.2 Chapter 4 constructs 
All constructs used in this chapter are in the pTrc99A plasmid 
 
Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM D120C  GAT TGT 
SecM L125C CTG TGC 
SecM G130C GGC TGC 
SecM K135C AAG TGC 
SecM D140C GAT TGT 
SecM T145C ACC TGC 
Table A2.6 SecM single cysteine mutants 
 
 
 
Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM Q158P CAG CCG 
SecM D120C/Q158P See above and 
Table A3.6 
For individual 
mutations 
SecM L125C/Q158P   
SecM G130C/Q158P   
SecM K135C/Q158P   
SecM D140C/Q158P   
SecM T145C/Q158P   
Table A2.7 SecM cysteine mutants with Q158P mutations 
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Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM P153A/G130C See Tables 
A3.1, A3.3 and 
A3.6 
For individual 
mutations 
SecM P153A/K135C   
SecM P153A/D140C   
SecM F150Y/G130C   
SecM F150Y/K135C   
SecM F150Y/D140C   
SecM I156L/G130C   
SecM I156L/K135C   
SecM I156L/D140C   
SecM G161S/G130C   
SecM G161S/K135C    
SecM G161S/D140C    
Table A2.8 SecM P153A and conservative mutants with cysteine mutations 
 
 
Construct Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM F150Y/P153A/G130C See Tables 
A3.1, A3.3 and 
A3.6 
For individual 
mutations 
SecM F150Y/P153A/K135C   
SecM F150Y/P153A/D140C   
SecM I156L/P153A/G130C   
SecM I156L/P153A/K135C   
SecM I156L/P153A/D140C   
SecM G161S/P153A/G130C   
SecM G161S/P153A/K135C   
SecM G161S/P153A/D140C   
Table A2.9 SecM conservative/P153A double mutants with cysteine mutations 
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A2.3 Chapter 5 constructs  
All pGEM-4Z plasmid constructs used in this study are in SP6 promoter orientation 
 
pTrc-SecM WT  
pGEM-SecM WT 
 
pTrc-SecM-AAP WT   pTrc-SecM-AAP WT+4 
pTrc-SecM-AAP D12N  pTrc-SecM-AAP D12N+4 
 
pGEM-SecM-AAP WT *  pGEM-SecM-AAP WT+4 * 
pGEM-SecM-AAP D12N *  pGEM-SecM-AAP D12N+4 * 
 
pTrc-SecM-TnaC   pTrc-SecM-TnaC+4 
pGEM-SecM-TnaC *   pGEM-SecM-TnaC+4 * 
 
* Asterix indicates constructs which have the following additional methionine mutations: 
 
Residue Original 
nucleotide 
sequence 
Mutated 
nucleotide 
sequence 
SecM V25M  GTT ATG 
SecM A26M GCG ATG 
SecM A27M GCG ATG 
 
Table A2.10 SecM methionine mutations 
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A2.4 Appendix 1 constructs 
pTrc-B2M-SecM 
pTrc-B2M-SecM P153A 
pTrc-B2M-5xPro SecM  
pTrc-B2M-5xPro SecM P153A 
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Appendix 3: Generation of plasmid constructs 
A3.1 pTrc-SecM 
pTrc-SecM was created by Dr Cheryl Woolhead as described in Woolhead et al., (2006). 
 
A3.2 pGEM-SecM 
SecM was cut from pTrc-SecM using Kpn1 and Xba1 restriction enzymes and transferred 
to empty pGEM-4Z plasmid vector also cut with Kpn1 and Xba1, this positioned SecM in 
the SP6 promoter orientation. 
  
A3.3 pTrc-SecM-AAP and pTrc-SecM-AAP+4 
AAP and AAP D12N constructs were originally obtained from Mathew Sachs laboratory 
(Texas A&M University).  These were PCR amplified using the oligonucleotide primers:  
5’-CATGGTACCGGCAGGAAACAGACCATGATGATGATGATG-3’ and  
5’-GTATCTAGAGTATTATTACACGGCGATCTTTCCGCCCTTC-3’ and cloned into 
separate pTrc99a plasmids using restriction sites Kpn1 and Xba1, to create pTrc-AAP WT 
and pTrc-AAP D12N.  From these constructs, AAP WT and AAP D12N were again PCR 
amplified using the following oligonucleotide primers:  
5’-CATCAATTGATGAACGGTCGCCCGTCAGTCTTCACTAGTC-3’ and  
5’-GTATCTAGAGTATTATTACGCGTTAAGGGCTCTCCACAGATGG-3’ (or 5’-
GTATCTAGAGTATTATTAGGTGAGGCGTTGCGCGTTAAGGGCTCTCCACAGAT
GG-3’ to create +4 constructs) and separately cloned into pTrc-SecM using Mfe1 and 
Xba1 restriction sites to produce pTrc-SecM-AAP WT and pTrc-SecM-AAP D12N (and 
similarly pTrc-SecM-AAP WT+4 and pTrc-SecM-AAP D12N+4) constructs.  Note, SecM 
contains a native Mfe1 restriction site, therefore cutting the pTrc-SecM construct with 
Mfe1 and Xba1 restriction enzymes removes residues 63-170. 
 
A3.4 pGEM-SecM-AAP and pGEM-SecM-AAP+4 
Both wild type and D12N mutant pTrc-SecM-AAP and pTrc-SecM-AAP+4 constructs 
were cut with Xba1 and Kpn1 restriction enzymes and transferred to separate empty 
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pGEM-4Z plasmid vectors also cut with these restriction enzymes, positioning these genes 
in the SP6 promoter orientation.  Three additional methionine residues were introduced in 
each construct at SecM V25, A26 and A27 by consecutive rounds of site-directed 
mutagenesis (see Section 2.2.5.3.1 for method).  
 
A3.5 pTrc-SecM-TnaC and pTrc-SecM-TnaC+4 
The tnaC gene was PCR amplified from the genomic DNA of E.coli strain MC4100 using 
the oligonucleotide primers: 
5’-CATCAATTGATGAATATCTTACATATATGTGTGACC-3’ and 5’-
GTATCTAGAGTATTATCAAGGGCGGTGATCGACAATTTTG-3’ (or 5’- 
GTATCTAGAGTATTATTAGGTGAGGCGTTGAGGGCGGTGATCGACAATTTTG-3’ 
to create +4 constructs).  These were separately cloned into pTrc-SecM using Mfe1 and 
Xba1 restriction sites to produce pTrc-SecM-TnaC and pTrc-SecM-TnaC+4 constructs. 
 
A3.6 pGEM-SecM-TnaC and pGEM-SecM-TnaC+4 
SecM-TnaC and SecM-TnaC+4 were cut from the pTrc99a plasmids using Xba1 and Kpn1 
restriction enzymes and inserted into empty pGEM-4Z vector cut with the same restriction 
enzymes.  This created pGEM-SecM-TnaC and pGEM-SecM-TnaC+4 constructs in the 
SP6 promoter orientation.  Three additional methionine residues were introduced in these 
constructs at SecM V25, A26 and A27 by consecutive rounds of site directed mutagenesis 
(see Section 2.2.5.3.1 for method). 
 
A3.7 pTrc-B2M-SecM constructs 
pBluescript-B2M plasmid was kindly provided by Prof. Neil Bulleid (University of 
Glasgow).  From this the B2M gene was PCR amplified using the following 
oligonucleotide primers:  
5’-CATGGTACCGGCAGGAAACAGACCATGTCTCGCTCCGTGGCC-3’ and  
5’-GTATCTAGACATGTCTCGATCCCACTTAACTATCTTGGG-3’.  This was then 
cloned into empty pTrc99a plasmid vector at Kpn1 and Xba1 cut sites to create pTrc-B2M.  
The C-terminal portion of SecM was then amplified from the pTrc-SecM plasmid using the 
oligonucleotide primers: 5’-CATTCTAGAGGCACGCCGTCTGAAAAGGGTTATCGC-
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3’ (or 5’-CATTCTAGAATGATGCCGCCGCCGCCGCCGTATCGCATTG-3’ for 5xPro 
SecM) and 5’-GTAAAGCTTGTATTATTAGGTGAGGCGTTGAGGGCCAGC-3’.  
These were then cloned into pTrc-B2M at Xba1 and HindIII restriction sites to create 
pTrc-B2M-SecM and pTrc-B2M-5xPro SecM.  This was also repeated with the same 
oligonucleotide primers but using pTrc-SecM P153A as the template to obtain pTrc-B2M-
SecM P153A and pTrc-B2M-5xPro SecM P153A constructs.  See Appendix 1, Figure 
A1.1B for a summary diagram of these four constructs. 
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